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Surely	mankind	must	believe	in	something,	or	at	least	seek	for	the	truth,	otherwise	life	is	just	emptiness.	To	live	and	not	to	know	why	the	cranes	fly,	why	children	are	born,	why	there	are	stars	in	the	sky…	Either	you	must	know	why	you	live,	or	everything	is	trivial	–	just	dust	in	the	wind.		
The	Three	Sisters	(Act	2),	Anton	Chekhov		
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Thesis	Abstract	
The	 aetiopathogenesis	 of	 Crohn’s	 disease	 (CD)	 is	 characterised	 by	 epithelial	barrier	 dysfunction	 and	 immune	 dysregulation	 in	 a	 genetically	 susceptible	 host.		Exposure	to	a	western	diet,	a	dysbiosis	and	bile	acid	(BA)	dysmetabolism	have	also	been	 implicated.	 	 The	 BA	 receptor,	 farnesoid-x	 receptor	 (FXR),	 is	 central	 to	 the	crosstalk	between	the	host	and	its	microbiota.		FXR	acts	to	maintain	the	epithelial	barrier	 and	has	 an	 immuno-modulatory	 function	 although	 the	mechanism	 is	 not	fully	understood.	The	 first	aim	of	 this	 study	was	 to	 investigate	 the	effect	of	FXR	agonism	using	 in-
vitro	 models	 of	 cytokine-induced	 epithelial	 barrier	 dysfunction.	 	 Functional	 and	morphological	 studies	 of	 Caco-2	 cell	 monolayers	 demonstrated	 that	 FXR	 acts	 to	maintain	 epithelial	 cell	 morphology,	 probably	 via	 a	 mechanism	 involving	 the	regulation	of	myosin	light	chain	kinase	expression.	 FXR	agonism	was	also	able	to	abolish	the	IL-8	response	of	HT29	cells	to	stimulation	with	TNF. The	 second	 aim	 of	 this	 study	 was	 to	 investigate	 the	 link	 between	 a	 western-lifestyle	diet,	 impaired	BA	signalling	and	 ileal	 inflammation	 in	a	mouse	model	of	obesity.	 	 Animals	 fed	 a	western-lifestyle	 diet	 expressed	more	 ileal	 inflammatory	cytokine.		There	was	a	trend	to	suggest	that	supplementation	with	an	FXR	agonist	reduced	inflammatory	cytokine	expression.	Finally,	this	study	aimed	to	both	measure	FXR	activity	in	patients	with	ileal	CD,	but	also	to	optimise	an	ex-vivo	tissue	culture	model	to	assay	the	effect	of	FXR	agonism	on	 ileal	mucosal	 cytokine	 production.	 	 FXR	 activity	was	 significantly	 reduced	 in	patients	with	ileal	CD	as	compared	with	controls.		An	ex-vivo	tissue	culture	model	was	optimised,	but	 there	was	no	evidence	 that	FXR	agonism	could	attenuate	 the	response	of	primary	tissue	to	stimulation	with	inflammatory	cytokine. 
		 xiv	
In	 summary,	 the	 data	 presented	 support	 the	 hypothesis	 that	 disrupted	 bile	 acid	signalling,	via	FXR,	may	predispose	to	the	development	of	ileal	CD	by	impairing	gut	epithelial	immune	homeostasis.		
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Chapter	1	–	Introduction	
This	thesis	 is	concerned	with	the	role	that	disruption	to	bile	acid	(BA)	signalling,	via	 the	 nuclear	 receptor,	 farnesoid	 X	 receptor	 (FXR),	 may	 play	 in	 the	aetiopathology	of	ileal	Crohn’s	disease	(CD).	This	 introductory	chapter	provides	background	information	on	CD,	 including	our	current	understanding	of	environmental	risk	factors,	the	role	of	the	microbiota	and	the	role	of	the	epithelial	barrier	in	disease	pathogenesis.		The	broader	function	of	FXR,	 including	 BA	 metabolism	 and	 what’s	 already	 known	 about	 its	 immuno-modulatory	role,	is	also	covered.		 	
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1.1	 Crohn’s	disease	Crohn’s	disease	(CD)	was	described	by	a	number	of	different	clinicians	in	the	early	20th	century,	with	case	reports	describing	a	‘regional	enteritis’	affecting	mainly	the	small	bowel,	with	no	evidence	of	mycobacterial	 infection(Dalziel,	 1913,	Crohn	et	al.,	 1932,	 Licharowicz	 and	 Mayberry,	 1988).	 	 The	 eponymous	 title	 of	 ‘Crohn’s	disease’	 was	 adopted	 following	 the	 description	 of	 14	 cases	 of	 terminal	 ileal	inflammation	by	Crohn,	Ginzburg	and	Oppenheimer,	in	the	Journal	of	the	American	Medical	Association	in	1932(Crohn	et	al.,	1932).		In	an	earlier	description	of	what’s	now	 known	 as	 CD,	 the	 Scottish	 surgeon,	 Dalziel,	 writes	 that	 ‘the	 etiology	 of	 the	condition	remains	in	obscurity,	but	I	trust	that	ere	long	further	consideration	will	clear	up	the	difficulty’(Dalziel,	1913).		Long,	further	consideration	has	indeed	since	occurred,	but	unfortunately,	the	aetiology	of	CD	remains	somewhat	obscure.	CD	 is	 one	 of	 two	 major	 forms	 of	 inflammatory	 bowel	 diseases	 (IBD),	 with	ulcerative	 colitis	 (UC)	 being	 the	 other	 form.	 	 IBD	 is	 characterised	 by	 chronic,	relapsing	 inflammation	 of	 the	 gastrointestinal	 (GI)	 tract.	 	 Both	 diseases	 have	distinct	 phenotypes	 and	 some	 shared	 presumed	 aetiological	 features.	  In	 UC,	inflammation	 is	 limited	 to	 the	 superficial	mucosal	 layers	 of	 the	 colon,	 classically	more	severely	affecting	 the	rectum,	whereas	 the	hallmark	of	CD	 is	a	deep,	 trans-mural	 inflammatory	 process	 affecting	 all	 levels	 of	 the	 gut	wall.	 	 Normal	 and	 CD	involved	 areas	 can	 occur	 in	 patches,	 known	 as	 skip	 lesions,	 throughout	 the	 gut.		Whilst	CD	can	affect	any	part	of	 the	gastrointestinal	(GI)	tract	 from	the	mouth	to	the	anus,	it	occurs	most	often	in	the	ileo-caecum.		The	chronic	GI	inflammation	of	CD	can	lead	to	complications	such	as	neoplasia,	strictures,	abscesses	or	fistula.	
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1.1.1	 Epidemiology	The	incidence	and	prevalence	of	CD	is	highest	in	the	Northern	hemisphere,	in	the	industrialised	 nations	 of	 Europe	 and	 North	 America(Molodecky	 et	 al.,	 2012).		However,	 the	 incidence	 of	 IBD	 is	 increasing	 in	 the	 Middle	 East	 and	 in	 Asia,	indicating	 the	 emergence	 of	 the	 disease	 as	 a	 global	 phenomenon(Leong	 et	 al.,	2004).		The	prevalence	of	CD	is	approximately	32	per	1,000	persons	in	Europe	and	North	 America	 with	 an	 annual	 incidence	 of	 approximately	 15-20	 per	 100,000	persons/year(Hanuer,	2006).		Disease	onset	can	occur	at	any	age,	but	the	peak	is	at	15	 to	 30	 years	 of	 age	 with	 a	 second	 small	 peak	 between	 50	 and	 70	 years.		Approximately	10%	of	patients	will	be	diagnosed	before	the	age	of	18(Hedin	et	al.,	2012).	 	 There	 are	 ethnic	 differences	 with	 the	 disease	 being	 more	 common	 in	Caucasians	 and	Ashkenazi	 Jews,	 although	 over	 recent	 years	 other	 ethnic	 groups,	including	African-Americans	and	Asians,	have	started	 to	catch	up(Hanuer,	2006).		This	 finding,	 along	 with	 the	 fact	 that	 immigrants	 from	 low	 prevalence	 to	 high	prevalence	areas	develop	an	increase	risk	for	development	of	the	disease(Probert	et	 al.,	 1992),	 suggests	 that	 environmental	 factors	 are	 important	 in	 disease	pathogenesis.		
	1.1.2	 Aetiopathology	The	 aetiopathology	 of	 CD	 remains	 incompletely	 understood	 but	 is	 complex	 and	multifactorial,	 involving	 defective	 epithelial	 function,	 immune	 dysregulation,	bacterial	 dysbiosis	 and	 other	 environmental	 risk	 factors	 in	 a	 genetically	susceptible	host(Xavier	and	Podolsky,	2007).	 	High	estimates	of	heritability,	with	monozygotic	 twin	 concordances	of	20%	 to	55%	 for	CD	and	15%	 to	18%	 for	UC,	highlight	the	importance	of	genetic	susceptibility	factors(Brant,	2011,	Hedin	et	al.,	2012).		Several	large	genome	wide	association	studies	(GWAS)	have	identified	over	
		 4	
160	 genetic	 loci	 associated	 with	 IBD(Wellcome	 Trust	 Case	 Control	 Consortium,	2007,	 Jostins	 et	 al.,	 2012).	 	 Detailed	 study	 of	 these	 loci,	 many	 of	 which	 overlap	between	CD	and	UC,	has	revealed	novel	molecular	mechanisms	in	the	pathogenesis	of	 IBD.	 	 These	 mechanisms	 include	 dysfunction	 within	 the	 epithelial	 barrier,	impaired	autophagy	and	impairment	of	the	Th17/IL-23	axis(Lees	et	al.,	2011).	Other	 experimental	 evidence	 has	 implicated	 defective	 barrier	 function	 in	 the	pathogenesis	 of	 CD.	 	 Several	 studies	 using	 non-invasive	 techniques	 have	demonstrated	 increased	 epithelial	 permeability	 in	 active	 CD(Soderholm	 et	 al.,	2002,	Soderholm	et	al.,	2004,	Keita	et	al.,	2008).		Recurrent	bacterial	translocation,	presumably	through	a	leaky	epithelium,	has	been	serially	demonstrated(McGuckin	et	 al.,	 2009).	 	 Alterations	 in	 epithelial	 tight-junction	 complexes	 and	 defensin	production	 have	 been	 described(Muniz	 et	 al.,	 2012).	 	 Clinically	 unaffected	 first-degree	 relatives	 of	 patients	 with	 CD	 demonstrate	 increased	 epithelial	permeability(Hedin	 et	 al.,	 2012).	 	 Finally,	 as	 demonstrated	 by	 confocal	 laser	endoscopy,	an	increase	in	ileal	epithelial	permeability	can	detect	disease	relapse	in	patients	with	quiescent	CD(Kiesslich	et	al.,	2012).			It	is	not	clear	whether	epithelial	barrier	function	is	a	cause	or	consequence	of	the	inflammation	associated	with	the	disease.		The	genetic	predisposition	to	impaired	barrier	 function	 suggested	 by	 GWAS	 and	 the	 findings	 in	 unaffected	 first-degree	relatives	would	suggest	the	former.		What	is	clear,	is	the	central	importance	of	the	epithelial	 barrier	 in	 CD	 pathogenesis	 and	 the	 potential	 therapeutic	 role	 of	maintaining	epithelial	homeostasis.	Despite	 these	advances	 in	our	understanding	of	 the	pathogenesis	of	CD,	much	 is	still	to	be	learned.		Much	of	the	heritability	suggested	by	twin	studies	has	not	been	explained	by	GWAS	and	 the	 search	 for	 further	genetic	 susceptibility	 factors	goes	on.	 	 The	 role	 of	 the	 environment,	 and	 particularly	 the	microbiome,	 has	 become	
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increasingly	 recognised	 over	 the	 last	 few	 years(Xavier	 and	 Podolsky,	 2007).			However,	 the	 interaction	of	genetic	 susceptibility	and	environmental	 factors	 that	leads	to	the	development	of	CD	is	still	unknown.	
1.1.3	 Treatment	The	aims	of	 treatment	are	 to	 induce	and	maintain	disease	 remission,	 to	 improve	quality	 of	 life,	 to	 prevent	 the	 development	 of	 complications	 and	 to	 prevent	 or	reduce	 the	 requirement	 for	 surgery.	 	 The	 chronic	 inflammation	 of	 CD	 results	 in	areas	 of	 narrowed,	 irreversibly	 damaged	 bowel	 for	 which	 surgery	 is	 the	 only	treatment.		The	formation	of	fistulas,	para-enteric	abscesses,	perforations	and	even	surgery	itself	can	cause	further	bowel	damage.	The	 current	 pharmaceutical	 armamentarium	 includes	 corticosteroids	 and	immunomodulators	 such	 as	 azathioprine,	 6-mercaptopurine	 (6-MP)	 and	methotrexate.		Over	the	last	20	years,	biological	therapy,	in	the	form	of	antibodies	to	 tumour	 necrosis	 factor-alpha	 (anti-TNFα)	 drugs,	 has	 revolutionised	 the	treatment	of	CD.		Unfortunately,	approximately	50%	of	patients	will	fail	to	respond	to	 optimal	 treatment	with	 anti-TNFα	 drugs	 and	 therefore	 disease	 complications	and	 associated	 morbidity	 remains	 common(Steenholdt	 et	 al.,	 2014).	 	 There	remains	the	need	for	more	efficacious	and	safer	treatments.	
1.2	 Environmental	risk	factors	for	Crohn’s	disease	Epidemiological	 evidence	 suggests	 that	 lifestyle	 and	 environmental	 factors	 are	important	in	the	aetiopathology	of	CD.		The	overall	incidence	of	CD	has	increased	in	 keeping	 with	 dietary	 changes	 in	 Europe	 and	 North	 America(Gibson	 and	Shepherd,	 2005,	 Richman	 and	 Rhodes,	 2013).	 	 In	 addition,	 whilst	 disease	prevalence	 in	 the	 developing	 world	 is	 lower	 than	 in	 the	 developed	 world,	 in	countries	undergoing	industrialisation,	such	as	India	and	The	People’s	Republic	of	
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China,	 the	prevalence	 is	 increasing(Ananthakrishnan,	2013).	 	Finally,	disease	risk	increases	for	immigrants	moving	from	an	area	of	low	prevalence	to	an	area	of	high	prevalence(Probert	et	al.,	1992,	Richman	and	Rhodes,	2013).			Several	 environmental	 risk	 factors	 are	 associated	 with	 CD,	 including	 diet,	 the	intestinal	 flora	 and	 fauna	 (gut	 microbiota),	 exposure	 to	 non-steroidal	 anti-inflammatory	 drugs,	 vitamin-D	 deficiency	 and	 smoking(Cosnes,	 2004,	Ananthakrishnan,	2013).	 	 	CD	is	a	complex,	heterogeneous	disease	and	it	 is	 likely	that	 multiple	 risk	 factors,	 in	 association	 with	 host	 genetic	 risk	 factors,	 are	important	in	disease	pathogenesis.			The	 importance	 of	 the	 gut	 microbiota	 has	 been	 highlighted	 by	 multiple	 large	studies	 that	 have	 identified	 an	 association	 between	 CD	 and	 a	 disruption	 to	 the	microbiome,	 known	 as	 a	 dysbiosis	 (Manichanh	 et	 al.,	 2006,	 Sokol	 et	 al.,	 2006,	Joossens	et	al.,	2011).	 	Alterations	in	dietary	intake	have	been	shown	to	alter	the	constituents	and	diversity	of	the	host	microbiota(G.D.	Wu	et	al.,	2011,	Albenberg	et	al.,	 2012,	 Leone	 et	 al.,	 2013).	 	 Microbes	 within	 the	 GI	 tract	 perform	 important	metabolic	 functions	 for	 the	 host,	 leading	 to	 the	 adoption	 of	 the	 term	 ‘super-organism’	 to	 describe	 the	host	 and	 its	 attendant	microbiota(Swann	 et	 al.,	 2011).		Bile	 acids	 (BA’s)	 have	 been	 shown	 to	 act	 as	 signalling	 molecules	 between	 the	microbiota	 and	 the	 host(Martin	 et	 al.,	 2007,	 de	 Aguiar	 Vallim	 et	 al.,	 2013).		Therefore,	the	dysbiosis	demonstrated	in	CD	may	be	associated	with	a	disruption	to	this	BA	signalling	pathway.	
1.2.1	 Diet		A	western	diet	is	typically	considered	to	be	high	in	animal	fat	and	sugar,	but	low	in	fruit	and	vegetables.		The	evidence	linking	dietary	constituents	to	the	development	of	CD	is	varied	and	should	be	approached	with	some	caution;	much	of	 it	 is	based	
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on	retrospective,	case-control	studies	that	are	 fraught	with	recall	bias.	 	However,	there	is	a	strikingly	conserved	finding	of	an	increase	in	the	consumption	of	refined	carbohydrates	both	in	patients	pre-disease	or	pre-diagnosis	and	for	those	patients	with	established	CD	in	comparison	to	healthy	controls.		In	one	review,	the	authors	describe	12	of	13	 case-control	 studies	 in	which	 refined	 sugars	were	 found	 to	be	consumed	in	excess	in	patients	with	CD(Gibson	and	Shepherd,	2005).		In	a	further	systematic	 review	 of	 case-control	 studies	 a	 positive	 association	 between	 the	diagnosis	of	IBD	and	high	dietary	intakes	of	total	fats,	polyunsaturated	fatty	acids,	omega-6	fatty	acids,	and	meat	was	described(Hou	et	al.,	2011).		Some	studies	have	also	 suggested	 a	 protective	 effect	 for	 dietary	 fibre,	 fruits	 or	 vegetables	 in	 the	development	of	IBD(Ananthakrishnan	et	al.,	2012).	
1.2.2	 Gut	microbiota	The	 human	 gut	 contains	 approximately	 1014	 bacterial	 cells	 with	 vast	 species	diversity	in	health(Fava	and	Danese,	2011).		A	symbiotic	relationship	has	evolved	whereby	 the	 human	 host	 provides	 nutrients	 and	 an	 ecological	 niche	 for	 gut	microbes,	whilst	 in	 return,	 the	microbiota	 perform	metabolic	 functions	 for	 their	host.	 	 In	 this	 regard,	 the	 intestinal	 bacteria	 can	 be	 viewed	 as	 an	 extra,	 ‘virtual’	mammalian	organ	performing	metabolic	functions	for	the	host(Martin	et	al.,	2007,	Swann	 et	 al.,	 2011,	 Leone	 et	 al.,	 2013).	 	 Some	 researchers	 go	 further	 with	 this	theme	with	Sonnenberg	describing	the	human	body	as	‘an	elaborate	vessel	for	the	growth	 and	 spread	 of	 our	 microbial	 inhabitants’(Pollan,	 2013). In	 health,	 the	microbiota	 also	 act	 to	 maintain	 epithelial	 homeostasis	 via	 a	 variety	 of	 immune	regulating	pathways	(see	1.2.4).	Disruption	 to	 the	 microbial	 ecosystem,	 with	 proliferation	 or	 loss	 of	 different	functional	 groups,	 is	 termed	 dysbiosis.	 	 Dysbiosis	 has	 been	 implicated	 in	 many	
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diseases,	 including	 IBD,	Type	2	diabetes	mellitus,	 obesity,	 cardiovascular	disease	and	inflammatory	arthropathies(Cho	and	Blaser,	2012).	There	 is	now	a	 consensus	view	 that	a	dysbiosis	 is	 central	 in	 the	pathogenesis	of	IBD(Huttenhower	 et	 al.,	 2014).	 	 Evidence	 comes	 from	 several	 sources	 including	animal	models,	human	GWAS	data,	clinical	observation	and	direct	analysis	of	 the	microbiome.	 	 In	 multiple	 animal	 models	 of	 IBD,	 mice	 grown	 in	 germ	 free	environments	 will	 not	 develop	 inflammation	 until	 enteric	 bacteria	 are	introduced(Sellon	et	al.,	1998,	Leone	et	al.,	2013).		Many	of	the	160	identified	host	genetic	risk	variants	for	the	development	of	CD,	have	implicated	bacterial	sensing	pathways	 in	 the	 innate	 immune	 system(Jostins	 et	 al.,	 2012).	 	 An	 early	 and	prominent	 breakthrough	 in	 understanding	 the	 pathogenesis	 of	 CD	 was	 the	discovery	 that	 homozygous	 mutations	 within	 the	 nucleotide-binding	oligomerization	 domain-containing	 protein	 2	 (NOD2),	 conferred	 a	 20	 fold	increased	 risk	 for	 developing	 CD(Hugot	 et	 al.,	 2001).	 	 The	 common	 ligand	 for	NOD2	 is	N-acetyl	muramyl	dipeptide	 (MDP),	 from	peptidoglycan	 in	bacterial	 cell	walls.	 	 NOD2	 activation	 is	 thought	 to	 impair	 innate	 immune	 cell	 function	 by	decreasing	nuclear-factor-kappa	B	(NF-κB)	activation,	impair	autophagy	pathways	(important	 in	 handling	 intracellular	 bacteria)	 and	 modulate	 toll-like	 receptor	(TLR)	function(Fritz	et	al.,	2011).		In	the	early	1990’s,	Rutgeerts	described	a	small	cohort	 of	 patients	 in	 whom	 post-operative	 CD	 recurrence	 could	 be	 avoided	 by	diverting	 the	 faecal	 stream	 away	 from	 the	 surgical	 anastomosis(Rutgeerts	 et	 al.,	1991).		This	finding	suggests	that	an	element	of	the	faecal	stream,	presumed	to	be	bacteria,	is	required	to	drive	the	inflammation.		Finally,	several	large	studies	have	measured	 the	 microbiota	 in	 CD,	 both	 by	 bacterial	 culture	 techniques	 and	 by	genetic	sequencing	from	faecal	samples	and	intestinal	mucosal	biopsies(Xavier	and	Podolsky,	2007,	Sokol	et	al.,	2008,	Sokol	et	al.,	2009,	Joossens	et	al.,	2011).		Whilst	
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no	 single	 contributing	 organism	 has	 been	 discovered,	 several	 reproducible	characteristics	have	emerged:	an	increase	in	the	total	bacterial	load	but	with	a	loss	of	biodiversity,	a	proportional	increase	in	the	numbers	of	adherent	bacteria	(such	as	 adherent	 invasive	 Escherichia	 coli)	 and	 a	 reduction	 in	 the	 phylum	firmicutes(Joossens	 et	 al.,	 2011,	 Hedin	 et	 al.,	 2012).	 	 Firmicutes	 species	 include	
Faecalibacterium	prausnitzii,	which	is	thought	to	be	protective	via	the	production	of	the	short	chain	fatty	acid,	butyrate	(see	below).			Most	researchers	accept	that	dysbiosis	 is	associated	with	the	development	of	CD.		Less	clear	is	whether	the	dysbiosis	is	a	cause	or	consequence	of	chronic	intestinal	inflammation.		The	evidence	presented	above	and	the	finding	that	innate	immune	dysfunction	and	epithelial	barrier	function	defects	are	genetic	risk	factors	for	CD,	suggest	the	central	role	for	dysbiosis	in	CD	pathogenesis.	
1.2.3	 Association	between	diet	and	microbiota	Recently,	much	 research	 interest	 has	 focused	 on	 the	 dysbiosis	 associated	with	 a	high	 fat	and/or	high	sugar	diet.	 	Turnbaugh	et	al	developed	a	gnotobiotic	mouse	model,	manipulated	to	harbour	human	intestinal	microbes,	and	demonstrated	that	a	 change	 to	 a	 high	 fat/high	 sugar	 content	 western	 diet	 changed	 the	 microbial	population	within	a	single	day(Turnbaugh	et	al.,	2009).	 	 	 In	humans,	specific	diet	types	 (e.g.	 those	 high	 in	 carbohydrates	 or	 protein)	 are	 associated	 with	 certain	microbial	 enterotypes(G.D.	 Wu	 et	 al.,	 2011).	 	 Faecal	 microbial	 studies	 of	geographically	 diverse	 human	 populations,	 and	 with	 different	 dietary	 habits,	demonstrate	differences	in	microbiota	ecology.		African	children,	with	a	diet	rich	in	fibre,	demonstrate	an	increase	in	the	bacterial	enterotype	Prevotella(De	Filippo	et	al.,	2010).			 In	comparison,	European	children,	with	a	diet	rich	 in	animal	 fats	and	protein,	demonstrate	an	increase	in	Bacteroidetes	sp.(Albenberg	et	al.,	2012).		High	
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fat/high	sugar	 feeding	of	mice	will	 lead	 to	a	dysbiosis	 that	 is	 comparable	 to	 that	seen	in	human	CD(Martinez-Medina	et	al.,	2014).			Interestingly,	when	rats	are	fed	a	diet	enhanced	with	the	primary	BA,	cholic	acid,	changes	 in	 the	 caecal	 microbiota	 are	 induced	 similar	 to	 the	 changes	 associated	with	 a	 diet	 rich	 in	 fat(Islam	 et	 al.,	 2011).	 	 BA’s	 are	 important	 metabolites	 for	certain	gut	microbial	 species.	 	This	 finding	suggests	 that	 the	concentration	of	BA	reaching	the	colon	may	be	a	mechanism	by	which	a	westernised	diet	can	influence	the	microbiota.			
1.2.4	 Microbiota	and	intestinal	homeostasis	The	 intestinal	 mucosa	 and	 microbiota	 are	 in	 close	 contact.	 	 Dendritic	 cells	 (an	antigen	presenting	cell)	sample	gut	bacteria	by	passing	their	dendrites	through	the	tight	 junction	 (TJs)	 of	 gut	 epithelial	 cells.	 	 A	 host	 of	 intra-epithelial	 lymphocytes	and	T-regulatory	cells	(Treg)	maintain	immune	homeostasis,	whilst	the	epithelial	barrier	 forms	an	 impermeable	barrier	 to	 the	microbes.	 	As	discussed	 in	 the	next	sub-sections	(1.2.5	to	1.2.8),	several	possible	pathological	mechanisms	have	been	suggested	 by	 which	 dysbiosis	 is	 thought	 to	 disrupt	 this	 homeostatic	 balance.		These	 mechanisms	 include	 bile	 acid	 dysmetabolism,	 a	 reduction	 in	 butyrate	producing	 bacterial	 species,	 the	 role	 of	 tight	 junction	 proteins	 in	 obesity	 and	specific	pathological	bacteria	(pathobionts),		
1.2.5	 Bile	acid	dysmetabolism	An	 inter-relationship	 exists	 between	 dietary	 intake,	 BA	 metabolism	 and	 the	microbiota.	 	 Microorganisms	 within	 the	 gut	 lumen	 metabolise	 BAs	 prior	 to	 re-uptake	 by	 the	 host.	 	 The	 production	 of	 secondary	 BAs,	 via	 the	 metabolism	 of	primary	 BAs,	 by	 mammalian	 gut	 microbes	 is	 an	 example	 of	 ‘mammalian–microbiotal	co-metabolism’(Nicholson	et	al.,	2005,	Martin	et	al.,	2007).			
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Changes	to	the	diet	or	 the	microbiota	have	been	shown	to	alter	 the	metabolomic	profile	of	a	host	organism	in	a	variety	of	animal	studies.		As	described	above,	rats	fed	 cholic	 acid	will	 demonstrate	 caecal	microbial	 changes	 akin	 to	 feeding	with	 a	high	fat	diet(Islam	et	al.,	2011).		Germ	free	mice	demonstrate	an	increase	in	certain	bile	acid	metabolites	on	colonisation	with	gut	microbes(Claus	et	al.,	2011).	 	 In	an	animal	model,	antibiotic	manipulation	of	the	microbiota	changes	the	systemic	BA	pool	with	 an	 increase	 in	 the	 concentration	 of	 taurine-conjugated	 BAs	 in	 diverse	organs	such	as	the	liver,	kidney,	heart	and	blood	plasma(Swann	et	al.,	2011).			Duboc	 et	 al	 studied	 faecal	 and	 serum	 concentrations	 of	 different	 BA	 species	 in	patients	with	 colonic	 IBD	 (CD	 and	UC)(Duboc	 et	 al.,	 2013).	 	 Patients	with	 active	IBD	demonstrated	a	BA	dysmetabolism	associated	with	the	dysbiosis	seen	in	IBD.		In	 comparison	 with	 controls,	 patients	 with	 disease	 demonstrated	 impaired	deconjugation,	desulfation	and	transformation	of	BAs.		The	study	by	Duboc	et	al.	is	interesting	in	that	it	provides	an	association	between	active	IBD,	dysbiosis	and	BA	dysmetabolism.		The	authors	suggest	that	the	increase	in	sulfated	BAs	reaching	the	colon	is	potentially	pro-inflammatory.			However,	an	alternative	explanation	to	the	mechanistic	conclusion	by	Duboc	et	al	may	be	that	a	dysbiosis-induced	disruption	to	BA	signalling	pathways	provides	a	pro-inflammatory	 stimulus.	 	 BAs	 act	 as	 signalling	 molecules	 via	 the	 nuclear	receptor,	 FXR	 and	 also	 the	 G-protein	 coupled	 receptor,	 TGR5.	 	 These	 signalling	pathways	are	explored	in	more	detail	later	in	this	chapter.		However,	activation	of	FXR	 is	 known	 to	 have	 diverse	 downstream	 effects,	 including	 regulation	 of	 BA	metabolism,	 but	 also	 in	 immunomodulation(de	 Aguiar	 Vallim	 et	 al.,	 2013).		Fascinatingly,	 in	 a	 study	of	diet–induced	 fatty	 liver	disease,	 a	 group	has	 recently	demonstrated	that	an	antibiotic-associated	dysbiosis	was	able	to	alter	the	ileal	BA	
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composition	 with	 subsequent	 inhibition	 of	 intestinal	 FXR	 signalling(Jiang	 et	 al.,	2015).			This	 thesis	 is	 concerned	 with	 investigating	 further	 the	 role	 that	 disrupted	 BA	signalling,	via	FXR,	may	play	in	the	pathogenesis	of	ileal	CD.		It	is	possible	that	the	dysmetabolism	 of	 BAs	 associated	 with	 an	 IBD	 dysbiosis	 disrupts	 this	 signalling	pathway,	predisposing	to	inflammation	within	the	ileum.		
1.2.6	 Short	chain	fatty	acids	(SCFAs)	In	 the	 gut,	 certain	 bacterial	 species	 ferment	 dietary	 fibre	 to	 produce	 the	 short	chain	 fatty	 acid	 (SCFA),	 butyrate.	 	 The	 dysbiosis	 associated	 with	 CD	 is	characterised	 by	 a	 reduction	 in	 firmicutes	 phyla,	 including	 Faecalibacterium	
prausnitzii,	bifidobacteria	and	clostridia	sp.(Sokol	et	al.,	2008,	Joossens	et	al.,	2011,	Eeckhaut	et	al.,	2013).		These	bacterial	species	are	all	butyrate	producing.		SCFAs,	 including	butyrate,	are	an	 important	source	of	energy	 for	colonocytes.	 	 In	addition,	 butyrate	 is	 thought	 to	maintain	 gut	 epithelial	 homeostasis	 by	 inducing	the	production	of	mucous	by	goblet	cells	within	the	epithelial	 layer,	 inducing	the	production	 of	 IgA,	 by	 facilitating	 Treg	 differentiation	 and	 by	 inhibiting	 NF-κB(Thorburn	et	al.,	2014).	 	Sokol	and	colleagues	demonstrated	 that	F.	prausnitzii	or	its	supernatant	could	inhibit	the	activation	of	NF-κB	by	IL-1β	in	a	cell	model	and	can	attenuate	colitis	in	the	TNBS	mouse	model(Sokol	et	al.,	2008).	
1.2.7	 Obesity	and	tight	junction	proteins	Like	CD,	obesity	has	been	associated	with	a	dysbiosis	and	 is	also	recognised	as	a	systemic	 inflammatory	 disorder,	 as	 measured	 by	 increased	 levels	 of	 circulating	inflammatory	 cytokine	 such	 as	 TNFα(Hotamisligil	 et	 al.,	 1995).	 	 Both	 obese	humans	 and	 obese	 mouse	 models	 demonstrate	 a	 dysbiosis,	 which	 incredibly	 is	transmissible;	 GF	 mice	 colonised	 with	 obese	 mouse	 microbiota	 will	 gain	 more	
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body	fat	compared	to	normal	controls(Turnbaugh	et	al.,	2009).		In	animal	studies,	a	high	fat	diet	increased	the	amount	of	plasma	circulating	lipo-polysaccharide	(LPS),	a	constituent	of	bacterial	cell	walls(Cani	et	al.,	2007).	 	On	antibiotic	manipulation	of	the	microbiota,	this	endotoxaemia	was	abolished.		Epithelial	barrier	dysfunction	has	been	implicated	in	the	aetiopathogenesis	of	CD.		Interestingly,	Cani	et	al,	were	able	to	demonstrate,	in	their	obese	mouse	model,	a	reduction	in	the	expression	of	genes	 encoding	 protein	 involved	 in	 the	 epithelial	 tight	 junction	 (TJ)	 complex,	including	zonulla-occludens	(zo-1)	and	occludin(Cani	et	al.,	2008).	 	The	reduction	in	 these	TJ	proteins	was	 associated	with	 the	observed	endotoxaemia	 induced	by	high	fat	feeding	and	was	again	abolished	with	antibiotic	treatment.	
1.2.8	 Specific	pathobionts	
Escherichia	 coli	 has	 been	 associated	 with	 CD	 by	 several	 research	 groups,	particularly	in	ileal	CD.		E	coli	is	found	within	granuloma	in	both	early	and	chronic	CD	and	has	been	described	as	adherent,	 invasive	E	coli	(AIEC),	given	its	ability	to	adhere	 and	 invade	 epithelial	 cell	 lines	 and	 also	 its	 ability	 to	 replicate	 within	macrophages(Glasser	et	 al.,	 1999,	Roberts	et	al.,	2010).	 	Recently,	AIEC	has	been	shown	 to	 be	 able	 to	 induce	 a	 chronic	 colitis	 in	 a	 genetically	 susceptible	 mouse	model	(toll	like	receptor	5	deficient)(Chassaing	et	al.,	2014).		In	addition,	AIEC	can	also	 induce	 epithelial	 barrier	 dysfunction,	 by	 upregulation	 of	 the	 leaky	 tight	junction	 protein	 claudin	 2,	 in	 a	 transgenic	 mouse	model,	 engineered	 to	 express	human	 carcinoembryonic	 antigen-related	 cell	 adhesion	 molecule	(CEACAM)(Denizot	et	al.,	2012).	A	molecular	mechanism	linking	diet	and	dysbiosis	to	the	development	of	IBD	has	been	suggested	by	Devkota	and	colleagues(Devkota	et	al.,	2012).	 	Mice	 fed	a	diet	rich	 in	 saturated	milk	 fat,	but	not	when	 fed	polyunsaturated	 fat,	demonstrated	a	
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bloom	in	a	novel	pathobiont,	Bilophila wadsworthia, mediated by an increase	 in	taurine	conjugated	bile	acids	(BAs).		An	overgrowth	of	B.	wadsworthia	was	able	to	induce	 a	 more	 severe,	 early	 onset	 colitis	 in	 the	 genetically	 susceptible	 IL-10	knockout	mouse.	In	 summary,	 a	 high-fat/high-sugar	 western	 diet	 has	 been	 linked	 both	epidemiologically	 and	 in	 case	 control	 studies	 with	 an	 increase	 in	 the	 risk	 of	developing	IBD.		A	western	style	diet	induces	changes	to	the	microbiome	and	this	dysbiosis	has	been	implicated	in	the	pathogenesis	of	IBD	via	a	variety	of	different	pathological	 mechanisms,	 including	 BA	 dysmetabolism,	 a	 reduction	 in	 butyrate	producing	bacteria,	an	 increase	 in	AIEC	and	epithelial	barrier	dysfunction	due	 to	alterations	in	TJ	protein	expression.	
1.3	 Bile	acids	BAs	 are	 amphipathic	 (contain	 both	 hydrophobic	 and	 hydrophilic	 components),	steroid	compounds	synthesised	by	the	catabolism	of	cholesterol	in	the	liver.	 	BAs	are	 a	 major	 constituent	 of	 bile	 juice,	 which	 also	 contains	 water,	 bile	 pigment,	cholesterol	 and	 other	 fats.	 	 Traditionally,	 the	 physiological	 role	 of	 BAs	 has	 been	viewed	as	simply	that	of	a	detergent	molecule,	facilitating	the	adsorption	of	dietary	fats.	 	Recently	a	broader	role	for	BAs	has	emerged	with	the	recognition	that	they	can	act	as	signaling	molecules.	
1.3.1	 Synthesis	and	structure	New	BAs	are	synthesised	from	cholesterol	 in	the	liver	and	are	known	as	primary	BAs,	in	the	human	being	cholic	acid	(CA)	and	chenodeoxycholic	acid	(CDCA).		Prior	to	excretion	into	the	biliary	canalicular	network	within	the	liver,	primary	BAs	are	conjugated	 to	 the	 amino-acids	 taurine	 or	 glycine,	 to	 increase	 their	solubility(Gadaleta	et	al.,	2010).		The	neosynthesis	and	subsequent	conjugation	of	
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BAs	requires	approximately	17	different	enzymatic	steps.		On	reaching	the	caecum,	primary	BAs	are	metabolised	by	enteric	bacteria.		Conjugated	primary	BAs	are	first	deconjugated	 by	 bacterial	 bile	 salt	 hydrolase	 (BSH).	 	 Then,	 further	dehydroxylation,	 dehydrogenation	 and	 sulfation reactions	 occur,	 to	 produce	 the	secondary	 BAs	 deoxycholic	 acid	 (DCA)	 and	 lithocholic	 acid	 (LCA)	 (see	 figure	1.1)(Jones	 et	 al.,	 2008).	 	 The	 position	 of	 hydroxyl	 groups	 on	 the	 steroid	 ring	structure	determines	BA	classification	and	alters	their	chemical	property	in	terms	of	 hydrophobicity,	 but	 also	 in	 signalling	 capacity(Payne	 et	 al.,	 2008).	 	 CDCA	(primary	BA)	demonstrates	the	highest	affinity	for	FXR,	with	CA	and	the	secondary	BAs	demonstrating	less	affinity(W.	Wang	et	al.,	1999).	
	
Figure	1.1;	The	structure	of	primary	and	secondary	bile	acids	 (BAs).	 	Primary	BAs	 (cholic	acid	
and	chenodeoxycholic	acid)	are	synthesised	and	conjugated	to	either	taurine	or	glycine	in	the	
liver.	 	 In	 the	 terminal	 ileum,	a	deconjugation	 reaction	occurs.	 	 Primary	BAs	are	 subsequently	
metabolised	to	the	secondary	BAs	deoxycholic	acid	and	lithocholic	acid	by	bacteria	within	the	
caecum	(modified	from	Payne	et	al.,	Clinical	and	Experimental	Gastroenterology,	2008) 
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1.3.2	 Entero-hepatic	circulation	Conjugated,	 primary	 BAs	 are	 avidly	 re-absorbed	 by	 enterocytes	 in	 the	 terminal	ileum	 with	 95-97%	 returning	 via	 the	 portal	 venous	 system	 back	 to	 the	liver(Hofmann,	 2009,	 Gadaleta	 et	 al.,	 2010).	 	 Absorption	 of	 BAs	 from	 the	 ileal	lumen	 is	 driven	 by	 the	 Apical	 Sodium-dependent	 Bile	 acid	 Transporter	 (ASBT).		BAs	are	transported	through	the	enterocyte	by	the	Ileal	Bile	Acid	Binding	Protein	(IBABP)	and	secreted	at	 the	basolateral	membrane	by	the	heterodimeric	Organic	Solute	 Transporters	 (OSTα/OSTβ).	 	 Hepatocytes	 actively	 re-absorb	 BAs	 and	 re-circulate	 them	 back	 into	 the	 bile	 canaliculi.	 	 Individual	 bile	 salts	 complete	 this	enterohepatic	circulation	several	times	a	day	(see	figure	1.2).	Neosynthesis	of	BAs	 is	 a	highly	entropic	pathway.	 	The	efficient	 re-circulation	of	BAs	means	 that	 the	 total	 proportion	 of	 the	BA	 pool	 that	 is	 newly	 synthesised	 is	low.		Interruption	to	the	re-absorption	of	BAs	increases	production	and	also	causes	an	irritant	diarrhoea	due	to	excess	BA	passing	into	the	colon(Hofmann,	2009).	
1.3.3	 Bile	Acids	as	signalling	molecules	The	 discovery	 of	 BA	 receptors	 throughout	 the	 mammalian	 body	 revealed	 that	these	sterol	compounds	have	important	physiological	roles	as	signalling	molecules.		The	 nuclear	 receptor,	 farnesoid	 X	 receptor	 (FXR)	 and	 the	 Transmembrane	 G-protein	coupled	bile	acid	receptor	(TGR5)	have	been	found	to	have	important	roles	in	controlling	lipid	and	glucose	homeostasis(Watanabe	et	al.,	2004,	Katsuma	et	al.,	2005).		The	expression	of	FXR	is	concentrated	in	the	liver	and	GI	tract,	particularly	in	 the	 ileum.	 	BA	receptors	have	also	been	 found	 in	diverse	organs	 including	 the	kidneys,	 the	 heart	 and	 vascular	 endothelium(Khurana	 et	 al.,	 2011).	 	 The	 total	signalling	 capacity	 of	 BAs	 throughout	 the	 whole	 organism,	 however,	 remains	unknown(Swann	et	al.,	2011).	
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Figure	 1.2;	 Schematic	 to	 demonstrate	 the	 enterohepatic	 circulation	of	 primary	BAs.	 	 BAs	are	
excreted	into	the	proximal	small	bowel	via	the	biliary	system	(1);	in	the	terminal	ileum,	BAs	are	
actively	re-absorbed	by	ASBT	(2);		BAs	are	transported	through	the	enterocyte	cytoplasm	by	the	
transport	protein	IBABP	(3);		BAs	bind	to	FXR	and	are	translocated	to	the	nucleus	where	bound	
FXR	 acts	 as	 a	 transcription	 factor	 (4);	 BAs	 are	 exported	 to	 the	 portal	 system	 via	 OSTα/β	
heterodimer	and	return	to	the	liver	for	re-circulation	(5).	
1.4	 Farnesoid	X	receptor		
1.4.1	 Structure	and	function	The	nuclear	 receptors	are	a	 superfamily	of	 ligand-activated	 receptors	 that	 act	 as	key	 regulators	 in	 a	 diverse	 range	 of	 cell	 function,	 including	 development,	differentiation	 and	 metabolism(Mangelsdorf	 et	 al.,	 1995).	 	 On	 activation	 by	lipophilic	 hormones,	 such	 as	 thyroxine,	 estrogen	 or	 vitamin	 D,	 the	 receptor	localises	to	the	nucleus	to	act	as	a	transcription	factor.		The	nuclear	receptors	are	characterised	 by	 a	 conserved	 structure	 featuring	 a	 central	 DNA	 binding	 domain	(DBD)	 which	 binds	 specific	 response	 elements,	 a	 C-terminal	 hormone	 specific	
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ligand	 binding	 domain	 (LBD)	 and	 an	 N-terminal	 transactivation	 domain	 (which	interacts	with	other	regulatory	proteins).		FXR,	 identified	 in	 1995	 as	 an	 orphan	 receptor,	 was	 named	 when	 a	 supra-physiological	 concentration	 of	 farnesol,	 an	 intermediate	 in	 the	 mevalonate	pathway,	 was	 found	 to	 demonstrate	 weak	 agonism(Modica	 et	 al.,	 2010).	 	 The	discovery	 that	 primary	 bile	 acids	were	 the	 natural,	 endogenous	 ligands	 for	 FXR	was	reported	by	several	groups	at	the	turn	of	the	century(Makishima	et	al.,	1999,	Parks	et	al.,	1999).	 	Two	genes,	NR1H4	and	NR1H5,	encode	for	two	different	FXR	isoforms,	 FXRα/β,	 although	 the	 FXRβ	 isoform	 is	 a	 pseudogene	 in	 humans	 and	primates	 and	 its	 physiological	 function	 remains	 unknown(Gadaleta	 et	 al.,	 2010).		On	activation	by	primary	BA’s,	FXR	forms	an	obligate	heterodimer	with	retinoic	x	receptor	(RXR)	to	become	functional	(see	figure	1.3).		The	DBD	recognises	a	motif	of	 repeated	 inverted	 response	 elements	 of	 AGGTCA	 separated	 by	 a	 single	nucleotide	(the	DNA	response	element).		 	
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Figure	1.3;	Schematic	representation	of	the	FXR	receptor.		FXR	receptor	acts	as	a	heterodimer	
with	RXR.		Following	activation	by	primary	BA	(CDCA	or	CA),	which	binds	to	the	ligand	binding	
domain	(LBD),	the	receptor	binds	to	its	DNA	binding	domain	(DBD)	and	acts	as	a	transcription	
factor	for	multiple	downstream	genes	(including	IBABP	and	SHP).		See	text	for	more	detail.	Activation	of	FXR	by	primary	BA’s	has	several	downstream	effects.	 	FXR	 is	a	key	regulator	of	BA	metabolism.		In	addition,	FXR	is	involved	in	the	control	of	glucose	metabolism,	lipid	metabolism	and	in	attenuating	inflammation	(see	section	1.4.3).	FXR	 is	most	widely	expressed	 in	 the	 liver	and	GI	 tract,	with	mRNA	 levels	of	FXR	three	times	higher	in	the	ileum,	the	site	of	active	BA	absorption,	than	elsewhere	in	the	 gut(Inagaki	 et	 al.,	 2006).	 	 Within	 the	 ileum,	 FXR	 is	 expressed	 in	 the	 villous	epithelium,	 with	 highest	 levels	 in	 the	 inter-villous	 region,	 with	 little	 or	 no	expression	in	the	crypts.	
1.4.2	 FXR	is	a	key	regulator	of	bile	acid	metabolism	FXR	 is	 a	 key	 regulator	 of	 BA	metabolism,	 acting	 to	 reduce	 BA	 production	when	activated	 by	 BAs	 in	 the	 terminal	 ileum(Modica	 et	 al.,	 2010).	 	 Activation	 of	 FXR	
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increases	 expression	of	 IBABP,	OSTα/β,	 fibroblast	 growth	 factor	19	 (FGF19)	 and	small	 heterodimer	 partner	 (SHP).	 	 The	 hormone	 FGF19	 completes	 a	 negative	feedback	loop	to	the	liver,	where	it	acts	to	inhibit	neosynthesis	of	BAs.		FGF19	also	inhibits	 the	 contraction	 of	 the	 gallbladder,	 and	 pancreatic	 exocrine	 function,	 to	impair	 the	 excretion	 of	 further	 bile	 and	 digestive	 enzymes	 into	 the	 duodenum.		This	process	has	been	described	as	the	‘ileal	brake’,	acting	as	a	signal	to	represent	progression	from	a	fed	to	a	fasting	state.		SHP	is	a	nuclear	receptor	that	acts	as	an	inhibitory	 protein,	 via	 the	 enzymes	 CYP7A1	 and	 CYP8B1,	 to	 downregulate	 the	neosynthesis	of	BA’s(Goodwin	et	al.,	2000).		
1.4.3	 FXR	and	IBD	The	 observation	 that	 a	 decrease	 in	 bile	 acids	 within	 the	 small	 bowel	 leads	 to	bacterial	 overgrowth	 has	 been	 recognised	 for	 many	 years(Berg,	 1995).	 	 This	observation	has	been	demonstrated	in	a	bile	duct	ligation	model	in	mice,	in	which	no	bile	acids	reach	 the	small	bowel,	and	also	 in	humans	with	 liver	cirrhosis	who	secrete	 smaller	 volumes	 of	 bile	 acid(Lorenzo-Zuniga	 et	 al.,	 2003,	 Ogata	 et	 al.,	2003).	 	In	the	bile	duct	ligation	model,	bacterial	proliferation,	mucosal	injury	and	bacterial	translocation	is	reversed	by	the	oral	administration	of	bile	acids.		Primary	bile	acids	are	only	weakly	bactericidal	and	therefore	an	alternative	mechanism,	by	which	BAs	could	control	bacterial	overgrowth,	must	be	responsible.	In	 a	 landmark	 study,	 Inagaki	 et	 al	 were	 able	 to	 demonstrate	 that	 BAs	 could	regulate	 an	anti-inflammatory	 response	via	FXR	 in	 the	 terminal	 ileum(Inagaki	 et	al.,	 2006).	 	 A	 genetically	modified	mouse	with	 low	 levels	 of	 endogenous	BA	was	treated	with	an	FXR	agonist	and	mRNA	expression	 from	the	 ileum	was	analysed.		Included	within	several	genes	whose	expression	was	increased	by	the	FXR	agonist,	were	 pathways	 involved	 in	 mucosal	 defence	 including	 iNOS	 (inducible	 nitrous	
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oxide	 synthase),	 IL-18,	 Angiogenin	 and	 Carbonic	 anhydrase	 12.	 	 In	 the	 bile	 duct	ligation	model,	the	FXR	agonist	also	protected	the	epithelial	barrier	and	decreased	the	number	of	bacteria	isolated	from	mesenteric	lymph	nodes.	Studies	 of	 FXR	 knockout	 mice	 have	 provided	 further	 evidence	 as	 to	 the	 anti-inflammatory	 role	 of	 FXR(Vavassori	 et	 al.,	 2009).	 	 FXR	 knockout	 mice	 do	 not	develop	 a	 de-novo	 colitis.	 	 However,	 as	 they	 age,	 histology	 of	 colonic	 mucosa	demonstrates	an	increase	in	collagen	deposition	within	the	lamina	propria	and	an	increase	 in	 the	 number	 of	 infiltrating	 inflammatory	 cells,	 particularly	macrophages.	 	 Cells	 isolated	 from	 the	 colon	 demonstrate	 an	 increase	 in	 the	expression	 of	 several	 pro-inflammatory	 and	 pro-fibrotic	 genes	 including	 tumour	necrosis	factor-α	(TNFα),	interleukin-1β	(IL-1β),	interferon-γ	(IFNγ),	transforming	growth	 factor-β	 (TGFβ),	 α1-collagen,	 tissue	 inhibitor	 of	 metalloproteinase-1	(TIMP-1)	and	α-smooth	muscle	actin	(αSMA).			The	two	common	mice	models	for	colitis	are	the	TNBS	(intra-rectal	administration	of	 trinitrobenzenesulfonic	 acid)	 model	 and	 the	 DSS	 (oral	 adminsitration	 of	dextransodiumsulfate)	model.	 	 In	 these	models,	normal	wild	type	(WT)	mice	will	develop	 a	 relatively	 mild	 colitis.	 	 However,	 FXR	 knockout	 mice	 exposed	 to	 the	irritant	will	develop	a	much	more	severe	inflammatory	condition(Vavassori	et	al.,	2009).		Gadaleta	et	al.	were	able	to	demonstrate	that	treatment	with	6-ethyl-CDCA	(INT-747,	 a	 semisynthetic	 FXR	 agonist)	 significantly	 reduced	 the	 inflammatory	process	in	both	of	the	colitis	models	in	WT,	but	not	FXR	knockout	mice(Gadaleta	et	al.,	2011b).		In	the	same	paper,	the	authors	also	demonstrated	that	FXR	activation	rendered	 several	 different	 immune	 cell	 types	 (macrophages,	 peripheral	 blood	mononuclear	 cells	 [PBMC],	 dendritic	 cells)	 refractory	 to	 stimulation	 with	 lipo-polysaccharide	(LPS),	a	bacterial	cell	wall	component,	measured	by	a	reduction	in	the	 production	 of	 TNFα.	 	 More	 recently,	 it	 has	 been	 demonstrated	 that	 FXR	
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agonism	 reduces	 the	 LPS-induced	 production	 of	 pro-inflammatory	 cytokines	 by	macrophages,	 whilst	 maintaining	 the	 production	 of	 anti-inflammatory	 IL-10(Haselow	et	al.,	2013).	In	patients	with	Crohn’s	colitis,	FXR	mRNA	levels	were	found	to	be	lower	in	areas	of	 macroscopically	 inflamed	 colon	 compared	 with	 areas	 that	 were	normal(Vavassori	et	al.,	2009).		Additionally,	the	activity	of	FXR	(by	measurement	of	downstream	gene	target	SHP)	 is	reduced	 in	the	 ilea	of	patients	with	quiescent	colonic	CD(Nijmeijer	et	al.,	2011).	Particularly	for	patients	with	CD,	fibrosis	within	the	GI	tract	is	a	significant	clinical	problem.	 	 Progressive	 fibrosis	 leads	 to	 stenosis	 of	 the	 gut	 lumen	 causing	obstruction,	often-requiring	recourse	to	surgical	resection	of	the	fibrosed	area.		As	above,	 the	 antifibrotic	 properties	 of	 FXR	 are	 suggested	 in	 the	 observation	 by	Vavasori	 et	 al	 that	 cells	 isolated	 from	 the	 colonic	mucosa	 of	 FXR	 knockout	mice	demonstrate	an	 increase	 in	 the	expression	of	pro-fibrotic	 cytokines	 (e.g.	TIMP-1,	αSMA,	TGFβ).		Further	evidence	is	provided	by	animal	research	in	liver	fibrosis	on	the	 function	 of	 hepatic	 stellate	 cells	 (HSCs)(Fiorucci	 et	 al.,	 2005,	 Renga	 et	 al.,	2011).		In	response	to	an	inflammatory	insult,	HSCs	undergo	a	phenotypic	change	to	 an	 extracellular	matrix	 producing,	myofibroblast	 like	 cell.	 	 In	 a	mouse	model,	treatment	with	an	FXR	agonist	promoted	a	quiescent	HSC	phenotype,	which	more	readily	underwent	apoptosis	and	was	inhibited	from	becoming	myofibroblast	like.		Nuclear	 factor	 kappa	 B	 (NF-κB)	 is	 a	 central	 nuclear	 receptor	 in	 both	 acute	 and	chronic	 inflammatory	 processes.	 	 NF-κB	 is	 activated	 via	 a	 variety	 of	 pathways,	including	 stimulation	 with	 LPS	 and	 TNFα,	 to	 upregulate	 a	 variety	 of	 pro-inflammatory	genes,	such	as	IL-1β,	IL-6,	TNFα	and	IL-8.		Activation	of	FXR	inhibits	the	expression	of	these	NF-κB	controlled	inflammatory	genes	in	both	cell	line	and	primary	tissue	culture(Y.	D.	Wang	et	al.,	2008).		However,	there	is	also	interesting	
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data	 from	 cell-line	 and	 animal	 models	 to	 suggest	 that	 FXR	 and	 NF-κB	mutually	antagonise	each	other(Gadaleta	et	al.,	2011a).	 	 In	 this	model,	 increasing	 levels	of	NF-κB	will	inhibit	FXR,	leading	to	less	repression	of	NF-κB	and	further	inhibition	of	FXR,	in	a	cycle	representing	chronic	inflammation.	
1.4.4	 FXR	agonists	The	 role	 of	 FXR	 in	 the	 metabolism	 of	 glucose,	 lipids	 and	 cholesterol	 and	 in	inflammation,	 identify	 it	 as	 a	potential	 therapeutic	 target.	 	 Several	 agonists	 have	been	developed,	three	of	which	are	used	in	the	experiments	within	this	thesis.		The	most	 clinically	 advanced	 therapeutic	 FXR	 agonist	 is	 INT747	 (Intercept	Pharmaceuticals,	New	York,	 U.S.A.).	 	 INT747	 is	 a	 steroidal,	 semi-synthetic	 BA,	 in	which	 CDCA	 has	 been	 modified	 by	 the	 addition	 of	 an	 alkyl	 group	 (6α-ethyl	chenodeoxycholic	 acid,	 6-ECDCA)	 to	 form	 a	 more	 potent	 agonist	 (EC50	0.1μM)(Pellicciari	 et	 al.,	 2002).	 	 INT747	 has	 entered	 phase	 III	 trials	 in	 the	treatment	 of	 primary	 biliary	 cirrhosis	 and	 demonstrated	 improved	 histological	scoring	 in	 a	 phase	 II	 trial	 for	 the	 treatment	 of	 non-alcoholic	 fatty	 liver	 disease	(NAFLD)(Nevens	et	al.,	2014,	Neuschwander-Tetri	et	al.,	2015).			INT747	was	used	in	 this	 thesis	under	a	product	 licence	 from	 Intercept	Pharmaceuticals.	 	However,	the	compound	is	now	commercially	available	as	a	generically	produced	molecule.		Hence,	 6-ECDCA,	 the	 biochemically	 correct	 notation,	 is	 used	 to	 represent	 the	Intercept	FXR	agonist	throughout	the	thesis.	Non-steroidal,	 fully	 synthetic	 agonists	 have	 also	 been	developed,	 the	 first	 patent	being	GW4064	(GlaxoSMithKline)	in	2000(Crawley,	2010).	 	This	compound	is	not	in	use	 in	clinical	 trials,	has	greater	potency	than	CDCA	(EC50	0.07μM)	and	can	be	commercially	 obtained	 from	 Sigma-Aldrich	 for	 experimental	 use.	 	 The	 final	 FXR	agonist,	 used	 in	 chapter	 3,	 is	 a	 non-steroidal	 compound,	 manufactured	 as	 a	
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modification	 of	 GW4064,	 known	 as	 Px-102	 (Phenex	 Pharmaceuticals	 AG,	Ludwigshafen,	 Germany).	 	 Px-102	 has	 demonstrated	 some	 efficacy	 in	 the	treatment	of	NAFLD	in	mouse	models(Hambruch	et	al.,	2013).		
1.4.5	 TGR5	The	 G-protein	 coupled,	 transmembrane	 receptor	 TGR5	 is	 expressed	 mainly	 in	adipose	 tissue	 and	 muscle,	 but	 expression	 has	 also	 been	 demonstrated	 in	monocytes	and	rat	colonocytes(Sato	et	al.,	2008,	Ward	et	al.,	2013).		In	contrast	to	FXR,	the	major	endogenous	TGR5	ligands	are	the	secondary	BAs,	LCA	and	DCA.		BA	signalling	via	TGR5	has	been	implicated	in	the	modulation	of	energy	expenditure,	glucose	metabolism	and	colonic	motility(Thomas	et	 al.,	 2009,	Ward	et	 al.,	 2013).		An	immuno-regulatory	role	has	been	suggested	by	the	finding	that	TGR5	activated	monocytes	are	less	sensitive	to	LPS	induced	stress(Yoneno	et	al.,	2013).	This	 thesis	 has	not	 explored	 the	 role	 of	TGR5	 in	 the	pathogenesis	 of	 CD.	 	 I	 have	chosen	 to	 concentrate	 on	 the	 role	 of	 FXR	 alone	 as:	 i)	 there	 is	 more	 scientific	evidence	concerning	 the	overall	 immuno-modulatory	role	of	FXR,	especially	with	respect	to	IBD;	and	ii)	TGR5	is	expressed	in	the	colon,	not	the	ileum,	and	so	is	less	likely	to	be	involved	in	the	pathogenesis	of	ileal	CD.		However,	the	role	of	TGR5	in	the	potential	pathogenesis	of	IBD	deserves	further	research.	
1.5	 Small	bowel	epithelium	The	epithelium	of	 the	GI	 tract	 is	 the	 largest	 surface	area	exposed	 to	 the	external	environment(Suzuki,	 2013).	 	 Impressively,	 it	 functions	 as	 a	 single	monolayer	 to	control	 the	absorption	of	nutrients,	 salts	and	water,	whilst	simultaneously	acting	as	 a	 physical	 barrier	 to	 the	 trillions	 of	 bacteria	 and	 other	 toxins	 within	 the	 gut	lumen.	 	The	 small	bowel	epithelium	 is	organised	 into	huge	numbers	of	villi	with	crypts	 (of	 Lieberkuhn)	 spaced	 at	 the	 base	 of	 the	 villi(Tesori	 et	 al.,	 2013).	 	 The	
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epithelial	 lining	 has	 a	 high	 rate	 of	 turnover	 with	 enterocytes	 shedding	approximately	 every	 five	 days.	 	 This	 high	 rate	 of	 turnover	 is	 controlled	 by	multipotent	columnar	stem	cells	that	reside	in	base	of	the	crypt	and	divide	to	form	daughter	cells	that	differentiate	as	they	migrate	into	the	villi.		Cells	differentiate	to	form	 a	 variety	 of	 functionally	 distinct	 cell	 types.	 	 Enterocytes	 are	 the	major	 cell	type	of	the	epithelium	and	are	responsible	for	the	absorption	of	nutrients	and	the	formation	of	 a	 selectively	permeable	physical	 barrier	 via	 tight	 cell-cell	 junctions.		Goblet	 cells	 produce	 mucous	 which	 lines	 the	 apical	 surface	 of	 the	 epithelium	throughout	 the	 GI	 tract.	 	 Enteroendocrine	 cells	 produce	 gut	 hormones	 that	 act	either	locally	or	on	the	enteric	nervous	system.		Paneth	cells	remain	within	crypts,	rather	 than	migrating	 into	 the	villous,	 and	produce	antimicrobial	 factors	 such	as	alpha-defensins.		Specialised	M	(or	microfold)	cells,	clustered	over	an	aggregation	of	 lymphoid	tissue	(a	Peyer’s	patch),	sample	 luminal	antigens	 for	presentation	to	the	immune	system.		
1.5.1	 The	epithelial	barrier	To	 function	 as	 a	 selectively	 permeable	 barrier,	 the	 epithelium	 transports	substances	 via	 two	 routes.	 	 	 The	 cell	 membrane	 is	 relatively	 impermeable	 and	nutrients,	 such	 as	 sugars,	 fats	 and	 amino	 acids,	 are	 actively	 absorbed	 via	 a	transcellular	route(Suzuki,	2013).		Water	and	electrolytes,	however,	are	absorbed	via	 a	 paracellular	 route,	 the	 flow	 of	 which	 is	 controlled	 by	 an	 apical	 junction	complex	 composed	 of	 tight	 junctions	 (TJ)	 and	 adherens	 junctions	 (AJ).	 	 The	 TJ	protein	 complex	 consists	 of	membrane	 spanning	 proteins,	 occludin	 and	 claudin,	attached	 to	 cytosolic	 proteins,	 zonulla	 occludens	 1	 (Zo-1)	 and	 the	cytoskeleton(Capaldo	and	Nusrat,	2009).		The	TJ	forms	around	the	apical	border	of	the	cell,	facilitating	polarisation	of	the	epithelial	layer	by	separating	the	apical	and	
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basolateral	 surfaces.	 	 The	 TJ	 acts	 as	 a	 sophisticated	 barrier	 to	 the	 intercellular	space	 by	 restricting	 the	 passage	 of	 gut	 bacteria,	 whilst	 allowing	 selective	 ion	uptake.	 	 A	 ‘leaky’	 epithelium	 may	 allow	 the	 transcellular	 passage	 of	 more	 gut	bacteria.		The	AJ	complex,	composed	of	members	of	the	cadherin	family,	provides	adhesive	bonds	between	cells	and	allows	intercellular	communication(Bruewer	et	al.,	 2003).	 	 A	 schematic	 representation	 of	 the	 apical	 junction	 complex	 is	demonstrated	in	figure	1.4.	
	
Figure	 1.4;	 	 A	 diagram	 to	 demonstrate	 intercellular	 protein	 complexes	 controlling	 the	
transcellular	movement	of	water,	solutes	and	micro-organisms.		The	tight	junction	(TJ)	complex	
is	 composed	 of	 membrance	 spanning	 occludin	 and	 a	 claudin	 protein	 anchored	 to	 the	 cell	
cytoskeleton	 via	 zonulla	 occludens	 1	 (Zo-1).	 	 The	 TJ	 complex	 controls	 the	 flow	 of	water	 and	
electrolytes	through	the	intercellular	space.		The	expression	of	different	claudin	proteins	alters	
the	 permeability	 of	 the	 epithelial	 barrier	 (see	 section	 1.5.3).	 	 Under	 normal	 physiological	
conditions,	the	epithelium	is	impermeable	to	micro-organisms,	but	may	become	pathologically	
more	permeable	(see	section	1.5.2)	
1.5.2	 Epithelial	barrier	dysfunction	in	Crohn’s	disease	Epithelial	barrier	function	can	be	viewed	both	as	a	physical	barrier	alone,	but	also	as	a	 function	of	the	physical	barrier	and	the	 innate	 immune	system.	 	Maintaining	the	epithelial	barrier	is	critical	to	health	and	dysfunction	has	been	implicated	in	a	
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variety	 of	 diseases	 including	 IBD,	 autoimmune	 disease,	 sepsis	 and	tumourigenesis(McGuckin	 et	 al.,	 2009,	 Su	 et	 al.,	 2009,	 Fasano,	 2012,	 Runkle	 and	Mu,	2013).	Impairment	 of	 the	 epithelial	 barrier	 is	 thought	 to	 be	 a	 major	 factor	 in	 the	pathogenesis	 of	 CD(Soderholm	 et	 al.,	 2002,	 Ma	 et	 al.,	 2004,	 Zeissig	 et	 al.,	 2007,	Fries	 et	 al.,	 2008,	 McGuckin	 et	 al.,	 2009,	 Su	 et	 al.,	 2009,	 Denizot	 et	 al.,	 2012).		Intestinal	 permeability	 is	 increased	 in	 the	 first-degree	 relatives	 of	 patients	with	Crohn’s	 disease(Hedin	 et	 al.,	 2012).	 	 GWAS	 studies	 have	 demonstrated	 an	association	 between	 disease	 and	 barrier	 function	 gene	 loci	 variants,	 such	 as	MUC19	and	ITLN1(Franke	et	al.,	2010,	Khor	et	al.,	2011).		MUC19	is	involved	in	the	production	of	 epithelial	 protective	mucin,	whilst	 ITLN1	 (intelectin)	 is	 thought	 to	
act by stabilising the enterocyte brush border membrane(Van Limbergen et al., 
2009).  IBD associated inflammatory	 cytokines,	 such	 as	 TNFα,	 IFNγ	 and	 IL-6,	increase	epithelial	permeability(Adams	et	al.,	1993,	Tazuke	et	al.,	2003,	Ma	et	al.,	2004,	Fries	et	al.,	2008).		In	FXR	knockout	mice,	defects	in	the	epithelial	barrier	are	seen	with	a	loss	of	immunohistochemical	(IHC)	staining	for	occludin(Inagaki	et	al.,	2006).	 	 Furthermore,	 FXR	 activation	 overcomes	 the	 increased	 intestinal	permeability	induced	in	an	animal	model	of	colitis(Gadaleta	et	al.,	2011b).		Finally,	confocal	 endoscopy,	 in	 which	 intravascular	 fluorescein	 dye	 can	 be	 seen	 leaking	from	ileal	villi,	can	predict	relapse	in	patients	with	IBD,	even	when	the	disease	is	confined	to	the	large	bowel(Kiesslich	et	al.,	2012,	Turcotte	et	al.,	2012). 
1.5.3	 Tight	junctions	Bile	 duct	 ligation	 (BDL)	mouse	models,	 in	 which	 BA	 flow	 to	 the	 small	 bowel	 is	disrupted,	demonstrate	epithelial	barrier	dysfunction,	with	bacterial	translocation	and	 decreased	 occludin	 at	 the	 TJ	 complex	 on	 IHC	 staining(Ogata	 et	 al.,	 2003,	
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Inagaki	et	al.,	2006).	 	However,	occludin	deficient	mice	have	unperturbed	barrier	function.	 	 Therefore,	 presumably,	 other	 proteins	within	 the	 TJ	 complex	must	 be	important	 in	maintaining	barrier	 function(Schulzke	et	al.,	2005).	 	Various	studies	have	implicated	changes	in	claudin	expression	in	the	pathogenesis	of	IBD.			The	 claudin	 family	 are	 trans-membrane	 spanning	 proteins	 that	 predominantly	contribute	 to	 barrier	 function(Turksen	 and	 Troy,	 2004).	 	 Some	 claudin	 proteins	form	very	tight	seals	(known	as	‘seal	forming’),	whilst	others	are	more	permeable	(‘pore	forming’).	 	Zeissig	et	al	demonstrated	changes	 in	the	expression	of	claudin	proteins	in	patients	with	active	CD(Zeissig	et	al.,	2007).		The	seal-forming	claudins	5	and	8	were	down	regulated	and	displaced	away	from	the	TJ	complex.		However,	the	 pore-forming	 claudin	 2	 was	 instead	 upregulated.	 	 Further	 studies	 have	 also	suggested	that	the	pathogenic	E.	coli,	AIEC,	can	induce	claudin	2	expression	in	an	animal	model	of	colitis(Denizot	et	al.,	2012). 
1.5.4	 Innate	immune	dysfunction	and	IBD	Innate	immune	mechanisms	that	protect	the	epithelial	barrier	include	the	mucous	layer	 and	 antimicrobial	 defensins(Ostaff	 et	 al.,	 2013).	 	 Epithelial	 cells	 recognise	microorganisms	 by	 pattern	 recognition	 receptors	 (PRRs)	 stimulating	 the	production	of	pro-inflammatory	cytokines,	such	as	the	chemo-attractant	IL-8,	and	can	 activate	 autophagy	 pathways	 to	 kill	 intracellular	 bacteria(Philpott	 and	Girardin,	 2004).	 	 Several	 genes	 involved	 in	 innate	 immune	 function	 have	 been	positively	 associated	 with	 CD	 in	 GWAS	 studies(Wellcome	 Trust	 Case	 Control	Consortium,	2007).			
Mucous	and	defensins	The	mucous	layer,	composed	of	structural	mucins	produced	by	goblet	cells,	coats	the	entire	surface	epithelium	of	the	GI	tract	and	contains	defensins	and	IgA(Ostaff	
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et	al.,	2013).		Defensins	are	small,	antibacterial	cationic	proteins	secreted	into	the	mucous	 layer	 by	 Paneth	 cells	 in	 the	 small	 bowel	 (alpha-defensins),	 or	 by	colonocytes	(beta-defensins)	in	the	large	bowel.	 	Defensins	have	a	broad	range	of	non-specific	 antimicrobial	 activity	 and	 function	 by	 forming	microbial	membrane	disrupting	 pores.	 	 Several	 studies	 in	 IBD	 have	 demonstrated	 disruption	 in	 the	mucous	layer	and	in	defensin	production.			Patients	with	IBD	demonstrate	various	degrees	of	goblet	cell	loss(Sommers	and	Korelitz,	1975).		Animal	models	deficient	in	 their	 ability	 to	 produce	 mucin	 demonstrate	 increased	 intestinal	 permeability	and	 spontaneously	 develop	 GI	 inflammation(Velcich	 et	 al.,	 2002).	 	 Some	 studies	have	demonstrated	a	reduction	in	alpha-defensin	expression	in	ileal	CD,	although	this	was	not	replicated	in	a	paediatric	study(Wehkamp	et	al.,	2005,	Zilbauer	et	al.,	2011).		Similarly,	a	decrease	in	beta-defensin	expression	has	been	demonstrated	in	UC(Zilbauer	et	al.,	2010).	
NOD2	Pattern	recognition	receptors	(PRRs)	are	an	evolutionary	conserved	element	of	the	innate	 immune	 system.	 	 They	 function	 by	 recognising	 particular	 microbial	structural	 motifs,	 known	 as	 pathogen-associated	 molecular	 patterns	 (PAMPs),	such	as	cell	wall	peptidoglycan	or	LPS(Philpott	and	Girardin,	2004).	 	Cytoplasmic	nucleotide-binding	 oligomerisation	 domain	 proteins	 (Nod	 1	 and	 Nod	 2)	 and	membrane	bound	toll-like	receptors	(TLRs)	are	two	such	PRRs.			Nod	2	has	been	strongly	implicated	in	the	pathogenesis	of	CD	by	both	genetic	and	functional	studies(Hugot	et	al.,	2001,	Maeda	et	al.,	2005).			Individuals	who	carry	a	homozygous	mutation	in	the	ligand-binding	domain	of	NOD2	exhibit	a	twenty-fold	increase	 in	 the	 risk	 for	 developing	 CD(Fritz	 et	 al.,	 2011).	 	 NOD2	 is	 broadly	expressed	 in	macrophages	 and	dendritic	 cells	 and	 its	 common	 ligand	 is	N-acetyl	
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muramyl	dipeptide	(MDP),	from	peptidoglycan	in	bacterial	cell	walls(Kannegati	et	al.,	 2007).	 	 It	 functions	 to	activate	NF-κB,	 can	modulate	 signalling	by	other	TLRs	and	 may	 be	 involved	 the	 stimulation	 of	 alpha-defensin	 secretion	 by	 Paneth	cells(Fritz	et	al.,	2011).	 	The	three	most	common	mutations	seen	associated	with	CD	 are	 loss	 of	 function,	 suggesting	 that	 downregulation	 of	 the	 innate	 immune	system	at	the	epithelial	barrier	is	a	risk	for	development	of	the	disease(Fritz	et	al.,	2011).	 	This	story	 is,	however,	complicated	by	 the	 finding	 that	a	gain	of	 function	mutation	 is	 also	 associated	with	 CD,	 possibly	 via	 a	mechanism	 that	 inhibits	 the	production	of	anti-inflammatory	interleukin-10	(IL-10)(Noguchi	et	al.,	2009).		The	debate	as	 to	 the	exact	mechanism	by	which	NOD2	can	predispose	 to	CD	remains	unknown.	
Autophagy	Autophagy	 is	 a	 fundamental	 cellular	 lysozymal	 degradation	 pathway	 in	 which	damaged	 proteins	 and	 organelles	 can	 be	 recycled.	 	 It	 occurs	 during	 cell	development,	repair	and	under	starvation	conditions(Levine	and	Kroemer,	2008).		Autophagy	pathways	are	also	activated	 to	destroy	 intracellular	pathogens	and	 in	this	 way	 act	 as	 an	 innate	 immune	 killing	mechanism.	 	 Several	 autophagy	 genes	have	been	strongly	associated	with	the	development	of	CD	including	ATG16L1	and	IRGM(Van	 Limbergen	 et	 al.,	 2009).	 	 IRGM	 is	 required	 during	 the	 initiation	 of	autophagy,	 whilst	 ATG16L1	 recruits	 other	 proteins	 to	 the	 autophagosome,	engulfing	the	content	identified	for	degradation.			Interestingly,	 NOD2	 also	 has	 a	 regulatory	 role	 in	 autophagy(Fritz	 et	 al.,	 2011).		Bacterial	 activation	 of	 NOD2	 leads	 to	 ATG16L1	 dependent	 formation	 of	autophagocytic	vacuoles.		NOD2	appears	to	recruit	ATG16L1	to	the	cell	membrane	at	site	of	bacterial	entry.	
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There	 is	 a	 potential	 mechanism	 by	 which	 BA	 signalling	 via	 FXR	 could	 regulate	autophagy	 and	NOD2.	 	 Sequestosome	1	 (Sqstm1/p62)	 is	 a	 cytosolic	 protein	 that	ubiquitinates	 cellular	 proteins,	 targeting	 them	 for	 degradation	 by	autophagy(Bjorkoy	et	al.,	2005).		Sqstm1/p62	also	interacts	with	NOD2,	enhancing	its	 effects,	 probably	 by	 preventing	NOD2	degradation(Park	 et	 al.,	 2013).	 	 Recent	research	has	suggested	that	the	expression	of	Sqstm1/p62	is	upregulated	by	FXR	activation(Williams	et	al.,	2012).		This	is	a	potential	mechanism	by	which	BAs	may	promote	innate	immune	function	and	may	form	the	basis	for	future	research.	
1.6	 Cytokine	profiles	in	Crohn’s	disease	The	 chronic	 inflammatory	 response,	 that	 is	 the	 hallmark	 of	 CD,	 is	 driven	 by	 an	inappropriate	 immune	 response	 to	 gut	 flora.	 	 An	 imbalance	 exists	 between	 pro-inflammatory	and	anti-inflammatory	cytokines,	driven	largely	by	an	imbalance	in	cytokine	secreting	T-lymphocytes	(see	figure	1.5).		
1.6.1	 T-helper	cell	phenotype	in	Crohn’s	disease	The	differentiation	of	T-helper	(Th)	cells,	either	to	IFNγ-producing	Th1	cells	or	to	IL4/IL5/IL13-producing	 Th2	 cells,	 was	 described	 almost	 30	 years	 ago	 by	Mosmann	et	al.(Mosmann	et	al.,	1986).		Th1	cells,	induced	by	IL-12,	are	thought	to	protect	against	intracellular	microorganisms,	whereas	Th2	cells	are	thought	to	be	active	against	extracellular	pathogens(Brand,	2009).		Traditionally,	CD	has	been	viewed	as	a	Th1-cytokine	mediated	disease	with	high	levels	 of	 both	 IL-12	 and	 IFNγ	 found	 both	 in	 animal	 models	 and	 isolated	 from	patients	with	 CD(Fuss	 et	 al.,	 1996,	 Hart	 et	 al.,	 2005).	 	 	 In	 contrast,	 UC	 has	 been	described	as	a	Th2-like	disease	with	associated	high	levels	of	 interleukin-5	(IL-5)	and	interleukin-13	(IL-13)	but	with	little	or	no	IFNγ(Strober	and	Fuss,	2011).		IL-
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13	 is	a	pro-fibrotic	 inflammatory	cytokine	and	has	been	associated	with	collagen	formation	in	the	strictures	of	CD(J.	R.	Bailey	et	al.,	2012).	Several,	more	 recent	 studies	 have	 also	 identified	 interleukin-23	 (IL-23)	 receptor	positive,	 interleukin-17/interleukin-22	 (IL17/IL22)-producing	 Th17	 cells	 in	association	 with	 CD(Brand,	 2009).	 	 Transforming	 growth	 factor	 β	 (TGFβ)	 has	traditionally	 been	 viewed	 as	 an	 anti-inflammatory	 cytokine,	 being	 anti-proliferative	 to	 T-lymphocytes,	 and	 by	 promoting	 the	 formation	 of	 T	 regulatory	(Treg)	 cells	 by	 inducing	Foxp3	 (Forkhead	Box	protein	3)	 expression(Konkel	 and	Chen,	2011).		However,	TGFβ	in	the	presence	of	other	inflammatory	cytokines	will	also	promote	 the	differentiation	of	T	cells	 to	a	Th17	phenotype(Wan	and	Flavell,	2007).		Recently,	so	called	‘Th17/Th1’	cells	have	also	been	identified	in	CD,	which	secrete	 both	 IFNγ	 and	 IL-17A(Acosta-Rodriguez	 et	 al.,	 2007,	 Annunziato	 et	 al.,	2008).	 	 Finally,	 in	 association	 with	 an	 increased	 proliferation	 of	 Th1	 and	 Th17	cells,	there	is	a	reciprocal	decrease	in	the	number	of	anti-inflammatory	Treg	cells	(see	figure	1.5).	The	 effector	 cytokines	 of	 Th1	 and	 Th17	 lymphocytes,	 via	 stimulation	 of	 innate	immune	 cells	 (such	 as	 antigen	 presenting	 cells	 and	 epithelial	 cells),	 lead	 to	 the	production	of	secondary	cytokines	such	as	TNFα,	IL-6	and	IL-1	β(Strober	and	Fuss,	2011).	 	 Acting	 via	 NF-κB	 and	 mitogen	 activated	 protein	 (MAP)	 kinases,	 these	secondary	 cytokines	 are	 responsible	 for	many	 of	 the	 downstream	 inflammatory	processes	seen	in	CD.	
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Figure	 1.5;	 	 The	 dysregulated	 cytokine	 profile	 in	 Crohn’s	 disease.	 	 Adapted	 from	 a	 figure	 by	
Brand	S.,	Gut	2009;58.		In	CD,	an	exaggerated	Th1	and	Th17	response	leads	to	the	production	
of	 pro-inflammatory	 effector	 cytokines.	 	 TGFβ	 promotes	 the	 proliferation	 of	 Treg	 cells.		
However,	 in	 the	presence	of	 inflammation,	TGFβ	will	 promote	 the	proliferation	of	Th17	cells.		
Effector	cytokines	in	italic/bold	are	used	in	this	thesis	The	chemo-attractant	cytokine,	 interleukin-8	(IL-8),	 is	released	by	epithelial	cells	in	 response	 to	 stress,	 such	 as	 inflammatory	 cytokine	 activation	 or	 bacterial	sensing(Eckmann	et	al.,	1993).	 	IL-8	is	a	potent	chemo-attractant	and	activator	of	polymorphonucleocytes	 (PMNs),	 acting	 as	 a	 mechanism	 by	 which	 gut	 epithelial	cells	can	alert	the	host	immune	defences	following	bacterial	invasion.		
1.6.2	 Effect	of	pro-inflammatory	cytokines	on	the	gut	epithelial	barrier	Pro-inflammatory	 cytokines,	 such	 as	 TNFα,	 IFN 	 and	 IL-6,	 increase	 the	permeability	 of	 the	 gut	 epithelial	 barrier,	 demonstrated	 both	 in-vivo	 and	 in	 cell	line	models(Adams	et	al.,	1993,	Musch	et	al.,	2002,	Tazuke	et	al.,	2003,	Ma	et	al.,	2004,	 Soderholm	 et	 al.,	 2004,	 Clark	 et	 al.,	 2005).	 	 	 Treatment	 with	 anti-TNFα	therapy	 has	 been	 shown	 to	 reverse	 epithelial	 barrier	 defects	 in	 patients	 with	
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CD(Suenaert	et	al.,	2002).		The	cellular	mechanisms	by	which	cytokines	disrupt	the	epithelial	 barrier	 include	 changes	 to	 the	TJ	 complex,	 re-arrangements	 of	 the	 cell	cytoskeleton	or	increased	epithelial	cell	shedding(Bruewer	et	al.,	2003).	Exposure	 to	 IFN 	 and	 TNFα	 have	 been	 shown,	 both	 independently	 and	synergistically,	 to	 reduce	 epithelial	 electrical	 resistance	 (a	 marker	 of	 barrier	function)	in	human	cell-line	models,	 including	Caco-2(Bruewer	et	al.,	2003,	Ma	et	al.,	 2005,	 F.	 Wang	 et	 al.,	 2005).	 	 In	 these	 studies,	 researchers	 demonstrated	changes	 to	 the	TJ	 complex,	with	downregulation	of	both	occludin	and	Zo-1,	with	cellular	internalisation	of	these	proteins	away	from	the	TJ	complex.			
Effector	 cytokines,	 particularly	 TNFα,	 disrupt	 the	 epithelial	 barrier	 via	 the	upregulation	of	myosin	light	chain	kinase	(MLCK).		Cell	to	cell	junctions	within	the	epithelium	 are	 diminished	 when	 the	 cellular	 actin	 -	 myosin	 ring	 contracts,	‘shrinking’	 the	 cell	 away	 from	 its	 neighbouring	 cells(Cunningham	 and	 Turner,	2012).	 	 This	 cytoskeletal	 re-arrangement	 is	 mediated	 by	 MLCK,	 which	 acts	 to	phosphorylate	 the	 myosin	 light	 chain	 (MLC)	 of	 myosin	 II,	 to	 contract	 the	cytoskeleton	(see	figure	1.6)	
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Figure	 1.6;	 	 A	 schematic	 diagram	 to	 represent	 the	 re-arrangement	 of	 the	 cytoskeletal	 actin-
myosin	ring.	 	Myosin	light	chain	kinase	(MLCK)	acts	to	phosphorylate	the	light	chain	(MLC)	of	
myosin	 II	 within	 the	 actin-myosin	 ring.	 	 The	 subsequent	 cytoskeletal	 contraction	 regulates	
epithelial	barrier	function.	TNFα	 increases	 the	 amount	 of	 MLCK	 protein,	 causing	 cell	 contraction,	 by	upregulating	its	genetic	transcription(Ma	et	al.,	2005).		A	mouse	model	of	systemic	T-cell	activation	(via	 injection	of	anti-CD3	antibodies)	causes	diarrhea	associated	with	increased	levels	of	both	TNFα	and	IFN(Musch	et	al.,	2002).		Clayburgh	and	colleagues	demonstrated	that	phosphorylation	of	MLC	increased	immediately	after	T-cell	 activation	 and	 that	 diarrhea	 could	 be	 ameliorated	 via	 knocking	 out	MLCK(Clayburgh	et	al.,	2005).		In	a	mouse	model	of	ileal	barrier	dysfunction,	anti-Il-6	antibody	was	found	to	reduce	the	phosphorylation	of	MLC(Zahs	et	al.,	2013).		These	 findings	 demonstrate	 the	 importance	 of	 cytoskeletal	 re-arrangement,	 via	MLCK,	in	the	disruption	of	the	epithelial	barrier.		
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1.7	 Hypothesis	and	Aims	A	 better	 understanding	 of	 the	 aetiopathology	 of	 CD	will	 help	 fulfill	 the	 need	 for	more	 efficacious,	 less	 toxic	 treatments.	 	 The	 aetiopathogenesis	 is	 complex	 and	multifactorial,	but	epithelial	barrier	dysfunction	and	dysbiosis	are	critical	 factors.		A	western	diet	is	associated	with	dysbiosis	and	is	also	associated	with	an	increased	risk	 in	 the	development	of	CD.	 	The	nuclear	 receptor	FXR	 is	 central	 to	 signalling	between	 the	 host	 and	 the	 microbiota.	 	 Evidence	 suggests	 that	 FXR	 is	 anti-inflammatory	and	helps	to	maintain	an	effective	epithelial	barrier.	The	 main	 hypothesis	 of	 this	 thesis	 is,	 therefore,	 that	 a	 diet-induced	 dysbiosis	disrupts	 bile	 acid	 (BA)	 signalling,	 via	 FXR,	 predisposing	 to	 ileal	 Crohn’s	 disease	(CD)(see	figure	1.7).	
	
Figure	1.7;		A	schematic	diagram	to	represent	the	original	hypothesis.		Dietary	changes	disrupt	
the	 microbiota	 and	 the	 bile	 acid	 pool	 (green	 dots)	 to	 impair	 FXR	 signalling.	 	 FXR	 has	
downstream	effects	on	the	maintenance	of	the	epithelial	barrier	and	on	immune	homeostasis,	
in	 addition	 to	 regulating	 BA	 metabolism	 in	 the	 liver.	 	 It	 is	 hypothesised	 that	 impaired	 FXR	
signalling	in	the	ileum	predisposes	to	gut	inflammation.			 	
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Therefore,	in	order	to	investigate	the	role	of	FXR	in	the	aetiopathogenesis	of	ileal	CD,	the	broad	aims	of	this	thesis	are:	1. To	investigate	the	role	of	FXR	agonism	in	maintaining	an	epithelial	barrier	using	gut-derived,	human	cell	lines.	2. To	 investigate	 the	 ability	 of	 FXR	 agonism	 to	 ameliorate	 the	 inflammation	associated	with	high-fat/high-sugar	feeding	in	a	mouse	model	of	obesity.	3. To	 investigate	FXR	activity	 in	patients	with	 ileal	CD	and	 to	develop	an	ex-
vivo	 ileal	 mucosa	 culture	 model	 to	 study	 FXR	 agonism	 and	 cytokine	secretion.		 	
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Chapter	2	–	FXR	Agonism	and	Gut	Epithelial	Barrier	Function	in	
Human	Cell	Lines	
2.1	 Abstract	CD	 associated	 inflammatory	 cytokines	 induce	 epithelial	 barrier	 dysfunction	 and	increase	 the	 leakiness	 of	 the	 gut	 mucosa(Bruewer	 et	 al.,	 2003,	 Suzuki,	 2013).		Farnesoid	 X	 receptor	 (FXR)	 agonism	 has	 been	 shown	 to	maintain	 the	 epithelial	barrier	in	a	mouse	model	of	colitis(Gadaleta	et	al.,	2011b).			
This	chapter	investigates	the	role	of	FXR	in	maintaining	the	epithelial	barrier	using	human,	 gut	 derived	 cell	 lines.	 	 The	 aims	 were	 to	 optimise	 a	 model	 of	 cytokine	induced	 barrier	 disruption	 and	 then	 to	 assay	 the	 effect	 of	 FXR	 agonism	 in	 this	model.		These	experiments	used	the	Caco-2	cell	line	as	a	model	of	the	human	small	bowel	epithelial	barrier	and	HT29	cells	as	a	model	of	the	IL-8	secreting,	immuno-phenotype	of	enterocytes.		Evidence	 is	 presented	 to	 demonstrate	 that	 FXR	 acts	 to	 maintain	 epithelial	 cell	morphology	after	stress	with	inflammatory	cytokine,	possibly	via	the	regulation	of	myosin	light	chain	kinase	(MLCK)	expression.		In	addition,	FXR	activation	is	shown	to	ameliorate	cytokine	induced	IL-8	secretion	by	gut	epithelial	cells.	
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2.2	 Introduction	and	aims	The	specialised	epithelium	of	the	GI	tract	is	formed	by	a	polarised	cell	monolayer	in	which	intercellular	TJ’s	control	the	paracellular	flux	of	solutes,	microorganisms	and	 other	 toxins(Suzuki,	 2013).	 	 As	 discussed	 in	 chapter	 1,	 disruption	 to	 this	epithelial	barrier	is	central	to	the	pathophysiology	of	IBD(Zeissig	et	al.,	2007,	Su	et	al.,	2009,	Hedin	et	al.,	2012).	The	effector	inflammatory	cytokine	profile	associated	with	CD	increases	epithelial	permeability,	 probably	 by	 altering	 claudin	 protein	 expression	 and	 by	 cell	cytoskeletal	 re-arrangement(Weber	 and	 Turner,	 2007).	 	 Inflammatory	 cytokine	induced	 expression	 and	protein	phosphorylation	 of	MLCK	 leads	 to	 alterations	 in	cell–cell	 junction	 morphology	 via	 re-arrangement	 of	 the	 apical	 cytoskeletal	band(Cunningham	and	Turner,	2012).			A	 variety	 of	 innate	 immune	 mechanisms	 contribute	 to	 the	 maintenance	 of	 the	epithelial	 barrier.	 	 When	 stressed	 by	 PAMPs,	 such	 as	 LPS,	 or	 by	 inflammatory	cytokine,	 epithelial	 cells	 secrete	 IL-8,	 which	 acts	 as	 a	 chemo-attractant	 to	circulating	polymorphonucleocytes(Eckmann	et	al.,	1993).	Gadaleta	 and	 co-workers	 have	 shown	 that	 activation	 of	 FXR	 can	 maintain	 the	epithelial	barrier	both	in-vivo	and	in-vitro,	although	the	mechanism	is	not	known.		In	 a	 DSS	 colitis	model,	 treatment	with	 an	 FXR	 agonist	maintained	 the	 epithelial	barrier	 in	WT,	 but	 not	Fxr-null	mice,	 as	measured	by	 the	 flux	 of	 FITC.dextran	 (a	high	molecular	weight	 fluorescein)	 from	the	gut	 lumen	to	plasma(Gadaleta	et	al.,	2011b).	 	 In-vitro,	 an	 FXR	 agonist	 was	 able	 to	 maintain	 an	 epithelial	 monolayer	barrier,	when	exposed	to	DSS(Gadaleta	et	al.,	2011b).	
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The	aims	of	these	cell	line	experiments	were,	therefore,	to:		
1. Optimise	a	model	of	inflammatory	cytokine	induced	barrier	dysfunction.		
2. Assay	 the	 effect	 of	 FXR	 agonism	 on	 this	 induced	 epithelial	 barrier	dysfunction.	
3. Assay	 the	 effect	 of	 FXR	agonism	on	 the	production	of	 IL-8	by	 gut	derived	epithelial	cells	in	response	to	cytokine	stress.	
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2.3	 Methods	
2.3.1	 The	Caco-2	and	HT29	cell	lines	The	 Caco-2	 and	 HT29	 cell	 lines	 are	 well-characterised	 and	 often	 studied	 GI-	derived,	human	epithelial	cell	models(Hidalgo	et	al.,	1989,	Jumarie	and	Malo,	1991,	Dalmasso	 et	 al.,	 2008,	 Lee	 et	 al.,	 2008,	 Modica	 et	 al.,	 2008).	 	 Caco-2	 is	 an	immortalised	 epithelial	 cell	 line,	 originally	 isolated	 from	 a	 human	 colonic	adenocarcinoma(Fogh	and	Trempe,	1975).	 	Although	originally	of	colonic	tumour	cell	origin,	on	reaching	maturity,	Caco-2	cells	exhibit	characteristics	of	enterocyte	differentiation.	 	 These	 enterocyte-like	 features	 include	 the	 growth	 of	 microvilli,	attachment	via	 tight	 junctions	and	the	production	of	enterocyte	specific	enzymes	including	amino-peptidases,	brush	border	enzymes	and	diamine	oxidase(Jumarie	and	 Malo,	 1991).	 	 Caco-2	 cells	 are	 well	 characterised	 in	 epithelial	 permeability	studies	due	to	their	ability	to	form	polarised	monolayers(Hidalgo	et	al.,	1989).		The	cells	 have	 a	 relatively	 slow	doubling	 time,	 of	 approximately	60	hours,	 and	 reach	full	 differentiation	 after	 maintenance	 in	 culture	 after	 approximately	 21	 days.		Previous	investigators	have	shown	that	FXR	is	only	expressed	and	fully	functional	in	fully	differentiated,	mature	Caco-2	cells(Modica	et	al.,	2008).			HT29	are	an	immortalised	gut	epithelial	cell	line,	derived	from	an	epithelial	crypt-like	cell	from	a	colorectal	adenocarcinoma(Fogh	and	Trempe,	1975).	 	Like	Caco-2	cells,	HT29	will	 develop	 some	enterocyte-like	 features,	 such	as	microvilli,	 on	 full	differentiation	 after	 7	 days	 in	 culture.	 	 HT29	 have	 been	well	 characterised	 as	 a	model	of	gut	epithelial	cytokine	or	chemokine	secretion	in	response	to	stimulation	with	inflammatory	cytokine	or	LPS(Riedel	et	al.,	2006,	Lee	et	al.,	2008,	Gadaleta	et	al.,	 2011b).	 	 Again,	 FXR	 has	 been	 shown	 to	 be	 expressed	 and	 functional	 in	 fully	differentiated	HT29	cells(Gadaleta	et	al.,	2011b).	
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2.3.2	 Optimisation	of	a	Caco-2	polarised	epithelial	monolayer		New	 Caco-2	 cells	 were	 purchased	 from	 the	 European	 Collection	 of	 Cell	 Culture	(ECACC),	 thawed	 and	 re-suspended	 in	 Caco-2	 growth	 media	 in	 a	 25cm2	 flask	(Greiner	Bio	One).	 	 All	 tissue	 culture	was	 performed	under	 a	 laminar	 flow	hood	using	sterilised	equipment.		Caco-2	growth	media	consisted	of	Dulbecco's	Modified	Eagle's	Medium	(with	4500	mg/L	glucose,	25	mM	HEPES,	sodium	bicarbonate	and	phenol	 red;	DMEM	 -	 Sigma),	 supplemented	with	10%	heat	 inactivated	 foetal	 calf	serum	(FCS	-Biosera),	10%	MEM	Non-essential	Amino	Acid	Solution	(Sigma),	2mM	L-glutamine,	100units/ml	penicillin	and	100μg/ml	streptomycin	(Sigma).			The	concentrations	of	bile	acid	within	a	variety	of	manufacturers’	FCS	preparations	was	 assayed	 (outsourced	 to	 Newcastle	 upon	 Tyne	 Foundation	 Hospitals	 Trust	pathology	 laboratory),	 including	 dialysed	 FCS,	 and	 were	 found	 to	 be	 similar	 at	levels	from	8	to	9µmol/l.			The	ileal	concentration	of	BA	in	humans	is	estimated	to	be	 approximately	 1	 x	 104	 µmol/l(Hofmann	 and	Eckmann,	 2006).	 	 Therefore,	 the	low,	 relative	 concentration	 of	 BA	 in	 FCS	 was	 assumed	 to	 be	 of	 little	 biological	importance	in	terms	of	confounding	FXR	agonism	in	comparison	to	either	the	in-vitro	concentration	of	FXR	agonist	or	the	treatment	of	cells	with	an	FXR	agonist.		Cells	were	incubated	in	5%	CO2	humidified	atmosphere	at	37oC	and	cultured	into	75cm2	 flask	when	 they	had	reached	70%	to	80%	confluence.	 	The	growth	media	was	changed	every	other	day	and	cells	were	co-cultured,	 following	washing	with	phosphate	buffered	saline	(PBS)	and	removal	with	5ml	of	trypsin-EDTA	(Sigma),	at	a	ratio	of	1:6.	For	 growth	 as	 a	 polarised	 monolayer,	 Caco-2	 cells	 were	 seeded	 into	 a	 hanging	insert	culture	well,	with	high	density	0.4	μm	pore	size,	permeable,	PET	membrane	(6	 or	 24-well	 Transwell	 Insert	 System,	 Corning	 Falcon),	 at	 a	 concentration	 of	50,000	 cells/ml,	 as	 shown	 in	 figure	 2.1.	 	 Cells	 were	 counted	 using	 a	 Neubauer	
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Improved	 haemocytometer	 by	 diffusing	 10μl	 of	 cell	 containing	 growth	 media	under	 a	 coverslip.	 	 A	 variety	 of	 different	 cell	 concentrations	 were	 used	 to	determine	the	most	efficient	number	of	cells	required	for	seeding.	
	
Figure	2.1;	 	 A	 schematic	 to	 represent	 the	 conditions	 required	 for	 culture	of	 Caco-2	 cells	 as	 a	
polarised	epithelial	monolayer.		The	cells	are	cultured	on	a	permeable	membrane,	both	covered	
by	 media	 and	 supported	 by	 a	 hanging	 well	 in	 media.	 	 As	 cells	 differentiate,	 apical	 and	
basolateral	surfaces	form,	separated	by	apical	tight	junctions.	Use	of	50,000	cells/ml	reliably	produced	monolayers	with	stable	and	consistently	high	 levels	 of	 trans-epithelial	 electrical	 resistance	 (TEER)	 after	 21	 days	 of	differentiation.		The	measurement	of	TEER	is	described	in	section	2.2.3.	
Cells	 in	 the	6-well	 system	were	 cultured	with	2ml	of	 growth	media	 in	 the	apical	chamber	and	3ml	of	media	in	the	basolateral	chamber,	whilst	cells	in	the	24	–well	system	were	cultured	with	500μl	of	media	in	apical	chamber	and	800μl	of	media	in	the	 basolateral	 chamber.	 	 	 The	 growth	media	was	 changed	 every	 other	 day	 and	
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cells	were	 allowed	 to	mature	 for	 21	days	post	 seeding	before	 experiments	were	performed.		For	 cytokine	 optimisation	 experiments,	 various	 concentrations	 (100ng/ml,	10ng/ml,	1ng/ml)	of	recombinant	TNFα,	IL-6	or	IFNγ	(R	&	D	Systems)	were	added	to	 the	 basolateral	 compartment.	 	 Previous	 studies	 have	 demonstrated	 that	receptors	for	TNFα,	IL-6	and	IFNγ	are	expressed	on	the	basolateral	membrane	in	polarised	Caco-2	cells(Adams	et	al.,	1993,	Tazuke	et	al.,	2003,	Ma	et	al.,	2004).		This	panel	 of	 inflammatory	 cytokines	 was	 chosen	 due	 to	 the	 important	 role	 these	particular	 cytokines	 play	 in	 the	 aetiopathology	 of	 CD,	 as	 described	 in	 chapter	 1	(see	figure	1.5).			
Growth	 media	 was	 changed	 after	 24	 hours	 exposure	 to	 the	 cytokine.	 	 In	subsequent	 experiments,	 100ng/ml	 of	 cytokine	 was	 used.	 	 Optimisation	experiments	 demonstrated	 that	 the	 upregulation	 of	 downstream	 FXR	 gene	products	was	 greater	 at	 24	hours,	 rather	 than	 at	48	hours,	 post	 exposure	 to	 the	FXR	agonist	(see	results	section	2.3.3).		Therefore,	in	experiments	utilising	the	FXR	agonists,	 GW4064	 and	 6-ECDCA,	 dosing	 experiments	 with	 1μM	 or	 10μM	 of	 the	compound	were	added	to	the	apical	cell	monolayer	compartment	24	hours	prior	to	exposure	 to	 the	 cytokine.	 	 Experiments	 were	 replicated	 with	 a	 minimum	 of	 3	different	monolayers.		TEER	was	measured	every	24	hours	as	described	below.	
2.3.3	 Mycoplasma	Initial	 attempts	 to	 culture	 the	 monolayers	 were	 hampered	 by	 unstable	 TEER	measurements	and	the	death	of	cells,	which	subsequently	lifted	off	the	well	insert.		Optimisation	 of	 growing	 conditions	 was	 performed	 by	 seeding	 different	concentrations	of	cells,	changing	growth	media	constituents	(e.g.	10%	FCS	versus	
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20%	 FCS),	 growing	 on	 a	 matrigel™	 scaffold,	 growing	 on	 inserts	 coated	 with	fibronectin	and	on	inserts	coated	with	rat	tail	collagen,	but	with	no	success.			An	outbreak	of	a	mycoplasma	infection	in	the	lab	was	eventually	identified	as	the	problem	 causing	 unstable	 monolayer	 formation.	 	 Figure	 2.2	 demonstrates	 an	example	of	 the	change	 in	TEER	as	 the	monolayer	developed	whilst	 infected	with	mycoplasma.			Typically,	an	initial	increase	in	TEER	was	not	maintained	and,	often,	whole	Caco-2	monolayers	would	die	before	the	end	of	the	assay	at	21	days.	
	
Figure	2.2;	 	Chart	of	change	in	TEER	with	time	for	various	seed	concentrations	of	Caco-2	cells	
cultured	 in	monolayers	 (50,000	cells/ml	 to	200,000	cells/ml).	 	Presented	here	to	demonstrate	
the	deleterious	effect	of	Mycoplasma	infection	on	the	ability	of	Caco-2	cells	to	form	a	polarised	
monolayer.	Mycoplasma	 are	 simple	 bacteria	 that	 lack	 a	 cell	 wall	 and	 are	 too	 small	 to	 be	detected	 by	 light	microscopy	 (0.3	 to	 0.8µm	 in	 diameter)(Robinson	 et	 al.,	 1956).		They	 grow	 readily	 in	 cell	 culture	media	 and	 can	 effect	 cell	 attachment,	 function,	growth	and	metabolism.		Mycoplasma	infection	is	a	common	problem	with	11%	to	15%	of	cell	lines	tested	in	the	U.S.	being	affected(Rottem	and	Barile,	1993).			A	 new	 cell	 line	was	 purchased	 and	 the	 protocol	 for	 growing	 Caco-2	monolayers	was	changed	to	include	a	step	to	filter	media	(0.2µm	pore,	sterile	filter)	and	to	test	for	Mycoplasma	every	month.	 	Mycoplasma	testing	of	growth	media	and	cell	 line	media	 was	 performed	 using	 the	 enzyme-linked	 immunosorbent	 assay	 (ELISA)	
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Mycoalert	 testing	 kit	 from	 Lonza.	 	 Testing	 was	 performed	 according	 to	 the	manufacturers	instructions.		
2.3.4	 Lactate	dehydrogenase	release	assay	To	demonstrate	that	changes	in	TEER	were	due	changes	in	paracellular	flux,	rather	than	monolayer	 disruption	 due	 to	 cell	 death,	 the	 level	 of	 lactate	 dehydrogenase	(LDH)	 in	 the	 apical	 compartment	was	measured	 after	 exposure	 to	 inflammatory	cytokine,	FXR	agonist,	dimethyl	sulfoxide	(DMSO)	as	a	vehicle	control	or	Triton	1%	(positive	 control).	 	 LDH	 is	 an	 abundant	 intracellular	 enzyme	 that	 converts	pyruvate	 to	 lactate	during	 anaerobic	metabolism.	 	 Elevated	 levels	 of	 LDH	within	the	supernatant	would	demonstrate	cell	lysis.		DMSO	is	a	common	solvent	used	to	re-suspend	 biologically	 active	 molecules.	 	 DMSO	 is	 toxic	 to	 cells	 at	 high	concentrations	(1-3%),	but	in	these	experiments	was	never	used	at	concentrations	greater	 than	 0.025%.	 	 A	 DMSO	 (vehicle)	 control	 was	 used	 in	 all	 cell	 line	experiments	to	control	for	the	potential	toxic	effect	of	DMSO. Supernatant	from	the	apical	compartment	was	analysed	for	LDH	by	the	Newcastle	upon	Tyne	Foundation	Hospitals	Trust	pathology	laboratory.	 	The	assay	required	phenol-red	free	growth	media	and	so,	for	these	experiments	only,	phenol-red	free	DMEM	(Sigma-Aldrich)	was	used.		Phenol-red	is	simply	a	pH	indicator	used	in	cell	culture	growth	media	 to	demonstrate	metabolic	activity.	 	Growing	Caco2	cells	 in	phenol-red	free	media	does	not	alter	cell	viability.	
2.3.5	 Measurement	of	trans-epithelial	electrical	resistance		Measurement	 of	 TEER	 provides	 a	 measure	 of	 epithelial	 barrier	 function.	 	 A	volthometer	 measures	 the	 electrical	 current	 across	 the	 insert	 and	 the	 cell	monolayer	giving	a	result	in	ohms	(Ω).		Increasing	levels	of	impendence	to	current	
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flow	demonstrates	that	the	cell	monolayer	is	less	permeable	to	the	flow	of	charged	ions	and	has	formed	a	more	effective	barrier.	A	 Millicell	 ERS-2	 voltohmeter	 with	 STX01	 chopstick	 electrodes	 (both	 Merck	Millipore,	MA,	USA)	were	 used	 (see	 figure	 2.3).	 	 Under	 a	 laminar	 flow	hood,	 the	chopstick	 electrodes	 were	 cleaned	 in	 70%	 ethanol	 before	 being	 allowed	 to	 dry.		The	electrodes	were	then	placed	such	that	 the	short	 tip	was	 in	the	 insert	culture	well	(apical	compartment)	and	the	long	tip	was	in	the	basolateral	compartment.	Reproducible	 positioning	 of	 the	 electrodes	 is	 important	 to	 provide	 reliable	readings.	 	 Readings	were	 always	made	with	 the	 electrodes	 perpendicular	 to	 the	monolayer	and	after	allowing	 the	 reading	 to	 settle	 for	3	 to	4	 seconds.	 	Care	was	taken	 to	 measure	 different	 wells	 as	 quickly	 as	 possible	 to	 minimise	 changes	 in	resistance	measurements	 caused	by	 cooling	of	monolayers	 to	 room	 temperature	after	removal	from	the	incubator.	
	
Figure	2.3;		The	Millicell	ERS-2	voltohmeter	and	chopstick	electrodes	from	the	product	literature	
of	 the	 manufacturers,	 Merk	 Millipore.	 	 To	 measure	 TEER,	 the	 electrodes	 are	 placed	 at	 a	
perpendicular	 angle	 to	 the	 surface	 of	 the	 monolayer,	 with	 the	 long	 chopstick	 arm	 in	 the	
basolateral	well	and	the	short	chopstick	arm	in	the	apical	well,	just	above	the	monolayer.	
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To	calculate	the	monolayer	resistance	corrected	for	the	area	of	the	culture	 insert	well	 (i.e.	 the	 unit	 area	 resistance)	 and	 for	 the	 resistance	 of	 the	 culture	 insert	membrane	(‘control’),	the	following	calculation	was	used:	Unit	area	resistance	(Ω	cm2)=	[Resistance	sample	(Ω)	-	Resistance	control	(Ω)]	x	effective	membrane	area	(cm2)	
2.3.6	 Measurement	of	Lucifer	Yellow	monolayer	flux	Lucifer	 Yellow	 (LY)	 is	 a	 cell	 impermeable	 compound	 and	 measurement	 of	 its	paracellular	 flux,	 from	 the	 apical	 compartment	 to	 the	 basolateral	 compartment,	forms	an	alternative	assay	of	monolayer	permeability	to	TEER.		For	 the	 LY	 assay,	 monolayers	 grown	 on	 24-well	 plate	 cell	 culture	 inserts	 were	used.		Cell	media	was	removed	from	both	apical	and	basolateral	compartments	and	the	 monolayer	 was	 washed	 in	 transport	 buffer.	 	 Transport	 buffer	 consisted	 of	Hank’s	Balanced	Salt	Solution	(HBSS,	Gibco,	Life	Technologies)	supplemented	with	140mg/l	 calcium	 chloride	 and	 100mg/l	magnesium	 chloride.	 	 500	 μl	 of	 LY,	 at	 a	concentration	of	100μM	in	transport	buffer,	was	added	to	the	apical	compartment	of	 each	 well,	 whilst	 800μl	 of	 transport	 buffer,	 without	 LY,	 was	 added	 to	 the	basolateral	compartment.	 	The	monolayers	were	incubated	in	5%	CO2	humidified	atmosphere	at	37oC	for	1.5	hours	and	then	for	30	minutes	on	an	orbital	shaker	at	37	oC,	at	100	rpm.		Following	incubation,	200μl	of	supernatant	from	the	basolateral	compartment	 was	 transferred	 to	 a	 96-well,	 black	 sided,	 clear-bottomed	 plate.		Fluorescence	 was	 then	 measured	 in	 a	 Synergy	 HT	 plate	 reader	 (BioTek,	 U.S.A.)	using	a	485nm	excitation	filter	and	a	530nm	emission	filter.		The	fluorescence	from	serial	 dilutions	 of	 LY	 from	 0.1	 to	 100μM	 was	 measured	 in	 order	 to	 produce	 a	standard	curve.	
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2.3.7	 Imaging	Caco-2	cell	monolayers	Images	of	Caco-2	cells	were	recorded	by	both	 light	microscopy	(bright	 field)	and	electron	microscopy	for	control	and	cytokine	+/-	FXR	agonist	treated	monolayers.		Bright-field	 microscopy	 was	 performed	 using	 the	 Cellix	 system.	 	 Fully	differentiated	Caco-2	monolayers	in	a	6-well	Transwell	Insert	System	were	treated	for	48	hours	with	basolateral	inflammatory	cytokine	(100ng/ml	TNFα,	IFNγ	or	IL-6)	with	24	hours	of	pre-treatment	with	apical	FXR	agonist	(1μM	6-ECDCA)	or	5μl	DMSO	as	a	vehicle	control.	 	6-ECDCA	was	re-constituted	in	DMSO	with	5μl	of	this	solution	 in	 2	 ml	 of	 apical	 growth	 media	 being	 equivalent	 to	 1μmolar.	 	 A	 1%	solution	of	Triton-X,	a	non-ionic	surfactant,	was	also	incubated	in	one	of	the	apical	compartments	 for	 10	minutes	 to	 create	 a	 negative	 control.	 	 The	Cellix	 incubator	was	pre-heated	to	37°C	and	images	were	captured	at	10x	magnification.	For	electron	microscopy,	fully	differentiated	21	day	monolayers	were	prepared	in	a	24-well	Transwell	Insert	System.	 	Monolayers	were	again	exposed	for	48	hours	to	 basolateral	 inflammatory	 cytokine	 (100ng/ml	 TNFα,	 IFNγ	 or	 IL-6)	 with	 24	hours	of	pre-treatment	with	apical	FXR	agonist	(1μM	6-ECDCA)	or	5μl	of	dimethyl	sulfoxide	(DMSO)	as	a	vehicle	control.	 	Treated	monolayers	were	then	washed	in	PBS	and	resuspended	in	a	2%	gluteraldehyde	solution	to	fix	the	monolayers.		The	monolayers	 were	 then	 prepared	 and	 imaged	 for	 transmission	 and	 scanning	electron	 microscopy	 (TEM	 and	 SEM)	 by	 the	 Electron	 Microscopy	 Research	Services,	Newcastle	University.			For	TEM,	sections	were	prepared	and	imaged	at	random	to	demonstrate	a	cell-cell	junction	with	its	associated	TJ	complex.	 	Sections	were	imaged	at	a	magnification	of	7900x	to	provide	a	representation	of	the	full	thickness	of	the	cell	monolayer.		In	this	way,	the	majority	of	the	cell-cell	junction	could	be	seen.			In	total,	20	junctions	per	 intervention	(e.g.	 control,	TNFα,	TNFα	with	FXR	agonist	etc.)	were	prepared.		
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The	 author	 and	 an	 independent	 researcher,	 who	 were	 both	 blinded	 as	 to	 the	intervention,	 then	 reviewed	 the	 images.	 	 The	 presence	 or	 absence	 of	 cell-cell	junction	fissures	was	counted	to	provide	evidence	of	the	degree	of	cell	cytoskeletal	re-arrangement.		
2.3.8	 HT29	cell	culture	A	 frozen	 cryovial	 of	 HT29	 cells,	 gifted	 to	 the	 laboratory	 (courtesy	 of	 Professor	Thwaites,	 Newcastle	 University),	 was	 re-suspended	 in	 5	 ml	 of	 warmed	 HT29	growth	media	in	a	25cm2	flask	(Greiner	Bio	One).		All	tissue	culture	was	performed	under	 a	 laminar	 flow	 hood	 using	 sterilised	 equipment.	 	 HT29	 growth	 media	consisted	of	Dulbecco's	Modified	Eagle's	Medium	(with	4500	mg/L	glucose,	25	mM	HEPES,	 sodium	bicarbonate	and	phenol	 red;	DMEM	-	Sigma),	 supplemented	with	10%	 heat	 inactivated	 foetal	 calf	 serum	 (FCS	 -Biosera),	 10%	MEM	 Non-essential	Amino	 Acid	 Solution	 (Sigma),	 2mM	 L-glutamine,	 100units/ml	 penicillin	 and	100μg/ml	streptomycin	(Sigma).			Cells	were	incubated	in	5%	CO2	humidified	atmosphere	at	37oC	and	cultured	into	a	75cm2	 flask	 (Greiner,	 Bio	 One)	 when	 they	 had	 reached	 80%	 confluence.	 	 For	cytokine	stimulation	experiments	25cm2	flasks	were	used.		The	growth	media	was	changed	 every	 other	 day	 and	 cells	 were	 co-cultured,	 following	 washing	 with	phosphate	buffered	saline	(PBS)	and	removal	with	5ml	of	trypsin-EDTA	(Sigma),	at	a	ratio	of	1:4.			
2.3.9	 Enzyme-linked	immunosorbent	assay	(ELISA)	An	enzyme-linked	immunosorbent	assay	(ELISA)	is	a	laboratory	technique	used	to	quantify	 the	 concentration	 of	 a	 specific	 antigen	 or	 antibody	 within	 a	 biological	substrate.		In	a	‘sandwich’	ELISA,	the	antigen	of	interest	is	sandwiched	between	a	specific	capture	antibody	and	a	biotinylated	detection	antibody,	as	seen	 in	 figure	
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2.4.	 	 A	 streptavidin	 conjugate	 is	 then	 added,	 which	 binds	 avidly	 to	 biotin	 (the	binding	of	biotin	to	streptavidin	is	one	of	the	strongest	non-covalent	 interactions	known	in	nature),	the	plate	is	developed	and	light	absorbance	measured	against	a	known	standard	to	calculate	the	concentration	of	the	antigen	of	interest.	
	
Figure	 2.4;	 	 A	 schematic	 diagram	 representing	 the	 process	 of	 a	 sandwich	 ELISA:	 (a)	 Capture	
antibody	 coated	 plate,	 (b)	 addition	 of	 substrate	 containing	 antigen,	 (c)	 addition	 of	 specific	
biotinylated	 detection	 antibody,	 (d)	 addition	 of	 streptavidin	 which	 binds	 to	 biotin,	 (e)	
streptavidin	is	developed	and	absorbance	is	measured.	HT29	cells	were	grown	in	25cm2	flasks	for	7	days.		At	full	differentiation,	cells	were	cultured	with	growth	media	containing	6-ECDCA	(0.1,	1,	10μM),	GW4064	(0.1,	1,	10μM),	or	DMSO	(as	vehicle	control)	 for	24	hours.	 	Some	flasks	were	pre-treated	for	 24	 hours	 with	 a	 growth	 media	 solution	 containing	 100μM	 guggulsterone	(Sigma	 Aldrich).	 	 Guggulsterone	 is	 a	 plant	 sterol	 compound	 that	 acts	 as	 an	 FXR	antagonist(Urizar	 et	 al.,	 2002,	 J.	 Wu	 et	 al.,	 2002).	 	 Previous	 studies	 have	demonstrated	 almost	 complete	 antagonism	of	 FXR	activity	 at	 doses	of	 100μM	 to	200μM(Capello	 et	 al.,	 2008).	 	 Following	 exposure	 to	 the	 FXR	 agonist	 +/-	guggulsterone,	 HT29	 cells	 were	 stimulated	 with	 growth	 media	 containing	100ng/ml	 TNFα	 for	 24	 hours.	 	 At	 the	 end	 of	 the	 experiments,	 growth	 media	supernatant	 was	 collected	 to	measure	 IL-8,	 secreted	 by	 the	monolayer,	 and	 the	cells	were	harvested	for	RNA	extraction	(see	section	2.2.9).	
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An	 ELISA	 detection	 kit	 for	 IL-8	 (PeproTech,	 NJ,	 USA)	was	 used	 according	 to	 the	manufacturers	guidelines.		Briefly,	100µl	of	a	0.5μg/ml	solution	of	specific	capture	antibody	 was	 added	 to	 wells	 in	 a	 96-well	 ELISA	 plate	 and	 stored	 at	 4°C	 for	 12	hours.	 	 The	 plate	 was	 washed	 in	 an	 automated	 plate	 washer	 (Thermo	 Fisher	Scientific,	MA,	USA),	using	a	wash	buffer	 comprised	of	1800ml	water,	200ml	1%	PBS	and	1ml	Tween-20.		150μl	of	block	buffer	(1g	bovine	serum	albumin	in	20ml	PBS)	was	added	to	each	well	and	left	on	an	orbital	shaker	at	room	temperature	for	1	hour.		A	standard	2000pg/ml	solution	of	IL-8	was	prepared	and	serially	diluted	1:2	a	further	7	times,	using	a	diluent	(1:10	solution	of	block	buffer	to	wash	buffer)	to	 produce	 known	 samples	 for	 a	 standard	 curve.	 	 100μl	 of	 standard	 or	 of	 cell	supernatant	was	 added	 to	 each	well	 and	 left	 on	 an	 orbital	 shaker	 at	 4°C	 for	 12	hours.		Each	well	was	reproduced	in	triplicate.		For	some	experiments,	IL-8	levels	were	 above	 the	 assay	 detection	 level	 (i.e.	 >2000pg/ml)	 and	 so	 cell	 supernatant	samples	 were	 diluted	 to	 1:10	 and	 1:100	 using	 the	 diluent.	 	 After	 12	 hours	incubation,	 2	 cycles	 of	 plate	 washing	 was	 performed,	 and	 100μl	 of	 0.25μg/ml	biotinylated	detection	antibody	was	added	before	incubating	on	the	orbital	shaker	at	room	temperature	for	2	hours.	 	The	plate	was	then	washed	twice	and	100μl	of	streptavidin-horseradish	peroxidase	(HRP)	conjugate	was	added	to	each	well	and	allowed	to	 incubate	at	room	temperature	 for	60	minutes.	 	The	plate	was	washed	twice	and	developed	with	100μl	per	well	of	a	solution	of	12.5ml	citrate,	200μl	o-Phenylenediamine	(OPD),	5μl	hydrogen	peroxide	(H2O2).		The	colour	was	allowed	to	 develop	 sufficiently	 before	 terminating	 the	 reaction	 with	 100μl	 per	 well	 of	sulphuric	acid.	 	The	absorbance	in	each	well	was	then	measured	in	a	Synergy	HT	plate	reader	(BioTek,	U.S.A.)	at	492nm.			
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2.3.10	 	 BSA	protein	assay	In	order	to	determine	the	level	of	IL-8	in	proportion	to	the	number	of	cells	in	the	monolayer,	a	measure	of	the	protein	content	of	the	monolayer	was	made.		Briefly,	the	monolayer	was	 removed	with	5ml	of	 trypsin-EDTA	and	washed	with	PBS	by	centrifugation.		The	cell	pellet	was	re-suspended	in	150μl	of	cell-lysis	buffer	(10ml	of	Cell	Lytic	M	cell	lysis	reagent,	Sigma	and	one	tablet	of	cOmplete,	Mini,	protease	inhibitor	cocktail,	Roche),	agitated	and	then	incubated	on	ice	for	10	minutes.		The	sample	was	then	spun	at	20,000	x	g	for	10	minutes,	4°C	to	pellet	nucleic	acid	and	debris.		The	remaining	supernatant	contained	the	protein	fraction.		Using	a	Pierce	BCA	Protein	Assay	kit	 (Thermo	Scientific),	a	standard	solution	of	2mg/ml	bovine	serum	albumin	(BSA)	was	prepared	and	serially	diluted	1:2,	7	 times.	 	 In	a	black-walled	 96-well	 plate,	 10μl	 of	 sample	 or	 of	 standard	 BSA	 dilution	 was	 added	 in	triplicate	to	each	well.	 	Again,	sample	supernatant	was	diluted	1:10	if	the	protein	concentration	was	above	the	limit	of	assay.		200μl	of	reagent	mix	is	then	added	to	each	 well,	 allowed	 to	 incubate	 for	 30minutes,	 37°C	 on	 an	 orbital	 shaker.	 	 The	absorbance	at	492nm	was	 then	measured	 in	a	Synergy	HT	plate	 reader	 (BioTek,	U.S.A.)	 and	 the	 protein	 concentration	 calculated	 as	 per	 the	 standard	 curve.	 	 The	experiment	 was	 repeated	 for	 3	 different	 25cm2	 flasks	 to	 give	 a	 mean	 average	protein	 content	 per	 monolayer.	 	 ELISA	 results	 were	 then	 converted	 to	 IL-8	concentration	per	mass	of	cellular	protein.		
2.3.11	 RNA	extraction		RNA	 extraction	 from	 25cm2	 Griener	 flask	 for	 Caco-2	 and	HT29	monolayers	was	performed	using	the	phenol-based	method	described	below.			RNA	extraction	for	polarised,	Caco-2	monolayers	grown	on	cell	culture	inserts	was	more	 difficult	 to	 achieve	 and	 required	 several	 optimisation	 attempts	 in	 order	 to	
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extract	 RNA	 of	 sufficient	 quality.	 	 Optimisation	 steps	 included	 using	 polarised	monolayers	from	both	24-well	and	then	6-well	culture	inserts	(providing	a	greater	concentration	 of	 genetic	material),	 using	 10mM	 EDTA	 to	 lift	 the	 cells	 or	 adding	TRIzol	 directly	 to	 the	 inserts	 to	 remove	 the	 cells,	 using	 the	 total	 phenol-based	method	 for	 RNA	 extraction	 or	 by	 using	 the	 spin	 column	 method	 for	 RNA	extraction.		Finally,	a	combination	of	both	phenol-based	and	spin-column	methods	was	used,	as	described	below.			An	example	of	the	spectrophotometer	reading	for	contaminated	Caco-2	RNA,	 prior	 to	 the	 optimisation	 of	 this	 process,	 is	 shown	 in	figure	2.5.	
2.3.12	 Phenol-based	RNA	extraction	As	described	initially	by	Chomczynski	and	Sacchi,	guanidinium-thiocyanate-phenol	in	 the	 form	of	TRIzol	 reagent	was	used	 to	 extract	RNA(Chomczynski	 and	Sacchi,	1987).	 	 Experiments	 were	 performed	 using	 nuclease	 free,	 sterile	 equipment;	surfaces	 were	 cleaned	 with	 RNase	 Zap	 (Life	 Technologies,	 UK),	 filter	 tips	 were	used	 for	 pipetting	 and	 latex	 gloves	 were	 worn.	 	 The	 TRIzol	 reagent	 (Life	Technologies)	 was	 used	 according	 to	 the	 manufacturers	 guidelines.	 	 Cells	 were	removed	from	a	25cm2	flask	using	10mM	EDTA,	pH	8.0	and	then	resuspended	in	TRIzol	at	a	concentration	of	1ml	per	106	cells.		The	TRIzol	suspension	was	left	for	5	minutes	at	room	temperature	before	adding	chloroform	at	a	concentration	of	20%	of	the	total	volume	of	TRIzol	used.	 	The	suspension	was	mixed	using	a	bench	top	vortex	and	then	spun	at	12,000	x	g	 for	15	minutes,	4oC.	 	The	aqueous	phase	was	removed	and	the	residual	phenol	was	discarded.		2-propanol,	at	a	concentration	of	50%	of	the	total	volume	of	TRIzol	used,	was	added	to	the	aqueous	phase	and	left	for	11minutes	at	room	temperature	and	spun	at	12,000	x	g	for	10minutes,	4oC	to	produce	 an	 RNA	 pellet.	 	 The	 supernatant	was	 carefully	 removed	 and	 discarded.		
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The	RNA	pellet	was	 then	precipitated	 in	1ml	75%	ethanol,	 spun	at	7,500	x	g	 for	5minutes,	4oC.		The	pellet	was	then	allowed	to	dry	before	reconstitution	in	50µl	of	RNAse	free	water.	
2.3.13	 Phenol-based	method	combined	with	spin	column-based	RNA	extraction	Spin	 Columns	 use	 a	 solid	 phase	 extraction	method	 in	 which	 RNA	 is	 purified	 by	binding	 to	 silica	within	a	manufactured	 tube(Boom	et	al.,	1990).	 	This	method	 is	more	expensive	than	the	phenol-based	method,	but	 is	 fast	and	produces	a	higher	yield	of	RNA	when	the	biological	sample	is	small(Boom	et	al.,	1990).	A	protocol	combining	both	 the	TRIzol	and	spin	column	methods	was	 followed	to	extract	 RNA	 from	 polarised,	monolayers.	 	 Again,	 RNA	 extraction	was	 performed	using	 nuclease	 free,	 sterile	 equipment.	 	 An	 RNeasy	 Mini-Kit	 (74104,	 Qiagen,	Netherlands)	was	used	as	per	the	following	protocol.		Fully	 differentiated	 polarised	 Caco-2	monolayers	were	 grown	 on	 6-well	 culture	inserts	as	described	in	section	2.2.2.	 	Growth	media	was	changed	every	48	hours.	Monolayers	were	co-cultured	for	24	hours	with	an	apical	growth	media	containing	1μM	6-ECDCA	(FXR	agonist)	or	equivalent	vehicle	(DMSO).		Inflammatory	cytokine	(100ng/ml	TNFα,	IFNγ	or	IL-6)	or	PBS	(vehicle)	was	then	added	to	the	basolateral	media.	 	 Previous	 experiments	 had	 demonstrated	 that	 TEER	 reached	 a	 nadir	 at	approximately	 48	 hours	 post	 exposure	 and,	 therefore,	 the	 monolayers	 were	exposed	 to	 inflammatory	 cytokine	 for	 48	 hours	 in	 total.	 	 At	 the	 end	 of	 the	experiment,	 the	 monolayers	 were	 washed	 in	 PBS	 and	 700μl	 TRIzol	 was	 added	directly	 to	 the	 culture	 insert.	 	 Experiments	were	performed	 in	duplicate	 and	 the	TRIzol/cell	 mixture	 from	 two	 identically	 treated	 culture	 inserts	 was	 then	combined	in	a	single	Eppendorf.	 	The	TRIzol	suspension	was	left	for	5	minutes	at	room	temperature	before	adding	chloroform	at	a	concentration	of	20%	of	the	total	
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volume	of	TRIzol	used.	 	The	suspension	was	mixed	using	a	bench	top	vortex	and	then	spun	at	12,000	x	g	for	15	minutes,	4oC.		Approximately	600μl	of	the	aqueous	phase	 was	 removed	 and	 an	 equal	 volume	 of	 70%	 ethanol	 was	 added	 and	 the	sample	mixed	 by	 pipetting.	 	 700μl	 of	 the	 sample	was	 transferred	 to	 a	 RNA	 spin	column,	 in	a	2ml	collection	tube,	and	spun	at	8,000	x	g	 for	15	seconds.	 	The	flow	through	was	discarded	and	700μl	of	buffer	RW1	was	added	and	spun	at	8,000	x	g	for	15	seconds.		The	spin	column	was	then	washed	with	two	cycles	of	500μl	buffer	RPE,	 spun	 for	 8,000	 x	 g	 for	 15	 seconds	 and	 2	minutes	 respectively.	 	 Finally,	 the	RNA	was	precipitated	 in	30μl	of	nucleic	 acid	and	RNase-free	water	and	spun	 for	8,000	x	g	 for	1	minute	 to	collect	 the	RNA	containing	precipitate	 in	a	 fresh,	1.5ml	Eppendorf.	
2.3.14	 RNA	quantity	and	quality	The	efficiency	of	downstream	assays	depends	on	the	purity	of	RNA	isolated.	 	The	quantity	and	quality	of	RNA	 isolated	by	 the	above	protocol	was	assessed	using	a	spectrophotometer	(Nanodrop	ND-1000)	and	by	gel	electrophoresis.			The	Nanodrop	spectrophotometer	measures	the	absorbance	(A)	of	light	at	260nm,	to	 give	 an	 estimate	 of	 RNA	 quantity,	 and	measures	 the	 absorbance	 of	 potential	contaminants	 at	 260nm	 and	 280nm.	 	 Potential	 contaminants	 include	 organic	solvents,	 such	 as	 phenol,	 peptides,	 carbohydrates,	 and	 salts	 such	 as	 guanidine	thiocyanate(von	Ahlfen	and	Schlumpberger,	2010).		The	ratio	of	A260/280nm	and	A260/230nm	gives	an	estimate	of	nucleic	acid	purity,	with	ratios	between	1.8	and	2.1	indicative	of	extremely	pure	RNA.	 	No	lower	limits	of	acceptable	contaminant	ratios	 exist,	 but	 for	 the	 purposes	 of	 these	 experiments,	 A260/280nm	 and	A260/230nm	of	1.5	to	2.2	were	accepted.		Low	levels	of	the	A260/230nm	ratio	are	usually	due	to	contamination	with	guanidine	thiocyanate,	which	is	found	in	many	
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RNA	extraction	buffer	reagents.		A	study	has	demonstrated	that	even	high	levels	of	guanidine	 thiocyanate	 contamination	 do	 not	 interfere	with	 downstream	RT-PCR	reactions(von	 Ahlfen	 and	 Schlumpberger,	 2010).	 	 Figure	 2.5	 demonstrates	examples	 of	 spectrophotometer	 readings	 for	 poor	 quality	 Caco-2	 RNA,	 purified	Caco-2	RNA	and	purified	HT29	RNA.		 	
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Figure	2.5;	 	Examples	of	spectrophotometer	readings	for	extracted	RNA	used	 in	chapter	2	(A)	
Purified	Caco-2	RNA,	(B)	purified	HT29	RNA,	(C)	Poor	quality	RNA	pre-optimisation	of	extraction	
technique.		The	Nanodrop	ND	1000	provides	a	visual	representation	of	absorbance	at	different	
wavelengths	and	calculates	the	A260/280	and	A260/230	as	described	in	the	text.		In	addition,	it	
provides	an	estimate	of	the	concentration	of	RNA	(ng/μl).	
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Gel	 electrophoresis	 of	 the	 RNA	 solute	 was	 performed	 by	 120v	 electrophoresis,	with	1xTAE	buffer,	 on	 a	 1.2%	agarose,	 0.5µg/ml	 ethidium	bromide	 gel.	 	 5µl	 of	 a	1kb	DNA	ladder	control	was	loaded	alongside	5µl	of	RNA,	mixed	with	Orange	G	at	a	ratio	 of	 1	 in	 10.	 	 RNA	molecules	 have	 a	 negatively	 charged	phosphate	 backbone	and	therefore	move	away	from	the	negatively	charged	cathode.		After	45	minutes,	the	electrophoresis	was	terminated	and	the	gel	was	illuminated	in	a	UV	light	box	to	highlight	the	ethidium	bromide	bound	proteins.		Pure	RNA	is	demonstrated	by	the	presence	of	discrete	bands	indicating	the	18s	and	28s	subunits	of	ribosomal	RNA.		Gel	 electrophoresis	 was	 performed	 for	 optimisation	 steps	 and	 intermittently	during	 RNA	 extraction	 to	 ensure	 RNA	 quality	 was	 maintained.	 	 Figure	 2.6	demonstrates	examples	of	UV	light	exposed	electrophoresis	gels	run	with	purified	RNA	from	Caco-2	and	HT29	cells.	
	
Figure	2.6;		Examples	of	electrophoresis	gels	for	purified	RNA	used	in	these	experiments	from	A)	
Caco-2	cells	and	B)	HT29	cells.		The	28s	and	18s	ribosomal	units	can	be	clearly	identified	
2.3.15	 Complementary	DNA	(cDNA)	synthesis	Complementary	 DNA	 (cDNA)	 was	 prepared	 using	 the	 Tetro	 cDNA	 Synthesis	 Kit	(Bioline)	as	per	the	manufacturers	guidelines.		As	for	RNA	extraction,	nuclease	free	equipment	 and	 reagents	 were	 used,	 surfaces	 were	 cleaned	 with	 RNase	
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decontamination	solution	(RNaseZap,	Ambion,	Life	Technologies)	and	filter	pipette	tips	 were	 used.	 	 All	 procedures	 were	 performed	 on	 ice	 to	 minimize	 RNA	degradation.	 	A	solution	of	isolated	RNA	was	prepared	in	an	autoclaved	PCR	tube	representing	up	to	5µg	of	total	RNA.		To	this	was	added	1µl	of	oligo	dT	primer;	this	recognises	and	binds	only	to	the	poly-A	tail	found	on	eukaryotic	mRNA	sequences.		Then	 in	 sequence	 was	 added	 1µl	 of	 10mM	 dNTP	 mix,	 4µl	 of	 5x	 reverse	transcriptase	 buffer,	 1µl	 of	 Ribosafe	 RNase	 inhibitor	 and	 1µl	 of	 Tetro	 reverse	transcriptase.	 	 The	 solution	 was	 made	 up	 to	 20µl	 using	 RNAse	 free	 water	 if	necessary	and	run	in	a	thermal	cycler	at	45oC	for	30	minutes	and	then	at	85oC	for	5minutes	 to	 terminate	 the	reaction.	 	 Samples	were	 then	stored	at	 -20oC	 for	 later	use	in	the	second	part	of	two-step	RT-PCR	experiments.	
2.3.16	 Real-time	reverse	transcription	polymerase	chain	reaction	(RT-PCR)	RNA	isolated	from	Caco-2	and	HT29	cells	was	used	to	measure	the	relative	mRNA	level	of	a	variety	of	genes	using	RT-PCR	via	a	TaqMan-based	chemistry	assay	(Life	Technologies).	 	The	relative	mRNA	 level	of	FXR	and	 its	downstream	targets,	SHP	and	IBABP,	was	measured	to	assess	the	effect	of	FXR	activity	in	both	cell	lines.		The	relative	mRNA	 expression	 of	 IL-8	 was	measured	 in	 HT29	 cells	 used	 in	 the	 IL-8	secretion	 experiments	 (section	 2.2.7).	 	 In	 addition,	 the	 relative	 mRNA	 levels	 of	myosin	light	chain	kinase	(MLCK)	were	measured	in	the	RNA	extracted	from	Caco-2	cells	grown	in	polarised	monolayers	and	treated	with	inflammatory	cytokine	+/-	FXR	agonist	(section	2.2.9).	Polymerase	chain	reaction	(PCR)	is	a	wet-lab	process	by	which	small	molecules	of	DNA	are	copied	and	amplified	many	times	using	sequence	specific	oligonucleotides	and	DNA	polymerases	 in	 repeated	 cycles	of	heating	 and	annealing.	 	 In	 a	RT-PCR	experiment,	 the	amount	of	DNA	is	measured	after	each	PCR	cycle	via	 fluorescent	
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dyes	 that	 produce	 increasing	 amounts	 of	 a	 fluorescent	 signal	 as	 the	 amount	 of	replicated	DNA	increases.		A	variety	of	fluorescence	reactions	are	available,	but	for	these	 experiments	 a	 TaqMan	 assay	 was	 utilised(Holland	 et	 al.,	 1991).	 	 TaqMan	chemistry	is	thought	to	be	relatively	specific	and	sensitive	in	comparison	to	other	methods,	such	as	SYBR	Green(Cao	and	Shockey,	2012).	The	TaqMan	assay	uses	a	pair	of	primers	and	a	potentially	fluorescent	probe.		Gene	of	interest	specific,	forward	and	reverse	primers	for	taq	DNA	polymerase	bind	to	a	single	 strand	 of	 DNA	 to	 produce	 two	 copies.	 	 The	 probe	 is	 an	 oligonucleotide,	containing	 a	 5’	 fluorophore	 and	 a	 3’	 quencher	 molecule	 that	 inhibits	 the	fluorescence	of	the	probe.		The	probe	anneals	to	a	specific	single	strand	of	DNA	for	the	 gene	 of	 interest	 within	 a	 region	 amplified	 by	 the	 taq	 polymerase	 primers.		Whilst	 the	 fluorophore	 and	 quencher	 molecule	 are	 in	 close	 proximity,	 any	fluorescence	 is	 absorbed.	 	 As	 it	 progesses,	 taq	 DNA	 polymerase	 cleaves	 the	fluorophore	 from	 its	 quencher,	 increasing	 the	 overall	 fluorescence	 signal.	 	 The	reaction	 continues	 to	 then	 release	 the	 residual	 probe	 from	 the	 DNA	 strand	allowing	DNA	synthesis	to	be	completed.	 	In	this	way,	with	each	cycle	of	PCR,	the	amount	of	fluorescence	increases.		Figure	2.7	demonstrates	this	process	in	a	single	cycle	of	PCR.		 	
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Figure	 2.7;	 	 A	 representation	 of	 a	 single	 cycle	 of	 PCR	 using	 a	 TaqMan	 probe-based	 assay.		
Heating	separates	two	strands	of	cDNA;	the	pair	of	taq	polymerase	primers	bind	and	taq	DNA	
polymerase	replicates	alternate	strands	of	cDNA	in	a	5’-3’	direction;	the	specific	oligonucleotide	
probe	 binds,	 but	 does	 not	 fluoresce	 whilst	 the	 quencher	 portion	 is	 in	 close	 proximity	 to	 the	
fluorophore;	 as	 DNA	 replication	 progresses,	 the	 probe	 is	 cleaved,	 releasing	 the	 fluorescing	
portion;	the	new	strands	anneal	to	complete	the	cycle	Human	specific,	TaqMan	Gene	Expression	Assays	(pair	of	PCR	primers	and	specific	hydrolysis	 probe)	 to	 FXR,	 SHP,	 IBABP,	 IL-8,	 MLCK	 and	 GAPDH	 were	 purchased	from	Life	Technologies.		Table	2.1	lists	the	primer/probes	and	their	targets	used	in	these	 experiments.	 	 In	 order	 to	 avoid	 false	 positive	 detection	 of	 genomic	 DNA	(gDNA),	 TaqMan	 primers/probes	 that	 span	 exon-exon	 junctions	 (intron-splice	sites)	were	used	in	these	experiments	where	possible.		 	
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Protein	 Gene		
Exon	
spanning	
Primer/Probe	
FXR	 NR1H4	 yes	 Hs01026590_m1	
SHP	 NR0B2	 yes	 Hs00222677_m1	
IBABP	 FABP6	 yes	 Hs01031183_m1	
IL-8	 IL8	 yes	 Hs00174103_m1	
MLCK	 MYLK	 yes	 Hs00364926_m1	
GAPDH	 GAPDH	 yes	 Hs02758991_g1	
Table	2.1;		List	of	genes	of	interest	and	TaqMan	primer/probes	used	in	chapter	2	In	a	96-well	PCR	plate,	10μl	of	2x	mastermix	(SensiFAST	Probe	Hi-ROX	kit,	Bioline,	UK),	 1μl	 of	 premixed	 primer/probe	 (TaqMan	 Gene	 Expression	 Assays,	 Life	Technologies),	1μl	of	cDNA	template	and	8μl	of	RNase	free	water	were	prepared.			Again	all	procedures	were	performed	on	 ice	 to	avoid	RNA	degradation	and	were	performed	with	RNase-free	materials.		Mastermix	contains	the	reagents	necessary	to	 perform	 PCR,	 including	 DNA	 polymerase,	 dNTPs,	 stabilisers	 and	 magnesium	chloride	 (enzyme	 co-factor).	 	 The	 addition	 of	 the	 ROX	 (5-carboxy-X-rhodamine)	fluorophore	 allows	 for	 the	 normalisation	 of	 non-PCR	 associated	 fluctuations	 in	fluorescence.		The	plate	was	centrifuged	at	500	x	g	for	1	minute	and	then	incubated	for	 20secs	 at	 95°C	 before	 going	 through	 40	 cycles	 of	 PCR	 of	 1	 second	 at	 90°C	followed	by	20secs	at	65°C	to	allow	primers	to	anneal	and	new	strands	to	extend.		Experiments	 were	 performed	 using	 an	 Applied	 Biosystems	 StepOnePlusTM	 Real-time	PCR	system	machine.	
2.3.17	 RT-PCR	quality	control	To	minimise	 assay	 errors	 due	 to	 incorrect	 pipetting,	 each	 RT-PCR	 reaction	 was	performed	 in	 triplicate.	 	 If	 the	 threshold	cycle	(Ct,	see	below)	differed	by	greater	than	 1.0	within	 triplicate	 samples,	 that	well	was	 excluded	 from	 further	 analysis.		
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For	each	96-well	PCR	plate,	a	no-template	control	(NTC)	triplicate	experiment	was	performed	 to	 ensure	 there	 was	 no	 DNA	 contamination	 within	 the	 mastermix,	primer/probe	 or	 water	 used	 in	 the	 experiments.	 	 To	 ensure	 no	 gDNA	contamination	of	the	RNA	preparation	used	to	make	the	cDNA	template,	an	RNA-template	reaction	was	performed	for	representative	samples.	
Relative	quantitative	RT-PCR	calculations	assume	that	the	reaction	efficiency	of	the	primer/probe	is	100%,	with	an	acceptable	range	of	90%	to	110%.		Primers	were	validated	by	measuring	Ct	 for	1/10	serially	diluted	cDNA	concentrations,	plotted	on	a	log10	scale.		The	slope	of	this	curve	can	be	used	to	calculate	the	efficiency	of	each	primer	via	the	equation:	
Efficiency	=	10(-1/slope)	–	1	
The	 R2	 co-efficient	 of	 the	 standard	 curve	 is	 a	 measure	 of	 the	 degree	 of	 fit	 and	therefore	of	replicate	reproducibility;	it	should	be	>0.98.		Figure	2.8	and	table	2.2	demonstrate	primer	validation	results	for	the	primers	used	in	these	experiments.	
Primer	 Slope	 Efficiency	 R-squared	
FXR	 -3.273	 102.1%	 1.00 
SHP	 -3.193	 105.7%	 0.99 
IBABP	 -3.17	 106.8%	 0.97 
IL-8	 -3.127	 108.8%	 0.99 
MLCK	 -3.279	 101.8%	 1.00 
GAPDH	 -3.349	 98.9%	 0.96 
Table	2.2;		Primer	efficiency	and	goodness	of	fit	(R2)	for	primers	used	in	chapter	2.		See	fig	2.8	
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Figure	 	 2.8;	 	 Primer	 validation	experiments	 for	 primers	used	 in	 chapter	 2.	 	 Threshold	 cycle	 is	
measured	for	serial	dilutions	of	cDNA.		See	table	2.2	for	R2	and	efficiency	calculation		 	
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2.3.18	 Threshold	cycle	and	relative	quantification	An	RT-PCR	 experiment	 creates	 an	 amplification	 plot	with	 fluorescence	 on	 the	y-axis	and	cycle	number	on	the	x-axis.		The	reaction	can	be	divided	into	3	phases;	a	baseline	phase	during	which	there	is	little	change	in	the	fluorescent	signal,	which	remains	 barely	 detectable;	 an	 exponential	 phase,	 during	 which	 ‘perfect’	 PCR	 is	occurring	with	 the	 concentration	 of	 DNA	 doubling	 every	 cycle;	 finally,	 a	 plateau	phase	when	reagents	begin	to	be	depleted	and	DNA	replication	begins	to	slow	(see	figure	2.9).	
	
Figure	2.9;		See	text	for	detail.		An	example	of	an	RT-PCR	amplification	plot	to	demonstrate	the	
concept	of	threshold	cycle	(Ct).		In	this	example,	highest	concentration	gives	Ct	20.	The	threshold	cycle	(Ct)	is	the	cycle	number	at	which	the	fluorescent	signal	crosses	a	determined	 level.	 	Samples	with	a	higher	concentration	of	DNA	at	baseline	will	cross	 the	Ct	earlier	 than	samples	with	 lower	 levels	of	DNA	at	baseline.	 	The	Ct	 is	
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determined	 during	 the	 exponential	 phase	 and	 is	 constant	 across	 all	 samples	 to	allow	relative	quantification.	
To	measure	the	expression	levels	of	mRNA	for	each	gene	of	interest	in	the	different	samples,	relative	quantification	was	used.	 	This	method	compares	the	expression	of	the	gene	of	 interest	(e.g.	TNFα)	in	comparison	to	a	standard	or	reference	gene	(also	known	as	a	housekeeper	gene).		The	expression	of	the	reference	gene	should	remain	stable	throughout	the	samples,	being	unchanged	by	any	intervention.		The	quantity	 of	 the	 gene	 of	 interest,	 relative	 to	 the	 reference	 gene,	 can	 then	 be	compared	 between	 a	 control	 sample	 and	 an	 intervention	 sample.	 	 Relative	quantification	 is	 faster	 than	 absolute	 quantification	 and	 doesn’t	 rely	 on	 the	production	of	sensitive	standard	curves.		
The	choice	of	reference	gene	is,	however,	critically	important	in	the	analysis	of	the	results.	 	 In	 these	 experiments,	 the	 commonly	 used	 reference	 gene	 for	glyceraldehyde	 3-phosphate	 dehydrogenase	 (GAPDH)	 was	 used(Barber	 et	 al.,	2005).	
2.3.19	 Fold	change	calculations	and	statistical	analyses	Relative	 quantification	 was	 calculated	 using	 the	 ΔΔCt	 method	 as	 described	 by	Livak	 and	 Schmittgen(Livak	 and	 Schmittgen,	 2001).	 	 From	 triplicate	 samples,	 a	mean	Ct	was	calculated	for	each	biological	sample.		The	relative	expression	of	the	gene	 of	 interest	 (GOI)	 in	 comparison	 to	 the	 reference	 gene	 (ΔCt)	 was	 then	calculated	by	the	equation:	ΔCt	=	mean	Ct	GOI	–	mean	Ct	reference	The	change	 in	relative	gene	expression	between	control	and	 intervention	groups	(ΔΔCt)	can	then	be	calculated	as:	
ΔΔCt	=	ΔCt	intervention		-	ΔCt	control	
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	The	 ratio	 of	 the	GOI	 in	 the	 intervention	 group	 relative	 to	 the	GOI	 in	 the	 control	group	(the	fold	change),	is	then	given	by:	Fold	Change	=	2-ΔΔCt	
This	converts	the	results	to	a	logarithmic	scale	(e.g.	2	fold	increase,	4	fold	decrease	etc.)	and,	therefore,	represented	error	bars	should	be	interpreted	with	caution.		A	fold	change	of	greater	than	2	is	thought	to	be	biologically	significant.	
Unpaired	Student’s	t-tests,	 two-way	ANOVA	(analysis	of	variance)	and	non-linear	regression	analyses	were	calculated	using	Prism	version	6.0e,	Graphpad	software,	San	Diego.		All	P	values	were	2-tailed,	and	a	P	value	of	0.05	or	less	was	considered	to	be	statistically	significant.	
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2.4	 Results	
2.4.1	 Optimisation	of	a	Caco-2	polarised	monolayer	model	Serial	measurements	 of	 the	 TEER	 of	 12	 different	monolayers	were	made	 over	 a	period	of	30	days,	 from	seeding	 to	 full	differentiation.	 	Figure	2.10	demonstrates	the	 mean	 (n=12)	 increase	 in	 TEER	 over	 time	 as	 the	 monolayer	 matures	 and	intercellular	 TJs	 form	 to	 decrease	 monolayer	 permeability.	 	 The	 Caco-2	monolayers	 formed	 high	 levels	 of	 unit	 area	 resistance	 with	 a	 best-fit	 peak	resistance	 of	 approximately	 2,700Ω/cm2	 and	 a	 subsequent	 slow	 decline	 in	resistance	up	to	30	days.	
	 	
Figure	2.10;	 	Mean	TEER	of	Caco-2	polarised	monolayers	with	time.	 	Dashed	line	is	best-fit	by	
non-linear	 regression.	 	 Dotted	 line	marks	 zenith	 of	 best-fit	 line.	 	 (For	 each	 data	 point,	 n=12,	
standard	error	of	mean	[SEM]).				 	
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In	 order	 to	 model	 the	 effect	 of	 CD	 associated	 inflammatory	 cytokines	 on	 gut	epithelial	 permeability,	 the	TEER	was	measured	at	 several	 time	points	 following	exposure	of	the	fully	differentiated	(>	21	day	post	seeding),	polarised	monolayer	to	IFNγ,	TNFα	and	IL-6.			
Figure	2.11	demonstrates	the	effect	on	mean	TEER	(n=4),	over	time,	of	100ng/ml	of	cytokine,	added	to	 the	basolateral	compartment.	 	The	results	are	presented	as	change	 in	 TEER	 normalised	 to	 a	 baseline	 of	 1.0.	 	 An	 untreated	 control	 group	 is	presented	as	a	comparison.		For	each	cytokine,	there	is	a	significant	decrease	in	the	epithelial	permeability,	over	the	120	hours	of	the	experiment,	in	comparison	with	control	(by	two-way	ANOVA,	IFNγ	p	<	0.0001,	TNFα	p	<	0.0001,	IL-6	p	<	0.0001).			
	
Figure	2.11;	 	 The	mean	change	 in	TEER	over	 time	 (normalised	 to	1.0)	 for	Caco-2	monolayers	
exposed	to	100ng/ml	of	IL-6,	IFNγ	or	TNFα	in	comparison	to	control	(n=4,	error=SEM).	TEER	is	
significantly	different	between	cytokine	treated	and	control	groups	(2-way	ANOVA	p<0.0001).	
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There	is	a	dose-response	relationship	between	the	concentration	of	inflammatory	cytokine	and	the	reduction	in	TEER.		Figure	2.12	demonstrates	the	mean	TEER	at	48	hours	for	different	concentrations	of	cytokine.	 	 It	can	be	seen	that	cytokine	at	10ng/ml	 and	 100ng/ml	 produces	 a	 significant	 reduction	 in	 TEER,	 as	 compared	with	control,	for	all	of	the	cytokines	tested.	 	At	concentrations	of	1ng/ml,	there	is	no	 significant	 difference	 in	 TEER	 as	 compared	 with	 control.	 	 Table	 2.3	demonstrates	 the	 results	 from	 unpaired	 Student’s	 t-tests,	 with	 95%	 confidence	intervals,	 for	 the	 TEER	 at	 48	 hours	 for	 each	 concentration	 of	 cytokine	 tested	 in	comparison	with	control.	
Cytokine	 Concentration	 P-value	 95%	Confidence	
interval	
TNF 	 0ng/ml	 N/A	 N/A	
	 1ng/ml	 0.180	 -243.5	to	930.1	
	 10ng/ml	 *0.011	 337.4	to	1406	
	 100ng/ml	 **0.002	 524.5	to	1203	
IFN 	 0ng/ml	 N/A	 N/A	
	 1ng/ml	 0.266	 -231.4	to	634.6	
	 10ng/ml	 **<0.001	 1003	to	1573	
	 100ng/ml	 **<0.001	 1001	to	1571	
IL-6	 0ng/ml	 N/A	 N/A	
	 1ng/ml	 0.336	 -291.4	to	669.4	
	 10ng/ml	 **0.002	 755.5	to	1694	
	 100ng/ml	 **0.001	 936.2	to	1866	
Table	 2.3;	 	 A	 table	 to	 demonstrate	 the	 results	 of	 unpaired	 Student’s	 t-tests	 for	 different	
concentrations	of	cytokine	versus	control	 (0ng/ml)	 for	TEER	at	48	hours	 in	Caco2	monolayers	
(results	given	to	3	decimal	places).		 	
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Figure	2.12;		The	mean	TEER	of	polarised	Caco-2	monolayers	at	48	hours	after	stimulation	with	
different	concentrations	of	CD	associated	cytokines	(n=4,	SEM,	2-tailed	unpaired	t-tests)	
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An	 LDH	 release	 assay	 demonstrated	 that	 the	 disruption	 to	 the	 epithelial	 barrier	observed	when	monolayers	were	challenged	with	cytokine	was	not	caused	by	cell	death	and	subsequent	cell	lysis,	as	seen	in	figure	2.13.	
	
Figure	2.13;	 	LDH	release	assay	for	polarised	Caco-2	monolayers	stimulated	with	100ng/ml	of		
IL-6,	 TNFα	or	 IFNγ.	 	 Controls	 are	monolayers	 treated	with	 vehicle	 (PBS),	 TritonX	1%	 (positive	
control)	and	fresh,	untreated	growth	media	(negative	control)	 	
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2.4.2	 6-ECDCA	and	GW4064	agonise	FXR	in	both	Caco-2	and	HT29	cells	A	 measure	 of	 FXR	 activity	 was	 performed	 by	 assaying	 the	 expression	 of	 FXR	downstream	targets,	SHP	and	IBABP.	On	 stimulation	 with	 the	 FXR	 agonists	 6-ECDCA	 and	 GW4064,	 both	 Caco-2	 and	HT29	cells	demonstrated	an	increase	in	the	level	of	mRNA	for	SHP	and	IBABP,	in	comparison	 to	 vehicle	 (DMSO)	 treated	 cells	 (see	 figures	 2.14	 and	 2.15).	 	 As	described	in	section	2.2.13,	relative	gene	expression	was	calculated	to	give	a	fold	change	in	mRNA	levels	between	control	and	FXR	agonist	treated	groups.	In	 Caco-2	 cells,	 both	 10μM	 6-ECDCA	 and	 10μM	 GW4064	 were	 able	 to	 induce	 a	positive	fold	change	in	FXR,	SHP	and	IBABP,	which	was	greater	at	24	hours	than	at	48	hours	(figure	2.14).		Under	these	experimental	conditions,	6-ECDCA	had	greater	downstream	 effects	 on	 SHP	 and	 IBABP	 expression	 than	 GW4064.	 	 6-ECDCA	induced	a	positive	fold	change	of	2.5	in	FXR,	41.3	in	SHP	and	29.3	in	IBABP	at	24	hours.		In	comparison,	GW4064	induced	a	positive	fold	change	of	8.9	in	FXR,	2.1	in	SHP	and	8.9	in	IBABP	at	24	hours.	However,	 when	 the	 same	 experimental	 conditions	 were	 applied	 to	 HT29	 cells,	slightly	 different	 results	were	 observed.	 	 Unlike	 Caco-2	 cells,	 neither	 of	 the	 FXR	agonists	was	able	to	induce	auto-upregulation	of	FXR	in	HT29	cells,	with	in	fact	a	biologically	significant	fold	reduction	in	relative	FXR	mRNA	(see	figure	2.15).	The	 EC50	 of	 both	 FXR	 agonists	 is	 close	 to	 0.1μM.	 	 Therefore,	 experiments	 were	repeated	using	this	 lower	dose,	to	test	whether	the	observed	results	were	due	to	any	potential	cytotoxicity	induced	by	higher	concentrations	of	agonist.		The	0.1μM	dose	of	both	agents	was	also	unable	to	upregulate	FXR	expression	in	HT29	cells.	The	downstream	FXR	targets	were,	however,	positively	induced	at	24	hours,	with	the	 higher	 10μM	 concentration	 of	 both	 agonists	 demonstrating	 a	 greater	 effect.		Only	 a	 small	 positive	 fold	 change	 was	 found	 at	 24	 hours	 for	 SHP,	 of	 2.2	 for	 6-
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ECDCA	 and	 1.2	 for	 GW4064.	 	 IBABP	 mRNA	 expression,	 however,	 was	 strongly	induced	 with	 fold	 changes	 of	 42.3	 and	 216.1	 for	 6-ECDCA	 and	 GW4064	respectively,	at	24	hours	(see	figure	2.15).		 	
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Figure	2.14;		The	relative	gene	expression	(as	fold	change)	of	FXR	and	its	downstream	targets,	
SHP	and	 IBABP,	 in	Caco-2	 cells	 treated	with	 6-ECDCA	 (10μM)	or	GW4064	 (10μM)	24	and	48	
hours	post	exposure	(n=3,	SEM,	y-axis	is	log	scale).	
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Figure	2.15;		The	relative	gene	expression	(as	fold	change)	of	FXR	and	its	downstream	targets,	
SHP	 and	 IBABP,	 in	HT29	 cells	 treated	with	 6-ECDCA	 (0.1μM	&	 10μM)	 or	 GW4064	 (0.1μM	&	
10μM)	24	hours	post	exposure	(n=3,	SEM,	y-axis	is	log	scale).	
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2.4.3	 Activation	 of	 FXR	 does	 not	 maintain	 Caco-2	 monolayer	 permeability	 when	
disrupted	with	inflammatory	cytokines	In	order	to	assay	whether	FXR	agonism	could	maintain	epithelial	barrier	function	when	disrupted	with	CD	associated	cytokines,	TEER	was	measured	 in	the	Caco-2	monolayer	model	after	insult	with	IFNγ,	TNFα	and	IL-6	both	with	and	without	6-ECDCA.			Figures	 2.16,	 2.17	 and	 2.18	 demonstrate	 the	 epithelial	 barrier	 dysfunction,	 as	measured	 by	 TEER,	 on	 exposure	 to	 IL-6,	 IFNγ	 or	 TNFα,	 during	 the	 period	 of	observation	(up	to	11	days).			The	TEER	remained	stable	or	increased	in	the	control	(DMSO	treated)	or	6-ECDCA	-alone	treated	monolayers.		There	is	a	significant	reduction	in	the	TEER,	compared	with	6-ECDCA	–alone	treatment,	when	monolayers	are	exposed	to	100ng/ml	IL-6,	IFNγ	or	TNFα	(two-way	ANOVA,	variance	from	baseline	p	<	0.001).			Pre-treatment	 of	 monolayers	 with	 6-ECDCA,	 at	 either	 10μM	 or	 1μM,	 did	 not	ameliorate	 the	 reduction	 in	 TEER	 observed	when	monolayers	 were	 stressed	 by	inflammatory	 cytokine.	 	Data	 are	only	 shown	 for	monolayers	 exposed	 to	1μM	6-ECDCA.	 	 There	 was	 no	 significant	 difference,	 as	 tested	 by	 two-way	 ANOVA,	between	the	inflammatory	cytokine	treated	groups	and	the	cytokine	plus	6-ECDCA	intervention	groups.	
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Figure	2.16;		Mean	TEER	for	polarised	Caco-2	monolayers	treated	with	IL-6	(100ng/ml	)	+/-	6-
ECDCA	(1μM),	or	control	(n=4,	SEM).	 	There	is	a	significant	reduction	in	TEER	from	control	for	
IL-6	 exposed	 monolayers	 (Two-way	 ANOVA	 p<0.001).	 	 The	 reduction	 in	 TEER	 was	 also	
significantly	different	in	the	IL-6	plus	6-ECDCA	monolayers.	
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Figure	2.17;		Mean	TEER	for	polarised	Caco-2	monolayers	treated	with	IFNγ	(100ng/ml	)	+/-	6-
ECDCA	(1μM),	or	control	 (n=4,	SEM).	There	 is	a	significant	 reduction	 in	TEER	from	control	 for	
IFNγ	 exposed	 monolayers	 (Two-way	 ANOVA	 p<0.001).	 	 The	 reduction	 in	 TEER	 was	 also	
significantly	different	in	the	IFNγ	plus	6-ECDCA	monolayers.	
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Figure	2.18;		Mean	TEER	for	polarised	Caco-2	monolayers	treated	with	TNFα	(100ng/ml	)	+/-	6-
ECDCA	(1μM),	or	control	 (n=4,	SEM).	There	 is	a	significant	 reduction	 in	TEER	from	control	 for	
TNFα	 exposed	 monolayers	 (Two-way	 ANOVA	 p<0.001).	 	 The	 reduction	 in	 TEER	 was	 also	
significantly	different	in	the	TNFα	plus	6-ECDCA	monolayers.		 	
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Lucifer	 yellow	 assays	 failed	 to	 demonstrate	 any	 significant	 difference	 in	paracellular	 flux	between	vehicle	 (DMSO)	 treated,	 inflammatory	cytokine	 treated	or	inflammatory	cytokine	plus	6-ECDCA	(10μM)	treated	monolayers.	 	Figure	2.19	demonstrates	 the	 basolateral	 supernatant	 fluorescence	 as	 a	 percentage	 of	 the	apical	supernatant	fluorescence	following	treatment	with	IL-6,	IFNγ	or	TNFα	+/-	6-ECDCA.		A	positive	control	with	1%	Triton-X	treated	monolayers	was	significantly	different	(2-tailed	t-test,	p=0.0026,	95%	CI	0.61-0.95).	
	
Figure	2.19;		Lucifer	yellow	flux	assay	in	polarised	Caco-2	monolayers	after	exposure	to	TNFα,	
IL-6	 or	 IFNγ	 +/-	 6-ECDCA	 (10μM)	 or	 vehicle	 (DMSO).	 	 1%	 Triton-X	 is	 included	 as	 a	 positive	
control.	 	The	flux	of	LY	 into	the	basolateral	compartment	 is	expressed	as	a	percentage	of	the	
apical	compartment	fluorescence	(n=3,	SEM,	t-test).	
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2.4.4	 Activation	of	FXR	maintains	Caco-2	cell	morphology	Bright-field	microscopy	revealed	no	differences	in	the	morphology	of	in-situ	Caco-2	 monolayers	 when	 treated	 with	 cytokine	 with	 or	 without	 FXR	 agonist	 as	compared	 to	 control.	 	 However,	 exposure	 did	 disrupt	 cell	 morphology	 when	monolayers	were	examined	in	cross-section	via	electron	microscopy.	Figure	 2.20	 (pages	 85-86)	 shows	 bright-field	 microscopy	 of	 cells	 treated	 with	vehicle	(DMSO),	100ng/ml	IL-6,	IFNγ	or	TNFα,	6-ECDCA	(10μM),	cytokine	with	6-ECDCA	 and	 1%	 Triton-X	 as	 a	 positive	 control.	 	 Intact	 cell	 junctions	 are	 clearly	visible.	 	 Also	 visible	 are	 the	 numerous	 vacuoles	 typical	 of	 Caco-2	 cells	 grown	 in	monolayers.	 	 In	 the	1%	Triton-X	 treated	 images,	 the	 junctions	between	 cells	 are	obviously	disrupted.	Transmission	 electron	 microscopy	 (TEM)	 of	 Caco-2	 demonstrates	 a	 well-differentiated	 polarised	 monolayer	 with	 enterocyte-like	 microvilli	 on	 the	 apical	surface	 (figure	2.22).	 	Also	visible	 are	 the	apical	TJ	 complex	and	 the	 invaginated	cell-cell	junctions.			
TEM	 reveals	 that	 cells	 stressed	 for	 48	 hours	 with	 IL-6	 and	 IFNγ	 show	morphological	 changes	 as	 compared	 with	 vehicle	 treated	 monolayers,	 with	multiple	 infra-TJ	complex	 fissures	within	the	cell-cell	 junctions	(see	white	arrow,	figure	2.22b).	 	Almost	no	morphological	changes	were	seen	(either	0	or	1	per	20	junctions	measured)	in	monolayers	stressed	with	TNFα.			
As	 described	 in	 section	 2.3.5,	 a	 standardised,	 blinded	 method	 was	 used	 to	determine	 the	 number	 of	 cell-cell	 junction	 fissures	 per	 20	 sections	 imaged.	Exposure	of	the	monolayers	to	6-ECDCA	for	24	hours	prior	to	stimulation	with	IL-6	or	 IFNγ	 reduced	 the	number	 of	morphological	 re-arrangements,	maintaining	 the	epithelial	 barrier	 (see	 fig	2.21).	This	was	 significant	 in	 the	 IFNγ	group	 (p	=	0.03	
		 85	
95%	CI	10.23-74.77),	but	 failed	 to	 reach	 significance	 in	 the	 IL-6	group	 (p	=	0.08	95%	 CI	 -9.01-59.02),	 where	 only	 a	 trend	 was	 observed.	 	 There	 were	 no	morphological	 re-arrangements	 in	 control	 (PBS)	 or	 6-ECDCA	 only	 treated	monolayers.	 	 The	 raw	 data	 are	 presented	 in	 table	 2.3	 and	 demonstrates	 the	reliability	of	findings	between	the	two	independent,	blinded	researchers.	
	
	
	
	
	
	
	
	
	
	
Figure	 2.20	 (pages	 86	 and	 87);	 Bright-field	 microscopy	 (10x)	 of	 in-situ	 Caco-2	 monolayers	
following	 treatment	 with	 A)	 6-ECDCA,	 B)	 vehicle,	 C)	 IFNγ,	 D)	 IL-6,	 E)	 TNFα,	 F)	 1%	 Triton-X.		
There	are	no	morphological	differences	between	control	and	cytokine	treated	monolayers.		The	
cell-cell	junctions	are	clearly	visible	(black	arrows).		1%	Triton-X	treated	monolayers,	shown	as	
a	positive	control,	demonstrate	grossly	disrupted	cell-cell	junctions	(white	arrows).	
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Figure	 2.22;	 	 TEM	 images	 demonstrating	 examples	 of	 Caco-2	 polarised	 monolayers	 with	
intervention	 groups	 (A)	 control,	 (B)	 IFNγ,	 (C)	 IL-6,	 (D)	 IFNγ	 +	 6-ECDCA,	 (E)	 IL-6	 +	 6-ECDCA	
(overpage).	 	Microvilli	 (black	 arrow),	 TJ	 complex	 (white	 arrow)	 and	 cell-cell	 junction	 fissures	
(dashed	arrows)	are	highlighted.		In	control	and	FXR	agonist	only	groups,	there	were	no	cell-cell	
junction	 fissures.	 	 Stress	with	 IL-6	and	 IFNγ	 (B	and	C)	produced	multiple	 fissures.	 	 Treatment	
with	FXR	agonist	(6-ECDCA)	reduced	the	number	of	observed	cell-cell	junction	fissures	(D	&	E)	
(A) 
(D) (C) 
(B) 
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2.4.5	 Activation	of	FXR	may	inhibit	cytokine	induced	upregulation	of	MLCK	In	order	to	test	whether	FXR	agonism	maintained	Caco-2	monolayer	morphology	via	 a	mechanism	 involving	 cytoskeletal	 re-arrangement	 facilitated	 by	MLCK,	 RT-PCR	was	performed	for	MLCK	mRNA	following	stimulation	with	IL-6,	IFNγ	or	TNFα	with	and	without	6-ECDCA.		Unfortunately,	data	was	only	collected	for	monolayers	exposed	 to	 IL-6,	 due	 to	methodological	 problems	 in	 extracting	 RNA	 of	 sufficient	quantity	or	quality	(see	section	2.3.9).	
When	stimulated	with	IL-6,	Caco-2	cells	grown	in	culture	as	a	polarised	monolayer,	demonstrated	a	marked	 increase	 in	 the	 relative	gene	expression	of	MLCK	with	a	positive	 fold	 change	 of	 435.4	 (figure	 2.23).	When	 cells	were	 pre-treated	with	 6-ECDCA	 for	 24	 hours,	 the	 IL-6	 induced	 upregulation	 of	 MLCK	 was	 completely	abolished.	
	
Figure	2.23;		Relative	gene	expression	for	MLCK,	as	measured	by	RT-PCR,	in	Caco-2	cells	grown	
as	a	polarised	monolayer	following	exposure	to	vehicle,	FXR	agonist	(6-ECDCA)	and	IL-6	+/-	FXR	
agonist	(6-ECDCA)	(n=3,	SEM)	
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2.4.6	 Optimisation	of	HT29	as	a	model	of	IL-8	secretion	In	 response	 to	 stress,	 epithelial	 cells	 up-regulate	 innate	 immune	 mechanisms,	including	the	production	of	the	neutrophil	chemo-attract	cytokine	IL-8.		In	order	to	model	 the	 effect	 FXR	 agonism	 may	 have	 on	 the	 production	 of	 IL-8	 when	 gut	epithelial	 cells	were	 stressed	with	 CD	 associated	 cytokines,	 several	 optimisation	experiments	were	performed	using	different	stressors	and	cell	lines.	Like	other	researchers,	Caco-2	cells	were	 found	 to	be	relatively	un-responsive	 to	stimulation	with	 IFNγ,	TNFα,	 IL-6	or	LPS,	as	measured	by	ELISA	for	 IL-8	(results	not	shown).			HT29	cells	were,	however,	 found	to	be	highly	responsive	to	TNFα.	 	On	co-culture	with	TNFα,	significantly	more	IL-8	could	be	detected,	in	comparison	with	control,	in	cell	supernatant	(p=0.0005	95%	CI	3727-6540)	(figure	2.24).			
	
Figure	 2.24;	 	 IL-8	 production	 by	 HT29	 cells	 when	 cultured	 with	 growth	 media	 containing	
100ng/ml	TNFα	in	comparison	with	control	(SEM,	n=3,	Student’s	t-test).	
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2.4.7	 FXR	agonism	reduces	the	IL-8	response	induced	by	TNFα	in	HT29	cells	In	order	to	assess	the	effect	of	FXR	agonism	on	the	production	of	IL-8,	HT29	cells	were	 cultured	 with	 TNFα	 following	 24	 hours	 of	 co-culture	 with	 different	concentrations	 of	 GW4064	 or	 6-ECDCA,	 with	 or	 without	 the	 FXR	 antagonist	guggulsterone.		The	IL-8	response	was	measured	both	at	a	protein	level	(by	ELISA)	and	at	a	gene	expression	level	(by	RT-PCR).	
When	HT29	 cells	were	pre-treated	with	high	doses	of	GW4064	 (10μM),	 the	 IL-8	response,	as	measured	by	ELISA,	to	TNFα	was	reduced	to	baseline	(p=0.0004,	95%	CI	3936-6728)(figure	2.25).	 	However,	 lower	doses	of	GW4064	(0.1μM	and	1μM)	had	no	significant	effect	on	the	concentration	of	IL-8.	
Guggulsterone	was	able	to	reverse	the	attenuating	effect	of	GW4064	(10μM),	with	significantly	 more	 TNFα-induced	 IL-8	 detected	 (p	 =	 0.0005,	 95%	 CI	 2423-4174)(figure	2.25).	 	Treatment	with	GW4064	alone	had	no	effect	on	the	baseline	IL-8	concentration.	
Measurement	 of	 IL-8	 gene	 expression	 confirmed	 the	 findings	 measured	 at	 a	protein	 level.	 	 As	 measured	 by	 RT-PCR,	 the	 higher	 dose	 of	 GW4064	 reduces	 to	baseline	the	up-regulation	of	IL-8	mRNA	associated	with	TNFα	stimulation	(figure	2.25).			
There	 is	 an	 inverse	 dose-response	 relationship	 between	 the	 co-treatment	concentration	 of	 GW4064	 and	 the	 TNFα-induced	 expression	 of	 IL-8.	 	 Again,	 co-treatment	with	guggulsterone	reverses	the	attenuating	effect	of	GW4064	(10μM),	this	time	measured	at	an	mRNA	copy	level.	
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Figure	2.25;		Graphs	to	demonstrate	the	concentration	(ELISA)	and	gene	expression	(RT-PCR)	of	
IL-8	 in	 HT29	 cultured	 with	 TNFα	 and/or	 GW4064.	 	 ‘Guggul’	 is	 the	 FXR	 antagonist	
guggulsterone.	(n=3,	SEM,	t-tests)	
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Under	 the	 same	 experimental	 conditions,	 a	 different	 dose-response	 relationship	was	 observed	 between	 the	 concentration	 of	 6-ECDCA	 and	 IL-8	 production,	 as	compared	with	GW4064	(see	figure	2.26).	
The	lowest	concentration	of	6-ECDCA	(0.1μM)	used	in	this	assay,	was	observed	to	reduce	the	TNFα	induced	IL-8	production	to	the	baseline	 level.	 	This	observation	was	 replicated	 at	 an	mRNA	 level.	 	 This	 in	 comparison	 to	 GW4064	 in	which	 the	highest	dose	(10μM)	had	this	effect.	
The	highest	dose	of	6-ECDCA	(10μM)	induced	the	paradoxical	effect	of	increasing	the	amount	of	IL-8	secreted	on	stressing	cells	with	TNFα.		6-ECDCA	(10μM)	alone	had	 no	 effect	 on	 the	 production	 of	 IL-8.	 	 This	 apparently	 synergistic	 effect	 was	observed	at	an	mRNA	level	and	was	a	consistent	finding	when	the	experiment	was	replicated	 on	 three	 separate	 occasions.	 	 Antagonising	 6-ECDCA	 10μM	 with	guggulsterone	reduced	the	concentration	of	IL-8	to	the	level	seen	when	cells	were	stimulated	with	TNFα	alone.	
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Figure	 2.26;	 	 Graphs	 to	 demonstrate	 the	 concentration	 and	 gene	 expression	 of	 IL-8	 in	 HT29	
cultured	with	TNFα	and/or	6-ECDCA.		‘Guggul’	is	the	FXR	antagonist	guggulsterone.	(n=3,	SEM,	
t-tests)	
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2.5	 Discussion		Gut	 epithelial	 barrier	 dysfunction	 is	 a	 crucial	 factor	 in	 the	 aetiopathogenesis	 of	CD(Zeissig	et	al.,	2007,	Su	et	al.,	2009,	Hedin	et	al.,	2012).		A	dysfunctional	barrier	allows	microorganisms	to	translocate	from	the	lumen	into	the	mucosa,	driving	an	inflammatory	 response(Soderholm	 et	 al.,	 2004,	 McGuckin	 et	 al.,	 2009).	 	 These	experiments,	in	human,	gut-derived	epithelial	cell	lines,	provide	evidence	that	FXR	agonism	 can	 maintain	 the	 epithelial	 barrier	 when	 exposed	 to	 CD	 associated	inflammatory	 cytokines	 by	 i)	 inhibiting	 disruption	 of	 cell	 morphology	 and	 ii)	attenuating	the	innate	immune	response	of	IL-8	production.	
A	 reproducible	 model	 of	 inflammatory	 cytokine	 induced	 epithelial	 barrier	dysfunction	was	optimised	 in	Caco-2	cells	grown	as	a	polarised	monolayer.	 	This	technique	was	new	to	our	group	and	is	now	being	used	in	other	areas	of	research	within	the	laboratory.			
Evidence	from	RT-PCR	experiments	demonstrates	that	both	6-ECDCA	and	GW4064	act	as	FXR	agonists,	as	shown	by	significant	upregulation	of	downstream	SHP	and	IBABP	 target	 gene	 expression,	 in	 two	 different	 epithelial	 cell	 lines.	 	 Differences	were	 seen	 in	 FXR	 agonism	 between	 the	 two,	 different	 compounds,	 but	 also	between	 different	 cell	 lines.	 	 In	 Caco-2	 cells,	 6-ECDCA	 induced	 a	 greater	 fold	change	 in	 downstream	 genes	 than	 GW4064,	 with	 its	 greatest	 effect	 seen	 when	measured	at	24	hours,	compared	with	48	hours.		The	assay	was	performed	at	these	time	points	 to	 allow	FXR	 activation,	 translocation	 of	 the	 receptor	 to	 the	 nucleus	with	subsequent	RNA	transcription	and	processing	of	downstream	targets.		It	is	of	course,	 possible	 that	 downstream	 activation	 occurs	 before	 24	 hours,	 with	preliminary	results	from	another	group	in	the	laboratory	suggesting,	in	particular,	that	SHP	levels	increase	much	sooner	after	FXR	agonism	than	24	hours.	
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These	results	confirmed	the	findings	of	previous	studies	in	demonstrating	that	FXR	activation	 induces	 its	 own	 expression	 in	 Caco-2	 cells(Gadaleta	 et	 al.,	 2011b).		However,	 the	 positive	 auto-regulation	 of	 FXR	 was	 not	 present	 in	 HT29	 cells,	 in	which	 a	 fold	 reduction	 in	 FXR	 mRNA	 was	 observed	 for	 both	 FXR	 agonist	compounds	 across	 a	 100	 fold	 dose	 range.	 	 Caco-2	 and	 HT29	 are	 of	 course	phenotypically	different	cell	types	with	different	origins.		HT29	are	thought	to	be	a	more	 crypt-derived	 epithelial	 cell,	 with	 Caco-2	 a	 more	 mature,	 villous	 like	epithelial	cell.		It	may	be	that	FXR	auto-regulation	in	different	epithelial	cell	types	is	 contradictory	 in-vivo,	 but	 this	would	 need	 further	 investigation	 to	 determine.		One	could	hypothesise	that	such	a	mechanism	could	be	related	to	the	increased	BA	uptake	 higher	 in	 the	 epithelial	 villous	 rather	 than	 the	 crypt.	 	 An	 alternative	explanation	would	be	that,	in	HT29	cells,	IBABP	and	SHP	are	under	the	control	of	another	nuclear	receptor,	agonised	off	target	by	the	FXR	agonist	compounds.	
The	 null	 hypothesis,	 that	 FXR	 agonism	 could	 not	maintain	 the	 epithelial	 barrier	when	 stressed	 by	 IFNγ,	 TNFα	 or	 IL-6,	was	 proved	when	measured	 by	 epithelial	electrical	 resistance.	 	 A	 functional	 assay	 using	 the	 paracellular	 flux	 of	 a	 cell	impermeable	 molecule	 failed	 as	 a	 model	 as	 no	 difference	 between	 control	 and	cytokine	induced	epithelial	dysfunction	could	be	demonstrated.			
However,	 FXR	 agonism	 did	 maintain	 epithelial	 morphology	 when	 cells	 were	stressed	 with	 the	 inflammatory	 cytokines	 IL-6	 and	 IFNγ,	 as	 measured	 by	 TEM.		Cytokine	 induced	 cytoskeletal	 re-arrangement	 occurs	 due	 to	 contractions	 in	 the	actin-myosin	ring,	 regulated	by	 the	phosphorylation	of	myosin	 II	 regulatory	 light	chain	 (MLC)	 by	MLCK(Cunningham	and	Turner,	 2012).	 	 I	 hypothesised	 that	 FXR	agonism	may	 maintain	 cell	 morphology	 by	 inhibiting	 MLCK	 at	 a	 transcriptional	level.	 	 Unfortunately,	 only	 data	 for	 Caco-2	 co-cultured	with	 IL-6	were	 produced	
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due	 to	problems	with	RNA	extraction.	 	However,	 these	preliminary	 results	 show	that	IL-6	induced	MLCK	transcription	is	reduced	by	FXR	activity.		Recently,	IL-6	has	been	shown	to	increase	phosphorylated-MLC(Zahs	et	al.,	2013).		By	inhibiting	the	transcription	 of	 MLCK,	 FXR	 may	 act	 to	 maintain	 the	 epithelial	 barrier	 by	preventing	cytokine	induced	cytoskeletal	re-arrangement	of	the	actin-myosin	ring.	
Published	 literature	 suggests	 that	 TNFα	 should	 also	 induce	 changes	 in	 the	cytoskeleton(Cunningham	and	Turner,	2012),	but	this	finding	was	not	observed	in	this	study.		It	may	be	that	TNFα	induced	morphological	change	may	occur	sooner	and	resolve	prior	to	the	48-hour	time	point	used	in	these	experiments.	
It	is	interesting	to	note	that	FXR	agonism	had	no	effect	on	the	loss	of	TEER	induced	by	inflammatory	cytokine,	but	did	maintain	epithelial	morphology.	 	This	suggests	that	 the	 cellular	mechanism	 by	which	 TEER	 is	 reduced	 is	 not	 wholly	 related	 to	cytoskeletal	re-arrangement.		Presumably	other	factors,	such	as	changes	in	claudin	protein	expression	at	 the	TJ	complex,	are	responsible	 for	 the	 increase	 in	 ion	 flux	seen	after	epithelia	are	stressed	with	cytokine.		If	FXR	agonism	maintains	epithelial	barrier	homeostasis	 in-vivo,	this	 is	 likely	to	be	due	to	a	process	that	 involves	cell	morphology	rather	than	via	a	process	that	only	maintains	the	TJ	itself.		In	addition,	other	 processes,	 such	 as	 the	 effect	 on	 IL-8	 production	 may	 be	 important	 in	maintaining	epithelial	homeostasis.	
These	experiments,	both	at	a	transcriptional	and	protein	level,	were	able	to	show	that	 FXR	 agonism	 decreased	 the	 IL-8	 response	 of	 HT29	 cells	 to	 TNFα.	 	 Gut	epithelial	IL-8	production	is	an	important	innate	immune	mechanism.		As	a	potent	pro-inflammatory	 cytokine,	 IL-8	 acts	 as	 a	 chemo-attractant	 for	 circulating	neutrophils(Eckmann	et	al.,	1993).		This	data	set	is	in	keeping	with	other	studies	in	demonstrating	 an	 immuno-modulatory	 role	 for	 FXR(Vavassori	 et	 al.,	 2009,	
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Haselow	et	al.,	2013).		Demonstrating	an	attenuated	IL-8	response	to	TNFα	at	both	a	 transcript	 and	 protein	 level	 adds	 strength	 to	 the	 evidence	 that	 FXR	 has	 an	immuno-modulating	effect	in	gut	epithelial	cells.		This	is	a	potential	mechanism	by	which	FXR	may	act	 to	maintain	epithelial	homeostasis.	 	HT29	cells	were	used	 in	these	 experiments	 as	 they	 demonstrate	 a	more	 responsive	 secretory	 phenotype	than	Caco-2.	
Again,	 differences	 in	 biological	 effect	 were	 observed	 between	 the	 two	 FXR	agonists,	 this	 time	 with	 respect	 to	 the	 attenuation	 of	 TNFα	 induced	 IL-8	production.	 	 A	more	 efficacious	 attenuating	 effect	 was	 observed	 for	 GW4064	 at	10μM	with	lower	doses	being	less	effective.		The	opposite,	however,	was	true	for	6-ECDCA	 with	 the	 0.1μM	 demonstrating	 complete	 attenuation	 of	 the	 IL-8	 stress	response.		In	fact,	at	high	dose	(10μM),	6-ECDCA	with	TNFα	appeared	to	produce	a	synergistic	response,	with	more	IL-8	produced	than	with	TNFα	stimulation	alone.		This	 unusual	 finding	 was	 reproduced	 at	 a	 transcriptional	 level	 and	 was	 a	consistent	finding	in	three	consecutive	experiments.		Therefore,	I	suspect	that	this	finding	is	robust	and	does	not	reflect	methodological	error.		It	is	possible	that	high	doses	of	6-ECDCA	have	an	off	target	effect	that	would	produce	such	a	result	or	are	directly	 toxic	 to	 the	 cell	 at	 high	 concentrations.	 	 It	 may	 be	 that,	 under	 these	experimental	 conditions,	 a	much	 lower	dose	 range	 (e.g.	 from	0.01μM	 to	1μM)	of	the	 6-ECDCA	 compound	 should	 have	 been	 assayed.	 	 The	 EC50	 for	 6-ECDCA	 is	approximately	0.1μM.	 	The	dose	 range	0.1μM	 to	10μM	was	 chosen	as	 the	higher	dose	of	6-ECDCA	had	produced	 the	greatest	 increase	 in	 fold	 change	 for	 SHP	and	IBABP	in	HT29	cells	in	earlier	experiments	(figure	2.15).	
There	are	several	potential	weaknesses	with	the	data	in	this	chapter.		Only	a	model	of	inflammatory	cytokine	induced	epithelial	barrier	dysfunction	has	been	studied.		
		 101	
It	is	widely	accepted	that	cytokines	cause	barrier	dysfunction	and	that	this	in	turn	leads	to	the	chronic	inflammation	of	CD.		However,	the	initial	pathological	process	that	 leads	 to	 the	 development	 of	 CD	 is	 unknown	 and	 may	 not	 necessarily	 be	inflammatory	 cytokine	driven.	 	 For	example,	predisposing	genetic	 factors	 (e.g.	 in	autophagy)	and	the	microbiota	(e.g.	AIEC	and	claudin	2	expression)	may	be	more	important	 in	 disease	 initiation	 or	 re-initiation	 in	 post-operative	 recurrence.	 	 It	would	 be	 interesting	 to	 investigate	 the	 role	 of	 FXR	 in	 these	 circumstances.	 	 For	instance,	 there	 is	 a	 putative	mechanism	 by	 which	 FXR	may	 promote	 autophagy	pathways	(via	p62/sequestosome	1)	and	NOD2.		This	may	form	the	basis	of	further	research.	
The	 finding	that	FXR	agonism	can	ameliorate	 IL-6	 induced	upregulation	of	MLCK	expression	is	of	interest	as	it	provides	a	potential	molecular	mechanism	by	which	FXR	 may	 act	 to	 maintain	 the	 epithelial	 barrier.	 	 However,	 it	 is	 important	 to	reproducibly	prove	this	finding	for	other	cytokines.		The	quality	of	RNA	extracted	from	Caco-2	cells,	grown	as	a	polarised	monolayer,	was	an	ongoing	problem.	 	As	discussed	 in	 the	 methods	 section,	 several	 different	 techniques	 to	 optimise	 RNA	extraction	were	 tried	 and	 I	managed,	 towards	 the	 end	of	my	 laboratory	 time,	 to	produce	reliable	results	for	IL-6	treated	cells.		Further	work	should	collect	the	data	for	IFNγ	and	TNFα	stimulated	cells,	perhaps	at	an	earlier	time	point.			
Some	 scientists	 have	 questioned	 the	 validity	 of	 the	 use	 of	 GAPDH	 as	 a	 reliably	stable	reference	gene	in	RT-PCR	experiments(de	Jonge	et	al.,	2007).	 	If	necessary,	future	studies	could	replicate	this	work	using	an	alternative	reference	gene,	such	as	ribosomal	protein	S13.	
Finally,	 these	are	cell	 line	studies	and,	 therefore,	provide	only	an	estimate	of	 the	process	 of	 FXR	 activation	 in-vivo.	 	 The	 experiments	 are,	 by	 design,	 reductionist,	
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assaying	 only	 the	 function	 of	 these	 genetically	 abnormal	 epithelial	 cells,	 distinct	from	any	interaction	with	the	multiple	other	cell	types	in	the	gut	mucosa.		The	next	two	chapters	provide	data	 from	more	complex	models	with	experiments	 in	mice	and	from	primary	human	tissue.			
In	 summary,	 however,	 these	 cell	 line	models	 suggest	 that	 BA	 signalling	 via	 FXR	acts	to	maintain	the	epithelial	barrier	by	attenuating	IL-8	production	in	response	to	cell	stress	and	by	maintaining	epithelial	cell	morphology.	
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Chapter	3	–	The	Effect	of	FXR	Agonism	on	Ileal	Inflammation	in	
a	Mouse	Model	of	Metabolic	Syndrome	
3.1	 Abstract	Evidence	from	epidemiological	and	case-control	studies	implicate	the	western	diet	in	the	pathogenesis	of	Crohn’s	disease	(CD).		The	pathological	mechanism	for	this	association	 is	 unknown.	 	High-fat/high-sugar	 (HF/HS)	 feeding	 of	mice	 induces	 a	dysbiosis	comparable	to	that	seen	in	inflammatory	bowel	disease	(IBD).	 	The	bile	acid	(BA)	receptor,	farnesoid	X	receptor	(FXR),	is	central	to	the	cross	talk	between	the	host	and	its	microbiota.		FXR	has	been	shown	to	have	an	immuno-modulatory	role	in	the	GI	tract.			The	 hypothesis	 was	 that	 disruption	 to	 BA	 signalling,	 induced	 by	 a	 HF/HS	 diet	associated	 dysbiosis,	 is	 a	 potential	 mechanism	 linking	 dietary	 risk	 to	 the	development	 of	 CD.	 	 The	 aims	 of	 this	 chapter	 were	 to	 investigate	 the	 effect	 of	HF/HS	 feeding	 and	 FXR	 agonism	 on	 ileal	 inflammation	 in	 a	 mouse	 model	 of	obesity.	Evidence	is	presented	demonstrating	that	animals	fed	a	western-like	diet	express	more	 ileal	 inflammatory	 cytokine.	 	 There	 is	 a	 trend	 to	 suggest	 that	supplementation	 of	 a	 western-lifestyle	 diet	 with	 an	 FXR	 agonist	 reduces	 diet-induced	inflammatory	cytokine	expression	in	the	mouse	ileum.		 	
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3.2	 Introduction	and	aims	A	high	fat,	high	sugar	(HF/HS)	content	diet	is	associated	with	CD	pathogenesis	in	several	case-control	studies(Hou	et	al.,	2011).		Epidemiological	data	demonstrates	an	increased	risk	of	developing	CD	for	populations	exposed	to	a	western	lifestyle,	which	is	in	turn	associated	with	a	HF/HS	diet(Probert	et	al.,	1992).	The	 so-called	metabolic	 syndrome	 of	 obesity,	 diabetes	mellitus	 type	 II,	 essential	hypertension,	 dyslipidaemia	 and	 non-alcoholic	 steato-hepatitis	 (NASH)	 is	 also	associated	with	a	HF/HS	diet(Bhatia	et	al.,	2012).	 	Obesity	is	a	low	grade,	chronic	inflammatory	 condition	 in	 which	 macrophages	 and	 adipocytes	 are	 activated,	producing	 inflammatory	 cytokines	 such	 as	 TNFα,	 IL-1	 and	 IL-6(Wellen	 and	Hotamisligil,	 2005,	 Cani	 et	 al.,	 2007).	 	 High	 fat	 feeding	 of	 mice	 produces	 an	endotoxaemia	 associated	 with	 an	 increase	 in	 epithelial	 permeability(Cani	 et	 al.,	2007,	Cani	et	al.,	2008).		Increased	epithelial	permeability	is	a	central	tenet	in	the	pathogenesis	of	IBD(McGuckin	et	al.,	2009).		In	patients	with	CD,	an	accumulation	of	 peri-enteric	 fat,	 known	 as	 ‘creeping	 fat’,	 is	 often	 observed	 around	 areas	 of	inflammed	tissue.		Creeping	fat	is	metabolically	active	and	produces	inflammatory	cytokines	such	as	TNFα	and	IL-6(Martinez-Medina	et	al.,	2014).	The	 American	 Lifestyle-Induced	 Obesity	 Syndrome	 (ALIOS)	 animal	 model	 was	developed	 to	 study	 the	 development	 of	 NASH	 in	 mice(Tetri	 et	 al.,	 2008).	 	 The	ALIOS	model	resembles	a	typical	 ‘fast-food’	diet,	being	rich	in	trans-fats	and	high	fructose	corn	syrup,	 in	association	with	reduced	energy	expenditure.	 	This	model	has	 been	 shown	 to	 closely	 resemble	 the	 metabolic	 syndrome,	 with	 genetically	normal	 mice	 developing	 obesity,	 fatty	 liver	 disease,	 hyperinsulinaemia	 and	hypercholesterolaemia(Tetri	et	al.,	2008,	Dowman	et	al.,	2014).	
Experiments	 in	 this	 chapter	 were	 intended	 to	 explore	 the	 potential	 association	between	 dietary	 risk	 factors,	 BA	 dysmetabolism	 and	 ileal	 inflammation.	 	 The		
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hypothesis	 was	 that	 mice	 fed	 an	 ALIOS	 diet	 would	 develop	 evidence	 of	 ileal	inflammation	and,	furthermore,	that	supplementation	of	feed	with	an	FXR	agonist	would	attenuate	any	observed	diet-induced	inflammation.		The	main	aims	of	the	experiments	in	this	chapter	were,	therefore,	to:	
1. Demonstrate	ileal	inflammation	in	a	mouse	model	of	diet-induced	obesity;	
2. To	 assess	 the	 ability	 of	 Px-102	 to	 act	 as	 an	 FXR	 agonist	 and	 upregulate	downstream	gene	expression,	and;	
3. To	 assay	 the	 effect	 of	 FXR	 agonism	 on	 any	 observed	 ileal	 inflammation	induced	by	HF/HS	feeding,	by	measuring	cytokine	gene	expression.	
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3.3	 Methods	
3.3.1	 Animal	care	Animal	 husbandry	 was	 performed	 by	members	 of	 Dr	 H	 Reeves’	 research	 group	under	 licence	 from	 the	 Home	 Office,	 in	 keeping	 with	 the	 requirements	 of	 the	Animals	(Scientific	Procedures)	Act	1986	(ASPA).		All	animal	care,	including	animal	sacrifice,	 was	 performed	 in	 the	 Comparative	 Biology	 Centre	 (CBC),	 Newcastle	University	by	members	of	Dr	Reeves’	team	or	by	university	staff	 in	the	CBC.	 	The	CBC	 ensures	 that	 animals	 are	 housed	 and	 cared	 for	 appropriately	 and	 that	research	 is	 performed	 in	 such	 a	 way	 to	 minimise	 any	 adverse	 effects	 on	 the	animals.			After	being	culled,	the	whole	GI	tract	from	each	mouse	was	gifted	to	our	group	in	order	to	perform	the	experiments	described	in	this	chapter.		The	author	assisted	in	the	dissection	of	the	GI	tract	and	was	responsible	for	subsequent	handling	of	this	tissue.	 	 The	 author	 was	 not	 responsible	 for	 animal	 care,	 animal	 handling	 or	Schedule	1	killing.	
3.3.2	 Mouse	strain	–	C3H/He	The	 mice	 used	 in	 this	 study	 were	 the	 genetically	 inbred	 mouse	 strain	 C3H/He,	purchased	 from	 Harlan	 Laboratories,	 Wisconsin.	 	 The	 C3H/He	 is	 a	 widely	 used	laboratory	 mouse	 strain	 which	 has	 previously	 been	 studied	 in	 models	 of	IBD(Bilger	 et	 al.,	 2004,	 Difedele	 et	 al.,	 2005).	 	 Importantly,	 with	 regards	 to	 this	study,	 unlike	 other	 C3H	 strains,	 C3H/He	 mice	 express	 a	 normal	 TLR4	 (LPS	sensing)	 receptor	 complex(The	 Jackson	 Laboratory,	 2015).	 	 In	 a	 model	 of	 diet	induced	 obesity	 it	 is	 expected	 that	 there	 will	 be	 an	 associated	 change	 in	 the	microbiota	and,	therefore,	the	expression	of	normal	bacterial	sensing	molecules	is	important	when	assessing	gut	inflammatory	responses.	
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C3H/He	mice	are	often	used	to	study	carcinogenesis	in	the	liver	and	the	mammary	gland.		In	tangent	with	these	experiments,	Dr	Helen	Reeves’	team	(NICR,	Newcastle	University)	was	studying	the	role	of	FXR	agonism	in	the	inhibition	of	the	formation	of	hepatocellular	carcinoma	(HCC).	C3H/He	spontaneously	develop	HCC,	with	30-50%	of	mice	affected	by	2	years	of	age(Bilger	et	al.,	2004).	
3.3.3	 Study	design	Animals	were	maintained	in	the	CBC,	Newcastle	University,	 in	a	temperature	and	humidity	 controlled	 environment.	 	 A	 standard,	 12	 hours	 diurnal	 light	 cycle	 was	applied.		In	contrast	to	the	Tetri	et	al	description	of	the	ALIOS	model,	unmodified,	standard	cages	were	used.		The	animals	were	checked	daily	and	weighed	weekly.	Mice	were	fed	either	standard	(control)	chow	or	ALIOS	feed	from	arrival	at	age	6	to	8	weeks.			Feed	and	drinking	water	was	provided	ad-libitum	with	feeds	supplied	by	 Harlan	 Laboratories	 (tables	 3.1	 and	 3.2).	 	 The	 control	 mice	 were	 fed	 a	 diet	containing	normal	levels	of	fat	(6.2%	by	weight)	and	no	trans-fats	(TD.110196	6%	Soybean	 Oil	 Diet,	 see	 table	 3.1	 for	 full	 detail).	 	 The	 ALIOS	mice	were	 fed	 a	 diet	enriched	with	 fat	 (23.2%	 by	 weight)	 and	 trans-fat	 in	 the	 form	 of	 hydrogenated	vegetable	oil	(6.6%	by	weight;	TD.110201	22%	HVO	Diet	(VI),	see	table	3.2	for	full	detail).			Mice	 in	 the	control	arm	were	given	normal	drinking	water.	 	ALIOS	animals	were	given	drinking	water	equivalent	 to	high	 fructose	corn	syrup	 (55%	 fructose,	45%	glucose	by weight)	at	a	concentration	of	42	g/l.			At	24	weeks	of	age,	intervention	groups	had	their	diet	supplemented	with	the	non-steroidal,	 small	 molecule	 FXR	 agonist, Px-102 (Phenex	 Pharmaceuticals	 AG,	Germany)	at	a	concentration	of	1mg/kg	or	5mg/kg	of	feed.		Mice	were	maintained	
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on	the	control	or	ALIOS	diets,	with	or	without	the	FXR	agonist,	up	to	42	weeks	of	age.	Following	 ASPA	 Schedule	 1	 killing	 at	 42	 weeks,	 mice	 were	 weighed	 and	 then	 a	midline	 laparotomy	 incision	was	made.	 	 The	GI	 tract	was	 sectioned	 at	 the	 distal	oesophagus	 and	 the	 rectum	 and	 the	 whole	 GI	 tract	 was	 removed	 en-bloc	 and	stored	 in	 a	 50ml	 Falcon	 tube	 at	 -80°C	 for	 later	 RNA	 extraction.	 	 The	 visceral	adipose	 tissue	 was	 also	 section	 and	 weighed.	 	 The	 GI	 tract	 from	 44	 mice	 was	obtained.	 	 Figure	 3.1	 gives	 an	 overview	 of	 the	 study	 design	 and	 the	 numbers	 of	animal	in	each	group.		 	
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Figure	 3.1;	 	 Schematic	 to	 represent	 study	 design	 for	mouse	 feeding	 regimen.	 	 C3H/He	mice	
were	fed	ALIOS	diet	or	a	control	diet	from	6	to	8	weeks	of	age.		At	24	weeks,	feed	was	either	
supplemented	with	a	Px-102	(FXR	agonist	-	FXRa),	at	a	dose	of	1mg/kg	or	5mg/kg	of	feed,	or	
was	continued	without	the	addition	of	the	FXR	agonist.		At	42	weeks,	mice	were	culled	as	per	
ASPA	Schedule	1	guidance.	 	Mouse	 total	body	weight	and	visceral	adipose	 tissue	weight	was	
measured.	 	The	GI	tract	was	dissected	and	RNA	was	extracted	from	the	ileum	as	described	in	
the	text.		Sufficient	quality	RNA	was	extracted	in	only	31	of	the	44	mice,	with	the	distribution	as	
demonstrated.		
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Table	3.1;		Control	diet	constituents	(from	Harlan	Laboratories	product	literature)	
	
Table	3.2;		ALIOS	diet	constituents	(from	Harlan	Laboratories	product	literature)	
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3.3.4	 Ileal	preparation		The	whole	GI	tract	from	distal	oesophagus	to	rectum	was	stored	at	-80°C	prior	to	ileal	 preparation.	 	 There	 was	 concern	 that	 thawing	 of	 samples	 to	 room	temperature	would	degrade	ileal	RNA.	 	Therefore,	samples	were	thawed	to	-20°C	for	16	hours	 in	6ml	of	RNAlater-ICE	Frozen	Tissue	Transition	Solution	 (Ambion,	Life	Technologies),	 in	a	50ml	Falcon	 tube,	prior	 to	dissection.	 	Care	was	 taken	 to	ensure	 that	 the	 tissue	was	 fully	 submerged	 in	 an	 adequate	 volume	 of	 transition	solution.	 	The	 transition	solution	allows	dissection	and	 tissue	homogenisation	as	the	 tissue	 becomes	 pliable	 and	 RNA	 stabilised	 at	 -20°C.	 	 After	 transitioning	 the	tissue	for	16	hours,	the	manufacturers	claim	that	the	tissue	RNA	will	then	be	stable	for	up	 to	30	minutes	 at	 room	 temperature(Life	Technologies	Product	 Literature,	2014).	Following	 overnight	 storage	 in	 the	 RNAlater-ICE	 Frozen	 Tissue	 Transition	Solution,	 the	 ileum	 was	 sectioned	 at	 the	 ileo-caecal	 valve	 and	 then	 at	 2	 cm	proximal	to	produce	a	short	segment	of	dissected	terminal	ileum.		Peri-enteric	fat	was	 trimmed	 from	 the	 serosal	 surface	 of	 the	 ileum	 to	 prevent	 contamination	 of	RNA	extract	with	adipose	 tissue.	 	Likewise,	 ileal	 contents	were	 flushed	out	using	the	blunt	edge	of	a	syringe	needle.		
	
Figure	3.2;		Schematic	representation	of	mouse	ileum.		Caecum	is	a	sac	like	structure	distal	to	
the	ileum.		Terminal	ileum	sectioned	at	the	ileo-caecal	junction	and	2	cm	more	proximal.	
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3.3.5	 RNA	isolation	RNA	was	isolated	using	the	RNeasy	Fibrous	Tissue	Mini	Kit	by	QIAGEN	(74704)	as	per	the	manufacturers	guidelines.		All	RNA	work	was	performed	using	RNase-free	reagents	 and	 equipment.	 	 Laboratory	 surfaces	 were	 cleaned	 with	 RNase	decontamination	 solution	 (RNaseZap,	 Ambion,	 Life	 Technologies)	 prior	 to	experiments	and	pipette	filter	tips	were	used.	Three	 ileal	 samples	 were	 weighed	 to	 ascertain	 that	 2cm	 of	 ileal	 tissue	 weighed	approximately	 100mg.	 	 A	 6mm	 length	 (approximately	 30mg)	 of	 terminal	 ileum	was	dissected	 from	 the	distal	 end	 of	 the	 sample	 and	was	 suspended	 in	 300μl	 of	buffer	 RLT	with	 β-mercaptoethanol	 (10μl	 per	ml	 of	 buffer),	 in	 a	 2.0ml	 Precellys	ceramic	 bead	 kit	 tube	 (1.4/2.8mm	 beads),	 manufactured	 by	 Peqlab.	 	 The	 tissue	was	then	homogenised	using	a	Bertin	Minilys	tissue	disruptor	using	6	x	25	second	cycles	of	disruption,	with	a	45	second	rest	between	cycles.	 	Samples	were	stored	on	 ice	 between	 cycles	 of	 disruption.	 	 Following	 disruption,	 590μl	 of	 RNase-free	water	 and	 10μl	 of	 proteinase-k	 was	 added	 to	 the	 homogenised	 solution	 and	incubated	in	a	pre-warmed	heater	block	at	55°C	for	10	minutes.	After	 incubation,	 the	 solution	 was	 spun	 at	 10,000	 x	 g	 for	 3	 minutes	 in	 a	temperature	 controlled	 centrifuge	 at	 4°C;	 the	 supernatant	 (~800μl)	 was	transferred	to	a	sterile,	1.5ml	Eppendorf	tube.	 	0.5	volumes	of	100%	ethanol	was	then	 added	 to	 the	 supernatant	 and	 the	 solution	was	 gently	mixed.	 	 700μl	 of	 the	sample	was	transferred	to	an	RNA	spin	column,	in	a	2ml	collection	tube,	and	spun	at	8,000	x	g	for	15	seconds.	 	The	flow	through	was	discarded	and	350μl	of	buffer	RW1	was	added	and	a	 further	8,000	x	g	 for	15	second	spin	was	performed.	 	The	flow	though	was	again	discarded.			
The	 nucleic	 acid	 trapped	 within	 the	 spin	 column	 filter	 was	 then	 treated	 with	 a	DNase	 I	step.	 	80μl	of	solution,	containing	10μl	of	DNase	 I	 in	70μl	of	buffer	RDD,	
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was	added	to	the	spin	column	and	left	to	incubate	on	the	bench	top	for	15	minutes.		After	 incubation,	 the	DNase	 I	 solution	was	 rinsed	out	with	350μl	 of	 buffer	RW1,	centrifuged	at	8,000	x	g	for	15	seconds.		The	flow	through	was	discarded.		The	spin	column	was	then	washed	with	two	cycles	of	500μl	buffer	RPE,	spun	for	8,000	x	g	for	15	 seconds	and	2	minutes	 respectively.	 	 Finally,	 the	RNA	was	precipitated	 in	30μl	of	nucleic	acid	and	RNase-free	water	and	spun	for	8,000	x	g	for	1	minute	to	collect	the	RNA	containing	precipitate	in	a	fresh,	1.5ml	Eppendorf.	
3.3.6	 RNA	quantity	and	quality	As	in	chapter	2,	 the	quantity	and	quality	of	extracted	RNA	was	measured	using	a	nanodrop	spectrophotometer	and	also	by	gel	electrophoresis.	For	 these	 experiments,	 A260/280nm	 and	 A260/230nm	 of	 1.5	 to	 2.2	 were	accepted.	 	 In	 cases	 where	 the	 A260/230nm	 ratio	 was	 unacceptably	 low	 or	 the	quantity	of	RNA	was	insufficient,	the	RNA	extraction	protocol	was	repeated	using	a	further	6mm	piece	of	 ileum.	 	Acceptable	quality	RNA	could	not	be	isolated	for	all	specimens.	Gel	electrophoresis	was	performed	as	described	in	the	methods	section	of	chapter	2.	 Gel	 electrophoresis	 was	 performed	 for	 optimisation	 steps	 and	 intermittently	during	RNA	extraction	to	ensure	RNA	quality	was	maintained.			Figure	 3.3	 and	 3.4	 demonstrate	 examples	 of	 RNA	 spectrophotometry	 and	electrophoresis	for	mouse	RNA	isolated	using	the	above	method.	
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Figure	3.3;		An	example	of	Nanodrop	spectrophotometry	for	mouse	ileum	RNA	purified	for	the	
experiments	in	this	chapter.	
	
Figure	 3.4;	 	 Gel	 electrophoresis	 of	 mouse	 ileum	 RNA	 purified	 for	 the	 experiments	 in	 this	
chapter.		As	in	chapter	2,	16s	and	28s	ribosomal	bands	are	highlighted	beside	DNA	ladder	
3.3.7	 mRNA	reverse	transcription	(cDNA	synthesis)	Complementary	 DNA	 (cDNA)	 was	 prepared	 using	 the	 Tetro	 cDNA	 Synthesis	 Kit	(Bioline)	 as	 described	 in	 the	 methods	 section	 of	 chapter	 2,	 as	 per	 the	manufacturers	 guidelines.	 	 As	 for	 RNA	 extraction,	 nuclease	 free	 equipment	 and	reagents	were	used,	surfaces	were	cleaned	with	RNase	decontamination	solution	(RNaseZap,	 Ambion,	 Life	 Technologies)	 and	 filter	 pipette	 tips	 were	 used.	 	 All	
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procedures	were	performed	on	ice	to	minimize	RNA	degradation.	 	cDNA	samples	were	 stored	 at	 -20oC	 for	 later	 use	 in	 the	 second	 part	 of	 two-step	 RT-PCR	experiments.	
3.3.8	 Real-time	reverse	transcription	polymerase	chain	reaction	(RT-PCR)	The	relative	levels	of	mRNA	for	the	inflammatory	cytokines	TNFα,	IFNγ,	IL-6	and	IL-8	were	measured	 to	assess	 inflammation	 in	 the	mice	 ilea.	 	The	relative	mRNA	level	of	FXR	and	its	downstream	targets,	SHP	and	IBABP,	was	measured	to	assess	the	 effect	 of	 Px-102	 (FXR	 agonist,	 Phenex)	 in	 the	 mice	 ilea.	 	 Relative	 mRNA	expression	was	measured	using	RT-PCR	via	a	TaqMan-based	chemistry	assay	(Life	Technologies).	 	 The	process	of	RT-PCR	by	 a	TaqMan-based	assay	 is	described	 in	chapter	2.	Mouse	specific,	TaqMan	Gene	Expression	Assays	(pair	of	PCR	primers	and	specific	hydrolysis	 probe)	 to	 FXR,	 SHP,	 IBABP,	 TNFα,	 IFNγ,	 IL-6,	 IL-8	 and	 β-actin	 were	purchased	 from	 Life	 Technologies.	 	 	 The	 expression	 of	 β-actin	 was	 used	 as	 the	reference	(housekeeper)	gene.		Table	3.3	lists	the	primer/probes	and	their	targets	used	 in	 these	experiments.	 	 In	order	 to	avoid	 false	positive	detection	of	genomic	DNA	 (gDNA),	 TaqMan	 primers/probes	 that	 span	 exon-exon	 junctions	 (intron-splice	sites)	were	used	in	these	experiments.		 	
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Protein	 Gene		
Exon	
spanning	
Primer/Probe	
FXR	 Nr1h4	 yes	 Mm00436425_m1	
SHP	 Nr0b2	 yes	 Mm00442278_m1	
IBABP	 Fabp6	 yes	 Mm00434315_m1	
IFNγ	 Ifng	 yes	 Mm01168134_m1	
IL-6	 Il6	 yes	 Mm00446190_m1	
TNFα	 Tnf	 yes	 Mm00443258_m1	
IL-8	 Cxcl15	 yes	 Mm04208136_m1	
-Actin	 Actb	 yes	 Mm01205647_g1	
Table	3.3;		List	of	the	genes	of	interest	and	their	TaqMan	primer/probes	used	in	chapter	3	
3.3.9	 RT-PCR	quality	control	As	described	in	chapter	2,	the	following	steps	were	taken	to	ensure	that	consistent,	good	quality	RT-PCR	was	performed;	 i)	 each	RT-PCR	 reaction	was	 performed	 in	triplicate.	 	If	the	cycle-threshold	(Ct)	differed	by	greater	than	1.0	within	triplicate	samples,	 that	well	was	 excluded	 from	 further	 analysis;	 ii)	 A	 no-template	 control	(NTC)	 triplicate	 experiment	 was	 performed	 to	 ensure	 there	 was	 no	 DNA	contamination	 within	 the	 mastermix,	 primer/probe	 or	 water	 used	 in	 the	experiments;	 iii)	To	ensure	no	gDNA	contamination	of	 the	RNA	preparation	used	to	 make	 the	 cDNA	 template,	 an	 RNA-template	 reaction	 was	 performed	 for	representative	samples	 (see	 figure	3.5).	 	No	gDNA	or	reagent	contamination	was	demonstrated.	
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Figure	3.5;		Amplification	plot	from	RT-PCR	experiment	using	an	RNA	only	template	to	test	for	
gDNA	contamination	of	cDNA	samples.		No	amplification	product	is	detected.		Primers	were	validated	by	plotting	a	standard	curve	of	Ct	against	serial	dilutions	of	representative	cDNA	concentrations	(log	10	scale),	as	described	in	chapter	2.		The	efficiency	 of	 the	 primer	was	 calculated	 using	 the	 slope	 of	 the	 curve.	 	 The	R2	 co-efficient,	 a	measure	of	 replicate	 reproducibility,	 should	be	>0.98.	 	 Figure	3.6	and	table	 3.4	 demonstrate	 primer	 validation	 results	 for	 the	 primers	 used	 in	 these	experiments.		At	low	concentrations	of	DNA	(less	than	1/10th	of	the	concentration	used	in	the	experiments)	the	primers	for	IL-6	and	TNFα	became	inefficient.	
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Primer	 Slope	 Efficiency	 R-squared	
FXR	 -3.122	 109.1%	 1.00 
SHP	 -3.419	 96.1%	 0.99 
IBABP	 -3.237	 103.7%	 1.00 
IL-6	 -3.226	 104.2%	 0.94 
TNFα	 -3.34	 99.3%	 0.98 
IFNγ	 -3.26	 108.8%	 0.99 
IL-8	 -3.263	 102.5%	 0.96 
-Actin	 -3.255	 102.9%	 1.00 
Table	3.4;		Primer	efficiency	and	goodness	of	fit	(R2)	for	primers	used	in	chapter	3.		See	fig	3.5.		
For	IL-6	and	TNFα,	the	efficiency	of	slope	2	is	expressed.		Slope	2	covers	the	assay	range	of	the	
primer	required	in	these	experiments.	
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Figure	3.6;		Primer	validation	experiments	for	primers	used	in	chapter	3.		Cycle	threshold	(Ct)	is	
measured	for	serial	dilutions	of	cDNA.		See	table	3.4	for	R2	and	efficiency	calculations		
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3.3.10	 Relative	quantification	and	statistical	analyses	Relative	quantification	was	used	to	calculate	the	relative	expression	of	the	genes	of	interest,	 as	 described	 in	 chapter	 2.	 	 The	 choice	 of	 reference	 gene	 is	 critically	important	 in	 the	 analysis	 of	 the	 results.	 	 For	 experiments	 in	 this	 chapter,	 the	commonly	used	mouse	reference	gene	Actb	(β	-	Actin)	was	utilised(Kouadjo	et	al.,	2007).	
Relative	 quantification	 was	 calculated	 using	 the	 ΔΔCt	 method	 as	 described	 by	Livak	and	Schmittgen(Livak	and	Schmittgen,	2001).	 	A	Ct	was	calculated	for	each	biological	sample	by	calculating	the	mean	result	from	triplicate	PCR	wells.	The	relative	expression	of	the	gene	of	interest	(GOI)	in	comparison	to	the	reference	gene	(ΔCt)	was	then	calculated	by	the	equation:	ΔCt	=	CtGOI	–	Ctreference	For	each	control	or	intervention	mouse,	a	ΔCt	was	calculated	for	each	GOI.		These	individual	 replicate	 ΔCt	 values	 were	 then	 used	 in	 a	 Student’s	 t-test	 to	 test	 the	difference	between	control	and	different	interventions.	For	 control	 and	 intervention	 groups,	 the	 mean	 CtGOI	 and	 mean	 Ctreference	 was	determined.	 	 To	 calculate	 the	 relative	 quantification	 (ΔΔCt)	 of	 gene	 expression	between	 the	 control	 diet	 group	 and	 the	 intervention	 groups	 (ALIOS	 diet,	 FXR	agonist	 supplementation)	 first	 the	mean	ΔCt	 for	 control	 and	 intervention	groups	was	calculated.		For	each	GOI	the	mean	ΔΔCt	was	then	calculated	as:	mean	ΔΔCt	=	mean	ΔCt	intervention	–	mean	ΔCt	control	Additive	 error	 is	 propagated	 as	 the	 standard	 error	 (SE)	of	 the	differences	of	 the	mean	(SEM).		This	can	be	calculated	by	the	equation:	ΔΔCt	SE	=	√Error	(control)2	+	Error	(intervention)2		
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Where:	
Error	(control)	=	√SEMreference2	x	SEMGOI2	Error	(intervention)	=	√SEMreference2	x	SEMGOI2	Finally,	the	fold	change	in	relative	gene	expression	can	be	calculated	as:	
Fold	change	=	2	meanΔΔCt	Fold	 change	 is	 a	 relative	 ratio	 and	 therefore,	 normally	 distributed	 error	 bars	cannot	 be	meaningfully	 represented	 on	 a	 bar	 chart	 (fold	 change	 is	 not	 normally	distributed).	 	 In	 order	 to	 represent	 the	 degree	 of	 SE,	 but	 also	 to	 give	 an	 idea	 of	relative	 ratio	 changes,	data	are	presented	both	as	ΔΔCt	values	with	error	and	as	fold	change.	Unpaired	 Student’s	 t	 tests,	 Chi-squared	 tests,	 Fisher’s	 exact	 tests,	 regression	analysis	 and	 Pearson	 correlation	 were	 calculated	 using	 Prism	 version	 6.0e,	Graphpad	software,	San	Diego.		All	P	values	were	2-tailed,	and	a	P	value	of	0.05	or	less	was	considered	statistically	significant.	
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3.4	 Results	
3.4.1	 Study	animals	Of	the	44	mice	in	the	study,	RNA	from	13	of	the	mice	was	of	insufficient	quantity	or	quality	and	so	 these	samples	were	discarded	 from	RT-PCR	analysis.	 	 If	 the	 initial	concentration	 of	 cDNA	was	 too	 low,	 the	 level	 of	 cytokine	 gene	 product	 became	undetectable	and	could	not	be	analysed.			To	 exclude	 the	 effect	 of	 intervention	 on	RNA	 extraction,	 both	 Fisher’s	 exact	 test	and	chi-squared	tests	were	performed	for	the	quality	of	RNA	(good	or	poor)	versus	control	 diet/ALIOS	 diet	 and	 FXR	 agonist/no	 FXR	 agonist	 (tables	 3.5	 and	 3.6).		There	was	 no	 significant	 difference	 between	 the	 groups	 demonstrating	 that	 any	analysis	of	results	is	not	confounded	by	the	effect	of	intervention	on	RNA	quality.	
	 RNA	good	 RNA	poor	 	
FXR	agonist	+ve	 19	 5	 24	
FXR	agonist	-ve	 12	 8	 20	
	 31	 13	 44	
Table	3.5;	Contingency	table,	chi-squared	test	not	significantly	different,	Fisher’s	test	p=0.199	
	 RNA	good	 RNA	poor	 	
ALIOS	diet	 14	 7	 21	
Control	diet	 17	 6	 23	
	 31	 13	 44	
Table	3.6;	Contingency	table,	chi	squared	test	not	significantly	different,	Fisher’s	test	p=0.743	The	 relative	 gene	 expression	 of	 inflammatory	 cytokines	 and	 FXR,	 along	with	 its	downstream	 targets,	 was	 measured	 in	 31	 mice.	 	 The	 body	 weight	 and	 visceral	
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adipose	tissue	weight	was	measured	in	all	44	mice.		Table	3.7	demonstrates	these	characteristics	for	all	mice	in	the	study.		 	
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Animal	
ID	
Intervention	 RT-
PCR	
Body	Weight	
(grams)	
VAT	Weight	
(grams)	
9218L	 Control	 Yes	 39.8	 0.4	
9218R	 Control	 No	 35.7	 0.3	
9217N	 Control	 No	 47.9	 0.5	
9217B	 Control	 Yes	 41.6	 0.6	
9217L	 Control	 No	 44.7	 0.7	
9217R	 Control	 No	 47.5	 0.5	
9218B	 Control	 No	 30.0	 0.2	
9839B	 Control	 Yes	 43.5	 0.3	
9839R	 Control	 Yes	 44.8	 0.7	
9839L	 Control	 Yes	 39.2	 1.2	
9839N	 Control	 Yes	 43.0	 0.6	
	 	 	 	 	
9224N	 ALIOS	 Yes	 49.6	 1.5	
9224B	 ALIOS	 Yes	 47.9	 2.4	
9224R	 ALIOS	 No	 47.9	 1.2	
9226N	 ALIOS	 No	 50.8	 1.7	
9226B	 ALIOS	 No	 45.8	 2.5	
9226R	 ALIOS	 Yes	 53.7	 1.8	
9226L	 ALIOS	 Yes	 45.5	 2.3	
9299N	 ALIOS	 Yes	 51.0	 1.2	
9299R	 ALIOS	 Yes	 57.1	 1.8	
	 	 	 	 	
9838L	 Control+1mg/kg	FXRa	 Yes	 37.4	 1.0	
9838R	 Control+1mg/kg	FXRa	 Yes	 44.9	 0.5	
9838N	 Control+1mg/kg	FXRa	 Yes	 42.4	 0.4	
9843R	 Control+1mg/kg	FXRa	 Yes	 40.8	 0.4	
9843B	 Control+1mg/kg	FXRa	 Yes	 49.1	 0.5	
9843L	 Control+1mg/kg	FXRa	 Yes	 43.2	 0.4	
9843N	 Control+1mg/kg	FXRa	 Yes	 43.2	 1.2	
9838B	 Control+1mg/kg	FXRa	 Yes	 40.5	 3.3	
	 	  	 	
9845N	 Control+5mg/kg	FXRa	 Yes	 44.1	 0.5	
9845R	 Control+5mg/kg	FXRa	 No	 43.3	 0.9	
9845B	 Control+5mg/kg	FXRa	 Yes	 43.4	 0.7	
9845L	 Control+5mg/kg	FXRa	 Yes	 47.9	 0.6	
	 	 	 	 	
9841N	 ALIOS+1mg/kg	FXRa	 No	 44.4	 1.9	
9841B	 ALIOS+1mg/kg	FXRa	 Yes	 44.6	 1.8	
9836B	 ALIOS+1mg/kg	FXRa	 Yes	 51.5	 1.5	
9841L	 ALIOS+1mg/kg	FXRa	 No	 49.4	 2.5	
9841R	 ALIOS+1mg/kg	FXRa	 Yes	 41.6	 1.7	
9298R	 ALIOS+1mg/kg	FXRa	 Yes	 49.3	 1.6	
	 	  	 	
9837L	 ALIOS+5mg/kg	FXRa	 No	 37.5	 1.7	
9842R	 ALIOS+5mg/kg	FXRa	 Yes	 48.6	 1.6	
9842N	 ALIOS+5mg/kg	FXRa	 Yes	 49.2	 1.0	
9837R	 ALIOS+5mg/kg	FXRa	 Yes	 43.7	 1.9	
9837N	 ALIOS+5mg/kg	FXRa	 Yes	 44.7	 3.2	
9837B	 ALIOS+5mg/kg	FXRa	 No	 45.9	 2.8	
Table	 3.7;	Mice	 characteristics,	 including	 identifier,	 intervention	 (FXRa	 is	 FXR	 agonist),	 yes	=	
used	for	RT-PCR,	No	=	not	used	for	RT-PCR,	measurement	of	weight	and	visceral	adipose	tissue	
(VAT)		
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3.4.2	 Mice	fed	a	HF/HS	diet	were	heavier	with	more	visceral	fat	At	42	weeks,	mice	in	the	ALIOS	group	were	significantly	heavier	than	control	mice	(mean	weight	 of	 49.9	 g	 versus	mean	weight	 of	 41.6	 g,	 p	 =	 0.0009,	 95%	CI	 3.91-12.71).	 	 In	addition,	ALIOS	mice	had	stored	significantly	more	visceral	 fat	 (mean	VAT	weight	1.8	g	versus	0.5	g,	p	<	0.0001,	95%	CI	0.99-1.70),	as	seen	in	figure	3.7.	
	
Figure	3.7;		Body	weight	and	visceral	adipose	tissue	weight	for	mice	fed	control	or	ALIOS	diet,	
with	or	without	different	concentrations	of	FXR	agonist	(FXRa).	(n=44,	SEM,	t-tests)	From	 these	 data,	 the	 supplementation	 of	 HF/HS	 diet	 with	 the	 FXR	 agonist	significantly	 reduced	 the	body	weight	 (p	=	0.032,	95%	CI	0.50-9.48),	but	not	 the	visceral	 fat,	of	mice	on	 the	ALIOS	diet.	 	The	reduction	 in	body	weight	 in	 the	FXR	agonist	supplemented	ALIOS	groups,	is	significant	only	for	the	high	dose	(5mg/kg),	but	not	for	the	low	dose	(1mg/kg)	of	FXR	agonist	(p=0.032,	p=0.141	respectively).	
3.4.3	 Increased	body	fat	 is	associated	with	higher	 levels	of	 inflammatory	cytokine	
expression	in	the	ileum	Body	weight	and	VAT	weight	were	compared	with	cytokine	expression	for	mice	in	the	 control	 and	 ALIOS	 group.	 	 Mice	 treated	with	 an	 FXR	 agonist	 were	 excluded	
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from	this	analysis	to	avoid	the	potential	confounding	effect	FXR	agonism	may	have	on	gene	expression	(n=12).	As	 seen	 in	 figure	 3.8,	 there	 was	 a	 positive	 correlation	 between	 the	 weight	 of	accumulated	 mouse	 visceral	 adipose	 tissue	 and	 relative	 inflammatory	 cytokine	expression	 in	 the	 ileum.	 	The	positive	correlation	 is	significantly	deviated	 from	0	for	TNFα	and	IFNγ	(p=0.049,	p=0.021),	but	falls	short	of	significance	for	IL-6	and	IL-8	(p=0.178,	p=0.07).		
	
Figure	 3.8;	 	 Correlation	 between	 visceral	 adipose	 tissue	weight	 and	 delta	 Ct	 (as	measure	 of	
relative	 gene	 expression)	 for	 TNFα,	 IFNγ,	 IL-6	 and	 IL-8.	 	 Note	 y-axis	 is	 inverted	 as	 lower	 ΔCt	
values	equate	to	higher	levels	of	relative	gene	expression.	(n=12,	linear	regression	analysis)	Figure	 3.9	 presents	 the	 association	 between	 total	 body	 weight	 and	 the	 relative	gene	 expression	 of	 CD	 associated	 inflammatory	 cytokine	 in	 the	mouse	 ileum.	 	 A	positive	 trend	 to	 increasing	 gene	 expression	 with	 increased	 weight	 was	
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demonstrated,	 but	 the	 correlation	 is	 relatively	 weak.	 	 None	 of	 the	 correlations	deviated	significantly	from	0.	
	
Figure	3.9;		Correlation	between	body	weight	and		ΔCt	(as	measure	of	relative	gene	expression)	
for	TNFα,	IFNγ,	IL-6	and	IL-8.		Note	y-axis	is	inverted	as	lower	ΔCt	values	equate	to	higher	levels	
of	relative	gene	expression.(n=12,	linear	regression	analysis)		 	
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3.4.4	 There	 is	 evidence	 that	 FXR	 activity	 is	 decreased	 in	 the	 ileum	 of	mice	 fed	 a	
HF/HS	diet	The	relative	expression	of	FXR	and	 its	downstream	 targets,	 SHP	and	 IBABP,	was	measured	 to	assess	 the	effect	of	HF/HS	 feeding	on	FXR	activity.	 	As	described	 in	section	 3.3.9,	 relative	 gene	 expression	 was	 calculated	 to	 give	 a	 fold	 change	 in	mRNA	 levels	between	control	 and	 intervention	groups.	 	A	 fold	 change	of	greater	than	2,	or	less	than	0.5,	is	thought	to	be	biologically	relevant(Inagaki	et	al.,	2006).	The	 relative	mRNA	 levels	 of	 FXR,	 SHP	and	 IBABP	were	 all	 reduced	 in	 the	ALIOS	group	 as	 compared	 with	 control,	 with	 a	 fold	 decrease	 of	 0.51,	 0.18	 and	 0.44	respectively	 (see	 figure	 3.10).	 	 This	 fold	 decrease	 was	 significant	 for	 IBABP	(p=0.04).	 	 The	 decreased	 trend	 observed	 for	 FXR	 and	 SHP	 was	 not	 significant	(p=0.30	and	p=0.34	respectively).	
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Figure	3.10;		The	relative	gene	expression	of	FXR	and	its	downstream	targets	in	ileum	of	mice	
fed	a	diet	rich	in	fat	and	sugar	(ALIOS)	as	compared	with	mice	fed	a	control	diet.		The	data	are	
presented	both	as	a	fold	change	and	as	delta	delta	Ct	to	allow	the	representation	of	the	degree	
of	error.(n=12,	**significant	by	t-test,	SE	–	see	section	3.3.10)	
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3.4.5	 There	is	a	trend	to	suggest	that	Ileal	inflammatory	cytokine	gene	expression	is	
elevated	in	mice	fed	a	HF/HS	diet	Mice	 fed	 a	 HF/HS	 diet	 in	 the	 ALIOS	 group	 demonstrate	 increased	 levels	 of	 ileal	TNFα,	IFNγ,	IL-6	and	IL-8	mRNA	in	comparison	to	control.		In	the	ALIOS	group,	ileal	mRNA	levels	of	TNFα,	IFNγ	and	IL-8	were	increased	by	a	factor	of	2	or	more	(2.49,	2.17	&	2.43	respectively),	whilst	IL-6	was	increased	by	a	factor	of	1.87,	as	compared	with	control	mice	(see	figure	3.11).	Due	to	the	broad	range	of	delta	Ct	values	within	each	sample,	 the	propagation	of	error	was	 large.	 	This	 is	demonstrated	by	the	size	of	 the	error	bars	on	the	 lower	graph	that	demonstrates	the	relative	expression	by	ΔΔCt	method,	figure	3.11.	There	was	a	consistent	trend	to	increased	levels	of	relative	ileal	mRNA	expression	for	TNFα,	IFNγ,	IL-6	and	IL-8	in	the	ALIOS	group	as	compared	to	control.		However,	this	 finding	 was	 not	 significant	 for	 any	 of	 the	 cytokines	 assayed	 (TNFα	 p=0.19,	IFNγ	p=0.28,	IL-6	p=0.35,	IL-8	p=0.26).	
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Figure	3.11;	 	The	relative	gene	expression	of	CD	associated	inflammatory	cytokine	 in	 ileum	of	
mice	fed	a	diet	rich	in	fat	and	sugar	(ALIOS)	as	compared	with	mice	fed	a	control	diet.		The	data	
are	presented	both	as	a	 fold	change	and	as	delta	delta	Ct	 to	allow	the	 representation	of	 the	
degree	of	error.	(n=12,	SE	–	see	section	3.3.10)	
3.4.6	 High	dose,	but	not	low	dose,	FXR	agonist	induced	FXR	activation	The	 relative	 expression	 of	 FXR,	 SHP	 and	 IBABP	 were	 measured	 to	 assess	 the	activity	 of	 the	 FXR	 agonist.	 	 TNFα,	 acting	 via	 NF-κB,	 can	 inhibit	 FXR	
TNFα IL-6 IFNγ IL-8
1.000
2.000
4.000
Relativ
e(expre
ssion((f
ol
d%
ch
an
ge
)
TNFα IL-6 IFNγ IL-8
0
1
2
3
Relativ
e(mRNA
(expres
sion((Δ
Δ
Ct)
		 132	
expression(Gadaleta	et	al.,	2011a).		Therefore,	in	order	to	assess	whether	the	FXR	agonist	supplementation	of	feed	produced	a	biological	effect	in	the	mouse	ilea,	the	levels	of	FXR	and	its	downstream	genes	were	measured	in	the	control	diet	and	the	control	with	FXR	agonist	groups	(n=17).	 	The	ALIOS	fed	groups	with	FXR	agonist	were	 excluded	 from	 analysis	 due	 to	 the	 potential	 confounding	 factor	 of	 any	inflammatory	suppression	of	FXR	activity.	Figure	 3.12	 and	 3.13	 demonstrate	 the	 effect	 of	 the	 two	 doses	 of	 FXR	 agonist	supplemented	feed	on	the	expression	of	FXR,	SHP	and	IBABP.		Again,	the	data	are	presented	 as	 a	 relative	 fold	 change,	 but	 also	 as	 the	 mean	 ΔΔCt	 value	 with	 SE	represented	by	error	bars.	
The	 higher,	 5mg/kg,	 dose	 of	 FXR	 agonist	 induced	 a	 significant	 increase	 in	 ileal	IBABP	expression	with	a	fold	increase	of	2.0	(p	=	0.01).		At	this	dose,	there	was	also	a	trend	towards	increased	relative	expression	levels	of	SHP	(fold	change	1.05)	and	FXR	(fold	change	1.52).		These	changes	were	not	significantly	different	(p=0.96	and	p=0.40	respectively)	and	only	an	increased	trend	was	suggested.	 	The	increase	in	IBABP	 and	 the	 trend	 to	 increased	 levels	 of	 FXR	 and	 SHP	 demonstrate	 that	 the	5mg/kg	dose	agonised	FXR	in	the	mouse	ileum.		
The	1mg/kg	dose	of	FXR	agonist	did	not	 increase	FXR,	SHP	or	 IBABP	expression	levels.	 	 In	 fact,	 there	 was	 the	 paradoxical	 observation	 of	 significantly	 reduced	downstream	IBABP	gene	expression,	suggesting	relative	inhibition	of	FXR	activity.		A	 trend	 to	reduced	expression	of	FXR	and	SHP	was	also	suggested.	 	There	was	a	0.57	 fold	 decrease	 in	 FXR	 (p=0.32),	 0.31	 fold	 decrease	 in	 SHP	 (p=0.32)	 and	 a	significant	0.41	fold	decrease	in	IBABP	(p=0.03).	
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Figure	3.12;		The	effect	of	1mg/kg	or	5mg/kg	FXR	agonist	(FXRa)	on	the	relative	expression	of	
ileal	 FXR,	 SHP	 and	 IBABP	 in	mice	 fed	 a	 control	 diet,	 as	 compared	with	mice	 fed	 control	 diet	
alone.		SHP	and	IBABP	are	downstream	of	FXR	and	are	a	measure	of	FXR	activity.		Results	are	
presented	as	a	fold	change.	(n=17)	
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Figure	3.13;		The	effect	of	1mg/kg	or	5mg/kg	FXR	agonist	(FXRa)	on	the	relative	expression	of	
ileal	 FXR,	 SHP	 and	 IBABP	 in	mice	 fed	 a	 control	 diet,	 as	 compared	with	mice	 fed	 control	 diet	
alone.		SHP	and	IBABP	are	downstream	of	FXR	and	are	a	measure	of	FXR	activity.		Results	are	
presented	as	mean	ΔΔCt	with	error	bars	to	represent	SE.	(n=17)	Taken	together,	these	results	suggest	that	the	FXR	agonist	was	biologically	active	in	the	mouse	ilea.		However,	only	the	higher,	5mg/kg	dose	was	able	to	agonise	FXR	under	these	experimental	conditions.		
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3.4.7	 There	 is	 a	 trend	 suggesting	attenuated	 levels	of	 ileal	 cytokine	expression	 in	
HF/HS	fed	mice	when	treated	with	an	FXR	agonist	The	 level	 of	 inflammatory	 cytokine	 expression	 in	 the	 ilea	 of	 ALIOS	 mice	 was	measured	with	and	without	the	FXR	agonist	supplemented	feed	in	order	to	assess	the	effect	of	FXR	on	HF/HS	associated	inflammation.	Results	 in	 section	 3.4.4	 demonstrated	 that	 ALIOS	 fed	 mice	 have	 higher	 relative	levels	of	ileal	inflammatory	cytokine	expression	compared	with	control	diet	mice.		When	 diet	 was	 supplemented	 with	 the	 FXR	 agonist,	 there	 was	 a	 trend	 for	 the	ALIOS	 induced	 increase	 in	 inflammatory	 cytokine	 expression	 to	 be	 attenuated.		Figure	3.14	and	3.15	demonstrates	the	effect	of	5mg/kg	or	1mg/kg	FXR	agonist	in	the	ALIOS	mice.	In	the	5mg/kg	FXR	agonist	supplemented	group,	the	expression	of	TNFα,	IFNγ	and	IL-6	was	reduced	from	a	relative	fold	increase	of	2.49	to	1.43,	2.17	to	1.93	and	1.86	to	1.53	respectively.	 	For	IL-8	there	was	increase	in	the	relative	fold	change	from	2.43	 to	 2.76.	 	 None	 of	 these	 changes	 were	 significantly	 different	 (TNFα	 p=0.51,	IFNγ	p=0.90,	IL-6	p=0.81,	IL-8	p=0.85).		In	the	1mg/kg	FXR	agonist	supplemented	group,	there	was	an	observed	reduction	in	the	relative	expression	of	each	cytokine	assayed.		The	expression	of	TNFα,	IFNγ,	IL-6	and	IL-8	was	reduced	from	a	relative	fold	increase	of	2.49	to	0.43,	2.17	to	0.74,	1.86	 to	 0.93	 and	 2.43	 to	 0.79	 respectively.	 	 Again,	 none	 of	 the	 changes	 were	statistically	significant	(TNFα	p=0.20,	IFNγ	p=0.27,	IL-6	p=0.32,	IL-8	p=0.26).	
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Figure	3.14;	 	 The	effect	of	ALIOS	diet	with	or	without	1mg/kg	FXR	agonist	 (FXRa)	or	5mg/kg	
FXR	 agonist	 on	 the	 relative	 gene	 expression	 of	 TNFα,	 IFNγ,	 IL-6	 and	 IL-8	 in	 the	 ilea	 of	mice.		
Results	are	presented	as	a	fold	change.	(n=14)	
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Figure	3.15;	 	 The	effect	of	ALIOS	diet	with	or	without	1mg/kg	FXR	agonist	 (FXRa)	or	5mg/kg	
FXR	 agonist	 on	 the	 relative	 gene	 expression	 of	 TNFα,	 IFNγ,	 IL-6	 and	 IL-8	 in	 the	 ilea	 of	mice.		
Results	are	presented	as	mean	ΔΔCt	with	error	bars	to	represent	SE.	(n=14)		 	
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3.4.8	 High	dose	FXR	agonist	may	cause	an	increase	in	ileal	cytokine	expression	The	level	of	inflammatory	cytokine	expression	in	control	mice	was	measured	with	and	without	 the	 FXR	 agonist	 supplemented	 feed.	 	 The	 finding	 that	 there	was	 an	inverse	dose	response,	such	that	1mg/kg	FXR	agonist	appeared	to	have	a	greater	effect	on	reducing	cytokine	expression	in	ALIOS	mice	than	5mg/kg	of	FXR	agonist,	suggested	 that	 high	 dose	 FXR	 agonism	might	 have	 a	 toxic,	 cytokine	 stimulating	effect.		Figure	3.16	and	3.17	demonstrate	 that	 in	 the	5mg/kg	FXR	agonist	supplemented	group,	 the	expression	of	TNFα,	 IFNγ,	 IL-6	and	 IL-8	was	 increased	with	a	 relative	fold	change	of	5.3,	2.2,	2.7	and	2.0	respectively,	as	compared	with	control.		None	of	these	changes	were	significantly	different	(TNFα	p=0.18,	IFNγ	p=0.14,	IL-6	p=0.12,	IL-8	p=0.52).	In	 the	 1mg/kg	 FXR	 agonist	 supplemented	 group,	 there	 was	 little	 change	 from	control	with	 fold	 changes	 of	 1.7,	 1.1,	 0.94	 and	 1.9	 for	 TNFα,	 IFNγ,	 IL-6	 and	 IL-8	respectively	(TNFα	p=0.39,	IFNγ	p=0.88,	IL-6	p=0.87,	IL-8	p=0.41).	
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Figure	3.16;	 	The	effect	of	1mg/kg	FXR	agonist	 (FXRa)	or	5mg/kg	FXR	agonist	on	the	relative	
gene	expression	of	TNFα,	IFNγ,	IL-6	and	IL-8	in	the	ilea	of	control	mice.		Results	are	presented	
as	a	fold	change	(n=17)	
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Figure	 3.17	 The	 effect	 of	 1mg/kg	 FXR	 agonist	 (FXRa)	 or	 5mg/kg	 FXR	 agonist	 on	 the	 relative	
gene	expression	of	TNFα,	IFNγ,	IL-6	and	IL-8	in	the	ilea	of	control	mice.		Results	are	presented	
as	mean	ΔΔCt	with	error	bars	to	represent	SE.	(n=17,	SE)		
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3.5	 Discussion	The	 high	 fat/high	 sugar	 (HF/HS)	 content	 western	 diet	 is	 associated	 with	 an	increased	risk	of	developing	CD(Hou	et	al.,	2011).		The	pathological	mechanism	by	which	a	HF/HS	may	induce	small	bowel	inflammation	is	unknown,	but	disruption	to	 BA	 signaling	 due	 a	 diet-induced	 dysbiosis	 has	 been	 postulated(Duboc	 et	 al.,	2013).		The	aims	of	this	chapter	were	to	assess	for	evidence	of	ileal	inflammation	associated	 with	 a	 western	 diet	 and	 to	 assay	 the	 effect	 of	 promoting	 ileal	 BA	signaling,	using	an	FXR	agonist,	in	this	model	system.	
Evidence	 from	 these	 mouse	 studies	 is	 in	 keeping	 with	 the	 hypothesis	 that	disruption	 to	 BA	 signalling,	 induced	 by	 a	 HF/HS	 diet	 associated	 dysbiosis,	 is	 a	mechanism	 linking	 diet	 to	 the	 development	 of	 CD.	 	 The	 ALIOS	 model	 has	previously	been	shown	to	 induce	physiological	changes	similar	 to	 those	 found	 in	patients	 with	 the	 metabolic	 syndrome,	 of	 obesity,	 hyperinsulinaemia	 and	dyslipidaemia(Dowman	 et	 al.,	 2014).	 	 Data	 presented	 here,	 demonstrates	 an	associated	 increase	 in	 the	 expression	 of	 CD	 associated	 inflammatory	 cytokines,	whilst	 the	 activity	 of	 FXR	was	 reduced,	 in	 the	 ilea	of	mice	 fed	 a	HF/HS,	western	diet.		There	was	a	strong,	significant	correlation	between	the	amount	of	visceral	fat	and	the	mRNA	levels	of	TNFα	and	IFNγ	expressed	in	the	ileum.		IL-6	and	IL-8	levels	were	also	associated	with	the	accumulation	of	visceral	fat,	but	the	correlation	was	less	 strong.	 	 This	 finding	 is	 concordant	 with	 the	 work	 of	 Hotamisligil	 et	 al	 and	others(Hotamisligil	 et	 al.,	 1993,	 Wellen	 and	 Hotamisligil,	 2005),	 who	 have	demonstrated	 that	 the	 obese	 state	 is	 one	 of	 a	 low	 grade	 inflammatory	 process,	with	 increased	 circulating	 LPS	 and	 cytokine	 expression	 in	 the	 liver	 and	subcutaneous	tissue.		In	these	experiments,	trimming	of	serosal	fat	prior	to	tissue	homogenisation	 ensured	 that	 the	 extracted	 ileal	 RNA	 was	 representative	 of	 the	
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cells	 in	 the	 ileum.	 	 The	 homogenised	 ileal	 tissue	 therefore	 included	 enterocytes,	intra-epithelial	lymphocytes	and	antigen	presenting	cells,	rather	than	peri-enteric	fat.	 	 In	 this	 respect,	 this	 model	 is	 much	 less	 reductionist	 than	 the	 chapter	 2	experiments	with	human	gut	derived	epithelial	cell	lines.	
This	study	did	not	measure	the	microbiome	and	so	a	direct	relationship	between	ileal	 inflammation	 and	 a	 diet-induced	 dysbiosis	 has	 not	 been	 demonstrated.		However,	 these	 findings	 build	 on	 work	 by	 Ding	 et	 al	 who	 have	 previously	demonstrated	an	increase	in	ileal	TNFα	mRNA	levels	in	HF	fed	conventional	mice,	but	 not	 germ	 free	 mice,	 demonstrating	 the	 importance	 of	 the	 microbiome	 in	promoting	gut	inflammation(Ding	et	al.,	2010).	
The	 upregulation	 of	 the	 FXR	 downstream	 gene,	 IBABP,	 demonstrates	 that	supplementing	feed	with	the	FXR	agonist	was	able	to	increase	the	activity	of	FXR,	for	the	higher,	5mg/kg,	dose	of	the	compound.			
In	the	HF/HS	fed	mice,	there	was	a	decrease	in	the	activity	of	FXR	as	demonstrated	by	a	significant	decrease	in	the	expression	of	IBABP	and	a	decreased	trend	in	the	expression	of	SHP	and	FXR.		This	is	merely	an	association	with	the	increase	in	the	inflammatory	cytokine	expression	and	does	not	demonstrate	causation.		
However,	there	is	a	trend	to	suggest	that	the	diet-induced	increase	in	ileal	cytokine	expression	may	be	attenuated	by	treatment	with	the	FXR	agonist,	particularly	for	the	1mg/Kg	FXR	agonist	dose.		This	was	only	a	trend	and	did	not	reach	statistical	significance.		This	trend	is	concordant	with	the	hypothesis	that	BA	dysmetabolism	is	a	potential	mechanism	by	which	HF/HS	diet	increases	the	risk	of	CD.			
As	measured	by	its	downstream	activity,	only	the	high	dose	of	Px-102	was	able	to	significantly	agonise	FXR.	 	 In	 the	study	design,	 the	FXR	agonist	was	added	to	 the	chow	and	not	lavaged.		Therefore,	there	is	possibly	some	variability	in	the	amount	
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of	drug	individual	mice	received.		However,	average	drug	dosing	should	have	been	similar	between	animals.			It	is	difficult	to	explain	the	observation	that	the	1mg/kg	dose	of	Px-102	seemed	to	antagonise	FXR.		The	standard	error	of	the	mean	in	this	group	 is	 large,	 representing	 a	 large	 range	 of	 values,	 and	 may	 contain	unrepresentative	 outliers.	 	 However,	 with	 only	 a	 small	 number	 of	 samples,	 it	 is	impossible	to	statistically	identify	any	potential	outliers	(e.g.	by	using	a	statistical	test	such	as	the	Grubb’s	test).			
There	is	the	suggestion	of	an	inverse	dose	response	for	the	attenuation	of	cytokine	expression,	 with	 the	 1mg/kg	 FXR	 agonist	 apparently	 producing	 a	 greater	 effect	than	the	5mg/kg	dose.	 	Also,	there	is	the	suggestion	that	the	5mg/kg	FXR	agonist	dose	in	control	animals	increased	cytokine	expression.		As	both	findings	were	only	a	trend,	it	is	difficult	to	analyse	this	finding.		However,	it	is	possible	that	the	higher	dose	is	producing	an	antagonising	effect.	 	This	may	be	as	a	result	of	an	off-target	effect	 or	 as	 a	 cell	 stressor	 (bile	 acids	 are	 detergent	 molecules)	 at	 high	concentrations.	 	 A	 similar	 potential	 toxic	 effect	 was	 seen	 with	 high	 doses	 of	 6-ECDCA	on	IL-8	production	by	HT29	cells	in	chapter	2.		A	repeat	experiment	using	a	larger	sample	would	provide	a	clearer	answer.	
ALIOS	 feeding	 over	 42	weeks	was	 associated	with	 a	 significant	 increase	 in	 body	weight	and	visceral	fat,	as	expected.		Interestingly,	treatment	with	the	FXR	agonist	was	 observed	 to	 inhibit	 this	 total	 weight	 gain,	 whilst	 visceral	 fat	 mass	 was	unchanged.		Presumably,	the	ALIOS	diet	mice	treated	with	the	FXR	agonist	failed	to	gain	weight	in	some	other	body	compartment,	such	as	liver,	muscle,	bone	or	other	fat	compartment.		Again,	this	observation	should	be	investigated	further.	
There	 are	 potential	 weaknesses	 in	 the	 methodology	 of	 these	 studies.	 	 The	 data	presented	are	from	a	mouse	model	that	closely	resembles	the	western	diet	that	has	
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been	 associated	 with	 CD	 pathogenesis.	 	 However,	 unlike	 patients	 with	 CD,	 the	C3H/He	mouse	 strain	 is	 genetically	 normal	with	 respect	 to	 its	 predisposition	 to	ileitis	 or	 colitis.	 	 Future	 studies	 may	 try	 to	 remedy	 this	 by	 using	 a	 genetic	 CD	animal	model,	such	as	the	TNF	ΔARE   (Pizarro et al., 2003) mouse,	with	the	ALIOS	diet.	These	 experiments	 have	 not	 demonstrated	 that	 the	 increase	 in	 inflammatory	cytokine	 expression	 associated	 with	 HF/HS	 feeding	 induced	 an	 actual	 ileitis.		Expression	 levels	 of	 cytokine	 mRNA	 does	 not	 necessarily	 equate	 to	 changes	 in	protein	 level	 and,	 when	 it	 does,	 may	 not	 lead	 to	 actual	 tissue	 inflammation.		Unfortunately,	storage	of	the	GI	tract	post-resection,	with	a	slow	freezing	process,	disrupted	 tissue	 architecture	 such	 that	 histology	 or	 protein	 assay	 could	 not	 be	performed	 reliably.	 	 Any	 future	 studies	 should	 attempt	 to	 assess	 for	 histological	evidence	of	inflammation.	Due	 to	 difficulties	 extracting	 high	 quality	RNA,	 the	 sample	 size	was	 small.	 	 This,	allayed	 to	 the	 large	 biological	 variability	 in	 mRNA	 expression	 between	 animals,	meant	 that	 results	were	 not	 statistically	 significant.	 	 Trends	were	 observed,	 but	these	 should	 be	 statistically	 verified	 by	 repeating	 a	 similar	 study	with	 a	 greater	sample	size.	
In	 summary,	 this	 chapter	provides	 tentative	 evidence	 to	 suggests	 that	 treatment	with	an	FXR	agonist	may	correct	the	disruption	to	BA	signalling	induced	by	HF/HS	feeding,	 dysbiosis	 and	BA	dysmetabolism.	 	 Studies	of	 FXR	activity	using	primary	tissue	 from	 patients	 with	 CD	 may	 provide	 further	 evidence	 for	 the	 role	 of	disrupted	BA	signalling	in	the	pathogenesis	of	the	disease.	
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Chapter	4	–	FXR	Activity	In	Patients	With	Ileal	Crohn’s	Disease	
4.1	 Abstract	The	 role	of	 farnesoid	X	 receptor	 (FXR)	 in	 the	 aetiopathogenesis	 of	 inflammatory	bowel	disease	(IBD)	has	been,	up	until	now,	studied	mainly	in	cell	line	and	animal	models.	 	 There	 are	 few	 studies	 on	 the	 role	 of	 FXR	 using	 primary	 tissue	 from	patients	with	Crohn’s	disease	(CD).			
Ex-vivo	organ	culture	of	small	intestinal	mucosa	has	been	used	to	study	a	variety	of	GI	diseases,	including	CD.		The	technique	of	ileal	organ	culture	allows	the	study	of	immune	function	in	an	architecturally	preserved	primary	tissue	sample.	The	broad	aims	of	 this	 chapter	were,	 therefore,	 to	 assay	FXR	activity	 in	patients	with	 ileal	 CD	 and	 to	 optimise	 an	 ex-vivo	 ileal	mucosa	 culture	model	 in	 order	 to	study	 the	 role	 of	 FXR	 agonism	 on	 cytokine	 secretion	 by	 primary	 gut	 epithelial	tissue.	
These	studies	demonstrate	that	FXR	expression	and	activity	is	decreased	in	the	ilea	of	patients	with	ileal	CD	as	compared	with	controls.		An	ex-vivo	explant	model	was	optimised	 as	 described	 in	 the	methods	 section.	 	 There	 is	 no	 evidence,	 from	 this	initial	pilot	study,	 to	support	 the	hypothesis	 that	FXR	agonism	can	reduce	TNFα-induced	mucosal	inflammatory	cytokine	secretion.	
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4.2	 Introduction	and	aims		The	 results	 presented	 in	 chapters	 2	 and	 3	 are	 of	 experiments	 performed	 using	epithelial	 cell-line	 and	mouse	models.	 	A	more	 accurate	prediction	of	 the	 role	 of	FXR	in	ileal	CD	may	be	provided	by	studies	utilising	primary	tissue	from	patients	with	the	disease.		The	studies	of	FXR	agonism	presented	here	are	intended	to	be,	in	part,	proof	of	concept	to	show	that	primary	ileal	tissue	can	be	successfully	cultured	and	experimentally	manipulated	ex-vivo.	There	are	only	a	few	studies	of	the	role	of	FXR	using	primary	tissue	from	patients	with	 CD.	 	 Nijmeijer	 et	 al.	 demonstrated	 that	 FXR	 activity,	 as	 measured	 by	 SHP	expression,	is	lower	in	the	ilea	of	patients	with	a	Crohn’s	colitis	as	compared	with	healthy	controls(Nijmeijer	et	al.,	2011).		There	are	no	published	data	on	the	role	of	FXR	in	patients	presenting	with	ileal	CD,	the	most	common	site	for	disease	activity.		This	 dearth	 of	 studies	 may	 be	 because	 access	 to	 primary	 ileal	 tissue	 is	 more	difficult	 than	 access	 to	 mucosal	 tissue	 from	 the	 colon,	 due	 in	 part	 to	 technical	issues	 (e.g.	 reaching	 the	 ileum	during	colonoscopy),	but	also	due	 to	 the	ethics	of	biopsying	normal	ileal	tissue	in	healthy	controls.		
The	 organ	 culture	 of	 small	 intestinal	 mucosal	 biopsies,	 originally	 described	 by	Browning	and	Trier(Browning	and	Trier,	1969),	has	been	used	to	study	a	variety	of	small	bowel	enteropathies.		This	technique	has	been	used	successfully	to	study	GI	 diseases	 as	 diverse	 as	 coeliac	 disease,	 necrotising	 enterocolitis,	 bile	 acid	malabsorption	and	IBD(Nanthakumar	et	al.,	2000,	Monteleone	et	al.,	2001,	Fina	et	al.,	 2011,	 Zhang	 et	 al.,	 2013).	 	 This	model	 provides	 an	 architecturally	 preserved	epithelial	 layer,	 complete	 with	 its	 associated	 stromal	 and	 immune	 cells	 (e.g.	 M-cells,	 dendritic	 cells,	 IELs,	 macrophages).	 	 This	 allows	 the	 experimental	manipulation	 of	 the	 intact	 human	 mucosa,	 providing	 a	 more	 holistic	 model	 of	mucosal	 immune	 function	 than	 simple	 epithelial	 cell-line	models.	 	 There	was	 no	
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expertise	 in	organ	 tissue	culture	within	our	group	prior	 to	 this	 thesis,	but	 it	was	felt	that	this	would	provide	a	good	model	system	for	the	study	of	FXR	agonism	in	ileal	CD.	
The	 hypotheses	 were	 that	 FXR	 and	 downstream	 gene	 expression	 would	 be	reduced	 in	 the	 ilea	of	patients	with	CD	as	opposed	 to	 controls;	 that	 the	 cytokine	milieu	 from	 diseased	 tissue	would	 be	more	 pro-inflammatory	 than	 control;	 and	that	 co-culture	 with	 an	 FXR	 agonist	 would	 attenuate	 the	 response	 of	 primary	tissue	to	stimulation	with	inflammatory	cytokine.	
Therefore,	the	aims	of	the	experiments	in	this	chapter	were:		
1. To	optimise	an	ex-vivo	ileal	mucosa	culture	model.	
2. To	assay	the	effect	of	FXR	agonism	using	this	optimised	model	as	a	proof	of	concept	pilot	study.		
3. To	compare	FXR	activity	in	patients	with	ileal	CD	as	compared	with	control.	
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4.3	 Methods	
4.3.1	 Ethics	and	consent	Samples	 were	 collected	 and	 stored	 in	 accordance	 with	 the	 Human	 Tissue	 Act	(2004),	 with	 approval	 from	 the	 Local	 Research	 Ethics	 Committee	 (LREC	 -	Newcastle	 and	 North	 Tyneside).	 	 The	 Hepatopancreatobiliary	 (HPB)	 and	Gastroenterology	 research	 groups	 at	 Newcastle	 University	 have	 an	 agreement,	from	the	LREC,	 to	 collect	and	store	 research	samples	without	 the	need	 to	obtain	specific	consent	for	individual	projects	(REC	number	10/H0906/41).		The	project	was	 approved	 by	 the	 HPB/Gastroenterology	 Biobank	 Committee	 prior	 to	 the	collection	 of	 any	 samples.	 	 Details	 of	 all	 projects	 falling	 within	 the	 remit	 of	 the	HPB/Gastroenterology	 Biobank	 are	 submitted	 to	 the	 LREC	 as	 part	 of	 an	 annual	report	for	audit	and	review.		A	copy	of	the	Biobank	submission	request	proforma	can	be	found	in	the	appendix.	Patient	 consent	 was	 obtained	 in	 accordance	 with	 the	 General	 Medical	 Council’s	‘Good	 Medical	 Practice’	 guidance(GMC,	 2013).	 	 A	 patient	 information	 leaflet	explaining	the	process	was	provided	to	all	participants.	 	Prior	to	their	procedure,	all	 patients	 provided	written,	 informed	 consent	 for	 their	 tissue	 to	 be	 stored	 and	analysed.		A	copy	of	the	patient	information	leaflet	and	patient	consent	form	can	be	found	in	the	appendix.	
4.3.2	 Patient	recruitment	and	control	group	Included	in	the	study	were	consecutive	patients	undergoing	right	hemi-colectomy	or	ileo-caecal	resection,	 for	colonic	cancer	or	 ileal	CD.	 	Patients	were	recruited	at	the	Royal	Victoria	Infirmary,	Newcastle	upon	Tyne,	between	March	and	July	2014.		In	 total,	 ileal	 samples	were	 collected	 from	11	patients,	 6	patients	with	CD	and	5	patients	with	some	form	of	colonic	or	caecal	tumour.	
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Patients	undergoing	ileo-caecal	resection	or	right	hemi-colectomy	for	cancer	were	included	 as	 controls.	 	 This	 patient	 group	 was	 chosen	 as	 a	 control	 group	 to	circumvent	 the	 ethical	 problem	 of	 collecting	 ileal	 tissue	 from	 healthy	 patients.		Whilst	ileal	tissue	can	be	readily	reached	by	the	colonoscope,	routinely	biopsying	normal	ileal	tissue	is	contra-indicated	due	to	the	small,	but	theoretically	increased	risk	 of	 variant	 Creutzfeld-Jacob	 disease	 transmission	 from	 prion	 proteins	prevalent	 in	 Peyer’s	 patches	 within	 the	 ileum(Rutter,	 2005).	 	 Collecting	 ileal	control	 samples	 from	 healthy	 human	 individuals,	 with	 no	 clinical	 indication	 for	biopsy,	could,	therefore,	be	potentially	unethical.	
Abundant	ileal	tissue	can,	however,	be	accessed	from	patients	undergoing	surgical	resection	 for	 cancer.	 	 As	 justification	 for	 using	 this	 control	 group,	 published	evidence	demonstrates	that,	whilst	FXR	expression	is	reduced	within	cancer	tissue	itself,	 it	 is	unaltered	 in	 the	surrounding	GI	 tissue	unaffected	by	cancer(Modica	et	al.,	2008,	A.	M.	Bailey	et	al.,	2014).	
There	were	no	exclusion	criteria.		Patient	demographics	were	collated	at	the	time	of	 recruitment	 to	 the	 study.	 	 Data	 as	 to	 final	 histological	 diagnosis,	 disease	phenotype	(stricturing,	penetrating	etc.)	and	medical	 treatment	 (including	use	of	biological)	was	recorded	using	patient	records	at	a	later	date.		Patient	identifiable	information	was	stored	in	a	separate	site	file	within	the	Newcastle	upon	Tyne	NHS	Foundation	Trust.	
4.3.3	 Ex-vivo	organ	culture	of	ileal	mucosa	By	 combining	 elements	 from	 several	 of	 the	 published	 techniques,	 a	 variety	 of	optimisation	 experiments	 were	 performed.	 	 These	 experiments	 included	 the	histological	comparison	of	 tissue	 following;	 i)	culture	with	different	 formulations	of	growth	media	with,	 for	example	CMRL	1066	or	RPMI	with	and	without	HEPES	
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buffer,	gentamycin	and	hydrocortisone;	 ii)	sample	preparation	as	a	 full-thickness	specimen	(all	mucosal	and	serosal	layers),	as	a	dissected	mucosal-role	(all	mucosa	with	serosa	removed)	or	with	biopsy	forceps	(epithelial	and	stromal	layer)	and;	iii)	tissue	 supported	 either	 completely	 submerged	 in	 growth	 media,	 on	 chemokine	filters	 in	 a	 6	 well	 plate	 or	 on	 organ	 tissue	 culture	 plates	 with	 a	 nylon	 filter	 to	provide	 an	 air-liquid	 interface.	 	 At	 40	 hours,	 the	 mucosal	 tissue	 samples	 were	formalin	 fixed	 and	 paraffin	 embedded	 (FFPE).	 	 Sections	were	 then	 stained	with	H&E	 and	 viewed	 microscopically	 to	 assess	 for	 histological	 architecture	 and	enterocyte	viability.		Examples	of	these	optimisation	H&E	sections	are	presented	in	the	results	section	(figure	4.7).		Standard	ELISA	experiments	were	also	performed	for	IL-6	and	IL-8	as	described	in	chapter	2.	
4.3.4	 Final	protocol	Following	 right	 hemi-colectomy	 or	 ileo-caecal	 resection,	 a	 2cm2	 longitudinal	section	of	 ileum	was	dissected	 from	 the	surgically	 resected	 ileo-caecal	 specimen.		Care	was	taken	to	avoid	the	ileo-caecal	resection	margin,	as	per	clinical	pathology	guidance.	 	 Dissection	 of	 the	 sample	 for	 experimentation	 was	 performed	 in	 the	operating	 theatre	 as	 soon	 as	 the	 ileo-caecum	was	 removed	 from	 the	 abdominal	cavity	 to	 minimise	 ischaemic	 time.	 	 The	 resected	 piece	 of	 ileum	 was	 then	suspended	 in	 ice-cold	 growth	 media	 and	 transported	 on	 ice	 to	 the	 laboratory	immediately.	 	 Growth	media	 consisted	 of	 CMRL	 1066	 (Gibco,	 Life	 Technologies)	supplemented	 with	 25	 mM	 HEPES	 buffer	 (Sigma),	 10%	 heat	 inactivated	 FCS	(Biosera),	 2mM	L-glutamine,	 100units/ml	 penicillin	 and	 100μg/ml	 streptomycin	(all	Sigma).			
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The	 tissue	was	washed	 on	 an	 orbital	 shaker	 in	 35ml	 of	 ice-cold	 PBS	 containing	100units/ml	penicillin	and	100μg/ml	streptomycin	for	1	minute.		The	ice-cold	PBS	was	replaced	and	the	washing	step	was	repeated.			The	 mucosal	 surface	 of	 the	 ileal	 section	 was	 identified	 and	 8	 mucosal	 biopsies	were	 taken	using	Radial	 Jaw	4	Biopsy	 Forceps	 (Boston	 Scientific,	 Alajuela,	 Costa	Rica).		The	use	of	forceps	standardised	the	sample	size	to	8mm	and	was	also	found	to	produce	a	mucosal	sample	that	was	thin	enough	to	allow	diffusion	of	oxygen	and	nutrients.	Two	 biopsies	 were	 snap	 frozen	 by	 submersion	 in	 liquid	 nitrogen-cooled	isopentane,	then	placed	in	cryovials	and	frozen	in	liquid	nitrogen	before	storage	at	-80	oC.	Six	biopsies	were	mounted	on	individual	100μm	nylon	filters	(BD	Falcon)	with	the	luminal,	mucosal	surface	facing	uppermost.		Filters	were	then	placed	on	the	central	well	 of	 a	 sterile	 organ	 culture	 plate	 (BD	 Falcon)	 as	 shown	 in	 figure	 4.1;	 2	ml	 of	growth	media	was	 added	 to	 the	 central	well,	 to	 just	 cover	 the	 tissue	 sample	 by	capillary	 action,	 and	 1	 ml	 of	 growth	 media	 was	 added	 to	 the	 moat,	 to	 prevent	samples	 from	dehydrating.	 	 The	 organ	 culture	 plates	were	 incubated	 in	 5%	CO2	humidified	 atmosphere	 at	 37oC.	 	 The	 growth	media	was	 changed	 after	 12	 hours	and	 the	 supernatant	was	 collected	 in	 a	1.5ml	Eppendorf	 and	 stored	at	 -80	oC	 for	later	cytokine	analysis.	 	At	12	hours,	vehicle	(DMSO)	or	1μM	6-ECDCA	was	added	to	 the	mucosal	 surface	of	 the	biopsy	sample	and	 the	plates	were	returned	 to	 the	incubator.	 	 At	 24	 hours,	 TNFα	 100ng/ml	was	 added	 to	 the	 growth	media	 in	 the	organ	 culture	plate	well.	 	At	40	hours,	 the	 supernatant	was	 again	harvested	 and	stored	 in	 a	 1.5ml	Eppendorf	 at	 -80	oC.	 	 The	biopsy	 samples	were	 snap	 frozen	 as	described	above	and	stored	at	-80	oC		 	
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Figure	4.1;	A)	Schematic	representation	of	organ	culture	dish	with	biopsy	placed	on	nylon	filter,	
epithelial	surface	uppermost.		B)	Photograph	of	sample	on	filter	in	organ	culture	dish.		Well	is	
filled	with	growth	media	such	that	it	is	drawn	over	the	mucosal	sample	by	capillary	action.	
4.3.5	 Real-time	reverse	transcription	polymerase	chain	reaction	(RT-PCR)	RNA	was	 isolated	 using	 the	 RNeasy	Mini	 Kit	 and	 the	 RNase-Free	 DNase	 Set,	 by	QIAGEN	(74104,	79254),	as	per	the	manufacturers	guidelines.	 	All	RNA	work	was	performed	using	RNase-free	 reagents	 and	 equipment.	 	 Laboratory	 surfaces	were	
A)	
B)	
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cleaned	 with	 RNase	 decontamination	 solution	 (RNaseZap,	 Ambion,	 Life	Technologies)	prior	to	experiments	and	pipette	filter	tips	were	used.	RNA	 was	 extracted	 from	 ileal	 biopsy	 samples	 that	 had	 been	 snap	 frozen	immediately	 following	 resection	 and	 washing	 and	 then	 stored	 at	 -80	 oC.	 	 Two	mucosal	 biopsy	 samples,	 from	 each	 patient,	were	 removed	 from	 the	 freezer	 and	suspended	in	600μl	of	buffer	RLT	with	β-mercaptoethanol	(10μl	per	ml	of	buffer),	in	 a	 2.0ml	 Precellys	 ceramic	 bead	 kit	 tube	 (1.4/2.8mm	beads),	manufactured	 by	Peqlab.	 	The	tissue	was	then	homogenised	using	a	Bertin	Minilys	tissue	disruptor	using	 4	 x	 25	 second	 cycles	 of	 disruption,	with	 a	 45	 second	 rest	 between	 cycles.		Samples	were	stored	on	ice	between	cycles	of	disruption.		A	700μl	solution	of	70%	ethanol	 was	 then	 added	 to	 the	 supernatant	 and	 the	 solution	 was	 gently	 mixed.		Next,	 700μl	 of	 the	 sample	 was	 transferred	 to	 an	 RNA	 spin	 column,	 in	 a	 2ml	collection	 tube,	 and	 spun	 at	 8,000	 x	 g	 for	 15	 seconds.	 	 The	 flow	 through	 was	discarded	 and	 350μl	 of	 buffer	 RW1	 was	 added	 and	 a	 further	 8,000	 x	 g	 for	 15	second	spin	was	performed.		An	80μl	solution,	containing	10μl	of	DNase	I	in	70μl	of	buffer	RDD,	was	added	to	the	spin	column	and	left	to	incubate	on	the	bench	top	for	15	minutes.	 	After	 incubation,	 the	DNase	 I	 solution	was	rinsed	out	with	350μl	of	buffer	 RW1,	 centrifuged	 at	 8,000	 x	 g	 for	 15	 seconds.	 	 The	 flow	 through	 was	discarded.		The	spin	column	was	then	washed	with	two	cycles	of	500μl	buffer	RPE,	spun	for	8,000	x	g	for	15	seconds	and	2	minutes	respectively.	 	A	drying	step	was	performed	with	the	spin	column	in	a	 fresh	2ml	collection	tube,	spun	at	8,000	x	g	for	1	minute.		Finally,	the	RNA	was	precipitated	in	30μl	of	nucleic	acid	and	RNase-free	 water	 and	 spun	 for	 8,000	 x	 g	 for	 1	 minute	 to	 collect	 the	 RNA	 containing	precipitate	in	a	fresh,	1.5ml	Eppendorf.		The	quantity	and	quality	of	extracted	RNA	was	 measured	 using	 a	 Nanodrop	 spectrophotometer	 and	 also	 by	 gel	
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electrophoresis	as	described	in	chapter	2.	 		A	spectrophotometer	example	of	RNA	purified	using	this	method	is	demonstrated	in	figure	4.2.	
	
Figure	4.2;	 	A	Nanodrop	spectrophotometer	reading	as	an	example	to	demonstrate	the	purity	
of	RNA	isolated	from	human	ileal	biopsy	as	described	in	the	text.	Complementary	 DNA	 (cDNA)	 was	 prepared	 using	 the	 Tetro	 cDNA	 Synthesis	 Kit	(Bioline)	as	described	 in	 chapter	2.	 	The	 subsequent	 cDNA	was	 then	used	as	 the	template	 to	 perform	 TaqMan-based	 (Life	 Technologies)	 RT-PCR	 experiments,	 as	previously	 described	 in	 chapter	 2.	 	 From	 the	 ileal	 samples	 of	 each	 patient,	 the	relative	 mRNA	 level	 of	 FXR,	 IBABP,	 SHP,	 TNFα,	 IL-6	 and	 IL-8	 were	 measured.		GAPDH	 was	 used	 as	 the	 reference	 (housekeeper)	 gene.	 	 Table	 4.1	 shows	 the	primer/probes	 used	 in	 these	 experiments.	 	 Quality	 control	 was	 performed	 as	described	 in	 chapter	 2	 (e.g.	 triplicate	 samples,	 no	 template	 control	 [NTC]	 and	primer	validation).		
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Protein	 Gene		
Exon	
spanning	
Primer/Probe	
FXR	 NR1H4	 yes	 Hs01026590_m1	
SHP	 NR0B2	 yes	 Hs00222677_m1	
IBABP	 FABP6	 yes	 Hs01031183_m1	
IL-6	 IL6	 yes	 Hs00985639_m1	
IL-8	 IL8	 yes	 Hs00174103_m1	
GAPDH	 GAPDH	 yes	 Hs02758991_g1	
Table	4.1;		List	of	genes	of	interest	and	TaqMan	primer/probes	used	in	chapter	4	Primer	 efficiency	 validation	 plots	 were	 produced	 for	 the	 human	 TaqMan	primer/probes	for	FXR,	IBABP,	SHP,	IL-8,	IL-6,	TNFα	and	GAPDH.		As	described	in	chapter	2,	 the	efficiency	 for	each	primer	can	be	calculated	using	 the	slope	of	 the	standard	curve	and	should	be	in	the	acceptable	range	90%	to	110%.		The	goodness	of	 fit	 (R2)	should	be	greater	 than	0.98.	 	Figure	4.3	and	table	4.2	demonstrate	 the	validation	 plots	 and	 primer	 efficiency	 for	 each	 primer/probe	 used	 in	 these	experiments.	
Primer	 Slope	 Efficiency	 R-squared	
FXR	 -3.273	 102.1%	 1.00 
SHP	 -3.193	 105.7%	 0.99 
IBABP	 -3.17	 106.8%	 0.97 
IL-8	 -3.127	 108.8%	 0.99 
MLCK	 -3.279	 101.8%	 1.00 
GAPDH	 -3.349	 98.9%	 0.96 
Table	4.2;		Primer	efficiency	and	goodness	of	fit	(R2)	for	primers	used	in	chapter	4.		See	fig	4.3	
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Figure	 4.3;	 	 Primer	 validation	 experiments	 for	 primers	 used	 in	 chapter	 4.	 	 Threshold	 cycle	 is	
measured	for	serial	dilutions	of	cDNA.		See	table	4.2	for	R2	and	efficiency	calculation	
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Relative	quantification	was	used	to	calculate	the	relative	expression	of	the	genes	of	interest,	as	described	 in	chapters	2	and	3.	 	Relative	quantification	was	calculated	using	 the	 ΔΔCt	 method	 as	 described	 by	 Livak	 and	 Schmittgen(Livak	 and	Schmittgen,	2001).		As	in	chapter	3,	in	order	to	represent	the	degree	of	SE,	but	also	to	 give	 an	 idea	of	 relative	 ratio	 changes,	 data	 are	presented	both	as	ΔΔCt	values	with	error	and	as	fold	change.	
4.3.6	 Detection	of	pro-inflammatory	cytokines	using	a	multi-array,	electro-chemical	
luminescence	assay	A	panel	of	pro-inflammatory	cytokines	was	measured	in	the	supernatant	from	the	organ	culture	experiments.			A	 cytokine	 assay	 for	 IFN-γ,	 IL-1β,	 IL-6,	 IL-8,	 IL-12p70,	 IL-13	 and	 TNF-α was	performed	 using	 a	 V-PLEX	 Multi-Spot	 Assay	 System	 (K15049D,	 Meso	 Scale	Diagnostics,	 Maryland,	 U.S.A.).	 	 This	 is	 a	 sandwich	 assay	 (capture	 antibody,	detection	 antibody	 with	 electrochemiluminescent	 probes)	 performed	 in	 pre-prepared	 plates	with	 all	 7	 cytokines	 being	 assayed	 in	 each	well.	 	 Figure	 4.4	 is	 a	schematic	representation	of	the	process	in	the	product	literature	provided	by	the	manufacturer.	
	
Figure	4.4;	A	 schematic	demonstrating	 the	placement	of	 capture	antibody	 in	each	well	of	an	
MSD	mutli-array	plate	(left)	and	sandwich	detection	assay	with	electro-luminescent	detection	
antibody,	cytokine	(analyte)	and	capture	antibody	(right).		
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The	 cytokine	 assay	 was	 performed	 as	 per	 the	 manufacturer’s	 guidelines.	 	 A	calibrating	 serial	 dilution	 was	 prepared	 by	 adding	 1000μl	 Diluent	 2	 to	 the	lyophilized	 calibrator	 vial,	 to	 produce	 the	 highest	 calibrator.	 	 The	 highest	calibrator	was	then	serially	diluted	1:4,	using	Diluent	2,	a	further	5	times.		Diluent	2	 is	used	as	a	 zero	 calibrator.	 	The	detection	antibody	 solution	was	prepared	by	adding	60μl	of	each	detection	antibody	(Anti-hu	IFN-γ,	IL-1β,	IL-6,	IL-8,	IL-12p70,	IL-13	and	TNF-α antibodies)	to	2400μl	of	Diluent	3.    50μl	 of	 sample	 (either	 supernatant	 or	 homogenised	 tissue)	 or	 calibrator	 was	added	 to	 each	well	 of	 a	 V-PLEX	 plate	 and	 incubated	 at	 room	 temperature	 for	 2	hours	 on	 an	 orbital	 shaker.	 	 The	 plate	 was	 washed	 x3	 in	 an	 automated	 plate	washer	(Thermo	Fisher),	using	a	wash	buffer	comprised	of	1800ml	water,	200ml	1%	PBS	and	1ml	Tween-20.		25μl	of	detection	antibody	solution	was	added	to	each	well	 and	 incubated	 for	 a	 further	 2	 hours,	 at	 room	 temperature,	 on	 an	 orbital	shaker.	 	The	plate	was	washed	3x	and	then	150μl	of	Read	Buffer	T	was	added	to	each	well.		The	plate	was	then	read	in	a	SECTOR	Imager	2400	machine	(Meso	Scale	Diagnostics).	A	Pierce	BCA	Protein	Assay	(Thermo	Scientific),	as	described	in	chapter	2	(section	2.3.8),	was	performed.		The	mean	protein	mass	per	tissue	sample	was	found	to	be	0.88	 +/-	 0.27	 mg/ml.	 	 Results	 from	 the	 cytokine	 detection	 assays	 were	 then	converted	 from	 concentration	 of	 cytokine	 per	 volume	 of	 supernatant	 (pg/ml)	 to	concentration	of	cytokine	per	mass	of	protein	(pg/mg).	
4.3.7	 Statistics	Unpaired	 Student’s	 t-tests	 and	 linear	 regression	 analyses	 were	 calculated	 using	Prism	version	6.0e,	Graphpad	software,	San	Diego.		All	P	values	were	2-tailed,	and	a	P	value	of	0.05	or	less	was	considered	statistically	significant.		The	cytokine	assay	
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data	set	was	tested	for	outliers	using	the	ROUT	method	(Q=1.0%),	as	described	by	Motulsky	 and	 Brown,	 in	 Prism	 version	 6.0e,	 Graphpad	 software,	 San	Diego(Motulsky	and	Brown,	2006).	
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4.4	 Results	
4.4.1	 Study	patient	demographics	Enrolled	 in	 the	 study	 were	 6	 patients	 with	 CD	 (mean	 age	 53	 +/-	 18	 years,	 all	female)	and	5	patients	with	a	caecal	cancer	(mean	age	68	+/-	19	years)	as	controls.		There	was	no	significant	difference	in	age	between	the	two	groups	(p=0.21).		The	majority	of	patients	included	in	the	study	were	female	(9/11).		No	patients	refused	consent	 to	 enter	 the	 study	 and	 there	 is	 no	 gender	 bias	 for	 either	 the	 risk	 of	developing	colorectal	cancer	or	CD.	Tables	4.3	and	4.4	demonstrate	patient	demographics	for	CD	patients	and	controls,	including	 disease	 phenotype,	 medical	 treatment	 at	 time	 of	 surgery	 and	 final	histology.	Two	patients	(1	with	CD	and	1	control)	were	used	for	organ	culture	optimisation	studies.	 	Tissue	from	the	other	9	patients	(5	CD,	4	control)	was	used	in	the	organ	culture	experiments.		RNA	of	sufficient	quality	was	only	isolated	from	8	patients	(5	CD	and	3	control)	for	RT-PCR	experiments.	
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Patient	
Identifier	
Age	 Gender	 Diagnosis	 Disease	Site	 Phenotype	 Treatment	 Histology	 Experiments	
CD47	PR	 67	 F	 Crohn’s	disease	 Ileocaecal	 Stricturing	 Nil	 Stricturing,	mildly	active	 PCR/Organ	culture	
CD45	ER	 69	 F	 Crohn’s	disease	 Ileocaecal	and	perianal	 Stricturing	 Thiopurine	 Stricture,	 active	inflammation	 PCR/Organ	culture	
CD75	SD	 39	 F	 Crohn’s	disease	 Terminal	ileal	disease	 Stricturing	 Steroids	 Stricture,	 active	inflammation	 PCR/Organ	culture	
CD85	SC	 29	 F	 Crohn’s	disease	 Terminal	ileal	 Fistulating	 Anti-TNFα	 Severe,	 active	disease	 PCR/Organ	culture	
CD45	LB	 69	 F	 Crohn’s	disease	 Terminal	ileal	 and	perianal	 Fistulating	 Steroids	 Perforated	stricture	 PCR/Organ	culture	
CD72	CM	 42	 F	 Crohn’s	disease	 Ileocaecal	 Stricturing	 Thiopurine/	Anti-TNFα	 Stricture,	 active	disease	 Optimisation	
Mean	 age	
(+/-SD)	
53	(+/-18)	 	 	 	
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Tables	4.3	(previous	page)	and	4.4	(this	page);	characteristics	of	patients	enrolled	in	the	studies	of	FXR	activity	in	ileal	mucosa	in	chapter	4			
	
Patient	
Identifier	
Age	 Gender	 Diagnosis	 Histology	 Experiments	
Ctrl80	RD	 34	 M	 Neuroendocrine	 tumour	of	appendix	 Unremarkable ileum, appendicectomy. 2/21 
nodes mets. disease (NET)	
PCR/Organ	culture	
Ctrl38	ML	 76	 F	 Caecal	adenocarcinoma	 Moderately differentiated 
adenoca. Dukes'A	 PCR/Organ	culture	
Ctrl43	LB	 71	 F	 Caecal	adenocarcinoma	 Poorly differentiated 
adenoca. pT3, N0	 PCR/Organ	culture	
Ctrl40	SL	 74	 M	 Caecal	adenocarcinoma	 Poorly differentiated 
adenoca. pT4b, N1	 Organ	culture	
Ctrl31	ER	 83	 F	 Caecal	adenocarcinoma	 Poorly differentiated 
adenoca. pT3 N0. Dukes B. 	 Optimisation	
Mean	 age	
(+/-SD)	
68	(+/-19)	 	 	 	 	
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4.4.2	 FXR	 expression	 and	 FXR	 activity	 is	 decreased	 in	 patients	 with	 ileal	 Crohn’s	
disease	Figure	 4.5	 demonstrates	 that	 there	 was	 significantly	 less	 FXR	 expression	 in	patients	 with	 ileal	 CD	 as	 compared	 with	 controls	 (p=0.004,	 ).	 	 In	 addition,	 the	activity	 of	 FXR,	 as	 measured	 by	 the	 downstream	 gene	 expression	 of	 SHP	 and	IBABP,	 was	 also	 significantly	 reduced	 (p=0.02	 and	 p=0.02	 respectively).	 	 Two-tailed	t-tests,	were	performed	by	comparing	ΔCt	values	for	each	biological	sample.		Figure	4.5	demonstrates	relative	mRNA	levels	of	FXR,	SHP	and	IBABP	expression	in	comparison	with	control	patients,	as	expressed	as	a	ΔΔCt	value.	 	As	detailed	in	chapter	 2,	 ΔΔCt	 is	 the	 difference	 in	 the	 relative	 expression	 level	 of	 the	 gene	 of	interest	 between	 the	 intervention	 group	 (those	with	 CD)	 and	 the	 control	 group	(those	without	CD).		Figure	 4.6	 demonstrates	 the	 change	 in	 relative	 expression,	 as	 compared	 with	controls,	as	a	fold	change.		A	fold	reduction	of	0.04	was	found	for	FXR,	0.11	for	SHP	and	0.01	for	IBABP.		Error	bars	are	not	included,	as	SE	becomes	meaningless	when	the	calculation	to	non-normally	distributed	data	is	made.	Data	 are	 presented	 in	 both	 formats	 (ΔΔCt	 and	 fold	 change)	 to	 allow	 an	appreciation	of	the	degree	of	error	in	addition	to	the	fold	increase	or	decrease.	
4.4.3	 There	 is	 a	 trend	 to	 increased	 levels	 of	 inflammatory	 cytokine	 in	 the	 ileal	
mucosa	of	patients	with	Crohn’s	disease	There	was	a	trend	suggesting	increased	relative	mRNA	levels	of	the	inflammatory	cytokines	IL-6,	TNFα	and	IL-8	in	the	ileal	mucosa	of	patients	with	CD	as	compared	with	controls	(see	figures	4.5	and	4.6).	 	A	fold	change	of	3.96	was	found	for	IL-6,	3.36	for	TNFα	and	6.44	for	IL-8.	 	However,	two-tailed	t-tests	are	not	significantly	different	 (IL-6	 p	 =	 0.44,	 TNFα	 p	 =	 0.51,	 IL-8	 p	 =	 0.24)	 and	 therefore	 the	 null	
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hypothesis	 is	not	disproved.	 	Figures	4.5	and	4.6	demonstrate	the	relative	mRNA	levels	 of	 IL-6,	 TNFα	 and	 IL-8	 expression	 in	 comparison	 with	 control	 patients,	expressed	both	as	a	ΔΔCt	value	and	as	a	fold	change.		Again,	data	are	presented	in	both	formats	to	allow	an	appreciation	of	the	degree	of	error	in	addition	to	the	fold	increase	or	decrease.		 	
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Figure	 4.5;	 	 Relative	 mRNA	 levels	 (ΔΔCt)	 of	 FXR	 and	 its	 downstream	 targets	 (A)	 and	
inflammatory	 cytokines	 (B)	 in	 the	 ileal	 mucosa	 of	 patients	 with	 CD	 as	 compared	 with	
controls.(n=8,	SE,	*	p<0.05	t-tests)	
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Figure	4.6;	Relative	mRNA	levels	of	FXR	and	downstream	genes	with	inflammatory	cytokine	in	
the	ileal	mucosa	of	patients	with	CD,	in	comparison	with	control.		Expressed	as	a	fold	change.	
(n=8)	
4.4.4	 Short-term,	ex-vivo	ileal	explant	culture	is	biologically	viable	Optimisation	 experiments	 were	 performed	 as	 described	 in	 section	 4.3.3.	 	 The	addition	of	hydrocortisone	and/or	gentamycin	to	the	growth	media	had	no	effect	either	on	the	histology	or	the	production	of	IL-6	and	IL-8	as	measured	by	sandwich	ELISA	(results	not	shown).		The	results	from	a	variety	of	experiments	demonstrate	that	the	ex-vivo	explant	culture	protocol	can	be	used	to	study	BA	signaling	via	FXR.			
4.4.4.i	 	 H&E	stains	demonstrate	viable	enterocytes	at	40	hours	A	variety	of	micrographs	of	H&E	stained	 ileal	explant	 tissue	are	demonstrated	 in	figure	 4.7.	 	 Micrographs	 from	 initial	 optimisation	 experiments	 are	 presented	 to	demonstrate	dead	tissue	with	few,	if	any,	viable	enterocytes.		The	crypts	are	empty,	with	 barely	 any	 nucleated	 enterocytes,	 in	 keeping	 with	 severe	 ischaemic	 injury	(see	figure	4.7	A	&	B).		In	these	images	the	tissue	has	been	sectioned	in	a	saggital	plane	(crypts	and	villi	longitudinally).	
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Explant	cultured	tissue	using	the	developed	protocol	is	also	shown	(see	figure	4.7	D	&	E).	 	In	these	micrographs,	the	villi	have	been	sectioned	in	a	transverse	plane.		Abundant,	nucleated	enterocytes	 can	be	 clearly	 seen	with	associated	goblet	 cells	and	inflammatory	cells	within	the	lamina	propria.			The	difference	in	the	planes	of	sectioning	was	due	to	the	orientation	of	the	tissue	when	embedded	within	the	paraffin	block.	 	 Ideally,	 to	allow	a	better	comparison,	H&E	 sections	 should	 have	 been	 presented	 using	 the	 same	 orientation,	 but	unfortunately	these	were	not	available.	
	
Figure	4.7	(A-D);		H&E	stains	(x10	to	x20	magnification)	of	ileal	explant	tissue	culture.		Slides	A	
&	B	are	from	optimisation	steps	at	40	hours	and	demonstrate	ischaemic,	dead	tissue	with	few	
if	 any	 viable	 enterocytes	 (saggital	 plane).	 	 The	 crypts	 are	 largely	 denuded.	 	 Slides	 C	&	D	are	
from	 cultured	 tissue	 at	 40	 hours	 using	 the	 final	 protocol	 (villi	 sectioned	 in	 transverse	 plain).		
Abundant	nucleated	viable	enterocytes	and	associated	goblet	cells	can	be	seen.		 	
A B
C D
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4.4.4.ii		 Ileal	 tissue	 from	 CD	 patients	 produces	 higher	 concentrations	 of	
inflammatory	cytokine	than	control	The	 concentration	 of	 a	 panel	 of	 inflammatory	 cytokines	 was	 measured	 in	 the	supernatant	from	ex-vivo	cultured	ileum	at	12	hours.		In	keeping	with	the	expected	finding,	the	secretion	of	inflammatory	cytokine	was	higher	from	the	ileal	tissue	of	patients	with	CD	as	compared	with	controls	(see	 figure	4.8	a,	b).	 	This	difference	was	significant	for	TNFα,	IL-12p70	and	IL-13	(p	=	0.04	95%	CI	1.06-53.33,	p	=	0.03	95%	 CI	 0.69-6.49	 and	 p	 =	 0.02	 95%	 CI	 4.21-22.91,	 respectively).	 	 Whilst	 not	significantly	different,	there	was	a	consistent	trend	for	increased	concentrations	of	IFNγ,	IL-6,	IL-1β	and	IL-8	in	the	supernatant	from	the	cultured	ileal	mucosa	of	CD	patients	versus	control.		 	
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Figure	4.8	(a);	The	concentration	of	IFNγ,	IL-6,	IL-1β	and	TNFα	in	the	supernatant	from	12	hours	
organ	culture	of	 tissue	 from	patients	with	Crohn's	disease	versus	 control.	 (n=9,	 SEM,	outliers	
tested	by	ROUT	method)	
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Figure	4.8	(b);	The	concentration	of	IL-8,	IL-12p70	and	IL-13	in	the	supernatant	from	12	hours	
organ	culture	of	 tissue	 from	patients	with	Crohn's	disease	versus	 control.	 (n=9,	 SEM,	outliers	
tested	by	ROUT	method)	
4.4.4.iii	 Evidence	 that	 explanted	 ileal	 tissue	 will	 produce	 cytokine	 when	
stimulated	with	TNFα	The	 concentration	 of	 a	 panel	 of	 inflammatory	 cytokines	 was	 measured	 in	 the	supernatant	 from	ex-vivo	cultured	 ileum	after	16	hours	of	co-culture	with	TNFα,	40	 hours	 after	 resection.	 	 Figure	 4.9	 (a	 &	 b)	 demonstrates	 the	 concentration	 of	
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cytokine	in	TNFα	stimulated	tissue	in	comparison	with	a	vehicle	(DMSO)	control.		There	 is	a	 significant	 increase	 in	 the	production	of	 IL-12p70	and	 IL-13	(p	=	0.04	95%	 CI	 0.15-7.24	 and	 p	 =	 0.01	 95%	 CI	 2.90-15.99,	 respectively)	 when	 tissue	 is	stimulated	with	TNFα.	 	 It	can	be	seen	that	there	is	a	trend	for	increased	levels	of	cytokine	 production	 in	 the	 TNFα	 stimulated	 group	 for	 all	 of	 the	 other	inflammatory	cytokines	assayed,	although	these	changes	fail	to	reach	significance.			The	highly	significant	increase	in	the	concentration	of	TNFα	(p<0.0001),	following	TNFα	 stimulation,	 acts	 as	 a	 positive	 control	 for	 the	 assay.	 	 The	 concentration	 of	TNFα	in	the	supernatant	should	clearly	increase	after	the	addition	of	100ng/ml	of	TNFα	 to	 the	 organ	 culture	 dish.	 	 The	 IL-8	 concentration	 is	 at,	 or	 above,	 the	detection	level	for	the	assay	and	therefore	cannot	be	interpreted.	 	A	repeat	assay	utilising	a	dilute	supernatant	sample	for	IL-8	was	not	repeated	due	to	the	high	cost	of	the	V-PLEX	plate.		 	
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Figure	4.9	(a);	Concentration	of	IFNγ,	IL-6,	IL-1β	and	TNFα	in	the	supernatant	from	ileal	tissue	
cultured	with	TNFα	(100ng/ml),	for	16	hours,	in	an	organ	culture	model.		Assays	for	TNFα	and	
IL-8	are	at	the	upper	limit	of	detection.	(n=14,	SEM,	outliers	tested	by	ROUT)	
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Figure	 4.9	 (b);	 Concentration	 of	 IL-8,	 IL-12p70	 and	 IL-13	 in	 the	 supernatant	 from	 ileal	 tissue	
cultured	with	TNFα	(100ng/ml),	 for	16	hours,	 in	an	organ	culture	model.	 (n=14,	SEM,	outliers	
tested	by	ROUT)		 	
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4.4.5	 Pilot	 data	 suggests	 that	 FXR	 agonism	 does	 not	 ameliorate	 the	 pro-
inflammatory	milieu	associated	with	TNFα	stimulation	The	 concentration	 of	 a	 panel	 of	 inflammatory	 cytokines	 was	 measured	 in	 the	supernatant	from	ex-vivo	cultured	ileum	following	12	hours	of	pre-treatment	with	6-ECDCA	 (1μM)	 or	 vehicle	 (DMSO)	 followed	 by	 stimulation	 with	 TNFα	 for	 16	hours.	From	 this	 pilot	 data	 set,	 treatment	 with	 an	 FXR	 agonist	 did	 not	 ameliorate	 the	inflammatory	 cytokine	 production	 of	 human	 ileal	mucosa	 after	 stimulation	with	TNFα,	as	demonstrated	in	figure	4.10.		There	was	no	statistical	difference	between	the	 cytokine	 concentrations	 from	 TNFα	 stimulated	 tissue	 treated	with	 6-ECDCA	versus	TNFα	stimulated	tissue	treated	with	vehicle.		No	consistent	trend	could	be	demonstrated	between	treatment	and	intervention	groups,	with	a	decrease	in	IL-1β	and	IFNγ,	but	an	increase	in	IL-12,	IL-13	and	IL-6.	Again,	the	TNFα	concentration	acted	as	a	positive	control	group.		Likewise,	IL-8	is	at	the	limits	of	the	assay	detection	level	and	therefore	cannot	be	interpreted.	
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Figure	4.10	(a);	The	concentration	of	CD	associated	cytokines	(IFNγ,	IL-6,	IL-1β	and	TNFα)	in	the	
supernatant	of	ex-vivo	cultured	ileal	mucosal	tissue	after	stimulation	with	TNFα	in	the	presence	
or	absence	of	6-ECDCA.		The	concentration	of	TNFα	is	at	the	limit	detection	in	this	assay.	
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Figure	4.10	(b);	The	concentration	of	CD	associated	cytokines	(IL-8,	 IL-12p70	and	IL-13)	 in	the	
supernatant	of	ex-vivo	cultured	ileal	mucosal	tissue	after	stimulation	with	TNFα	in	the	presence	
or	absence	of	6-ECDCA.		The	concentration	of	IL-8	is	at	the	limit	detection	in	this	assay.		 	
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4.5	 Discussion	There	is	little	published	evidence	regarding	FXR	activity	in	patients	with	CD.		The	
ex-vivo	culture	of	ileal	mucosa	is	a	good	model	in	which	to	study	the	role	of	FXR	in	primary	 tissue	as	 it	 allows	 the	 experimental	manipulation	of	whole	 ileal	mucosa	under	controlled	conditions.			The	aims	of	this	chapter	were	to	optimise	an	ex-vivo	ileal	mucosal	culture	model,	to	assay	 the	 role	 of	 FXR	 using	 this	 model	 and	 to	 measure	 the	 activity	 of	 FXR	 in	patients	with	ileal	CD.	This	chapter	has	demonstrated	that	FXR	expression	and	activity	is	reduced	in	the	ilea	of	patients	with	 ileal	CD.	 	These	patients	were	undergoing	 ileal	 resection	 for	complications	of	CD	and	all	patients	had	active	 inflammation	when	 the	histology	was	examined.		This	is	in	keeping	with	Nijmeijer	et	al.	who	demonstrated	that	FXR	activity	was	 suppressed	 in	 the	 ileal	mucosa	of	 patients	with	quiescent	CD	 colitis	(rather	than	ileitis)(Nijmeijer	et	al.,	2011).		
Pilot	data	demonstrates	that	the	technique	of	ex-vivo	organ	culture	of	ileal	mucosa	can	be	used	to	study	the	role	of	FXR	agonism	in	GI	inflammation	and	fibrosis.		This	technique	 was	 successfully	 optimised	 and	 is	 new	 to	 our	 laboratory	 group.		However,	the	pilot	data	presented	here	does	not	support	the	hypothesis	that	FXR	agonism	 can	 attenuate	 the	 response	 of	 primary	 tissue	 to	 stimulation	 with	inflammatory	 cytokine.	 	 Further	 study,	 using	 a	 larger	 sample	 and	 different	concentrations	or	different	 types	of	FXR	agonist	would	provide	a	more	complete	answer.	
The	 finding	 that	 FXR	 expression	 and	 activity	 is	 reduced	 in	 the	 ileum	of	 patients	with	CD	is	in	keeping	with	the	hypothesis	that	a	dysregulated	BA	signalling	cascade	may	predispose	 to	 inflammation	within	 the	 gut	mucosa.	 	 There	 is	 some	 cell-line	
		 178	
evidence	to	suggest	that	FXR	may	induce	its	own	expression(Modica	et	al.,	2010).			Therefore,	 a	 reduction	 in	 primary	BA	 signaling	within	 the	 terminal	 ileum	would	lead	to	a	reduction	in	FXR	mRNA	levels	in	addition	to	a	reduction	in	the	expression	of	its	downstream	targets.		However,	 FXR	 is	 antagonised	 by	 NF-κB,	 a	 common	 end	 point	 in	 multiple	 pro-inflammatory	 cellular	 pathways(Gadaleta	 et	 al.,	 2011a).	 	 In	 addition,	 in	 active	inflammation,	 the	 villous	 architecture	 is	 denuded	 and	 BA	 uptake	 reduced.		Therefore,	an	alternative	hypothesis	would	be	that	the	process	of	inflammation	in	CD	suppresses	FXR	expression	and	activity.		In	order	to	help	unravel	this	causality	conundrum,	the	ex-vivo	organ	culture	experiments	were	designed	to	test	whether	FXR	agonism	could	reverse	the	pro-inflammatory	effect	of	stimulation	with	TNFα.		Unfortunately,	the	sample	size	is	too	small	to	answer	this	question	and	so	data	are	presented	as	part	of	a	pilot	study.	By	 applying	 a	 variety	 of	 different	 methods	 from	 published	 descriptions,	 the	optimisation	of	an	ileal	mucosa	organ	culture	technique	is	an	important	outcome	from	this	 thesis.	 	This	 is	a	good	model	of	 the	 immune	function	of	 the	mucosa	ex-
vivo.		It	is	less	reductionist	than	an	epithelial	cell	line	model,	as	all	cell	types	within	the	 mucosa	 are	 included,	 yet	 allows	 for	 a	 similar	 degree	 of	 experimental	manipulation.	 	 It	 is,	 of	 course,	 still	 only	 an	 approximation	 of	 the	 in-vivo	mucosa,	being	starved	of	a	blood	supply	and	neuro-humoral	inputs.	The	evidence	that	the	organ	culture	model	is	viable	up	until	40	hours	includes	the	H&E	FFPE	sections	and	the	functional	data	that	are	in	keeping	with	what	would	be	expected.	 	 Ex-vivo	 ileal	 tissue	 from	 patients	 with	 active	 CD	 produces	more	 pro-inflammatory	 cytokine	 than	 control.	 	 In	 addition,	 there	 is	 evidence	 that	 the	cultured	 ileal	 tissue	 remains	 metabolically	 active	 as	 it	 produces	 more	inflammatory	 cytokine	 when	 stimulated	 with	 TNFα.	 	 Significantly	 for	 IL-12,	 the	
		 179	
main	 driver	 of	 Th1	 differentiation	 and	 IL-13.	 	 IL-13	 is	 a	 pro-inflammatory,	 pro-fibrotic	Th2	cytokine	that	has	been	shown	to	be	important	in	the	pathogenesis	of	fistulae	 in	 CD(Jovani	 et	 al.,	 2013).	 	 There	 is	 also	 a	 trend	 for	 all	 other	 effector	cytokines	assayed	to	increase	when	tissue	is	stimulated	with	TNFα.	Missing	from	the	optimisation	studies	is	a	measure	of	FXR	expression	following	a	period	 of	 ex-vivo	 culture.	 	 An	 assumption	 has	 been	 made	 that	 FXR	 is	 no	 more	affected	by	a	period	of	relative	ischaemia	than	other	cellular	receptors.	 	A	simple	immunohistochemical	stain	and/or	RT-PCR	experiment	for	FXR	expression	should	be	performed	to	confirm	that	FXR	is	still	expressed	in	the	enterocytes	at	40	hours.			There	 are	 limitations	 affecting	 these	 experiments.	 	 In	 general,	 the	 sample	 size	 is	too	 small	 to	 determine	 significance	 in	 several	 assays,	 although	 significance	 for	some	cytokine	concentrations	is	demonstrated	in	association	with	the	same	trend	for	 others.	 	 The	 small	 sample	 size	 meant	 that	 analyses	 of	 cytokine	 response	 to	TNFα	stimulation	could	not	be	subdivided	into	CD	versus	control.	 	 It	would	be	of	interest	 to	 determine	whether	CD	patients	 respond	 to	TNFα	 stimulation	with	 or	without	 FXR	 agonism	 in	 the	 same	 way	 as	 controls.	 	 The	 statistical	 problem	encountered	when	 the	 sample	 size	 is	 small	 is	 well	 demonstrated	 by	 the	 gender	ratio	 in	 the	 study	 group.	 	 Consecutive	 patients	 were	 entered	 into	 the	 study,	 no	patients	refused	consent	and	there	is	no	significant	gender	bias	in	the	presentation	of	CD	or	of	caecal	cancer.	 	The	preponderance	of	 females	within	 the	study	group	can,	therefore,	only	be	explained	as	a	statistical	quirk.			
Another	 criticism	 is	with	 the	choice	of	 cancer	patients	as	 ‘healthy’	 controls.	 	The	justification	 for	 the	 choice	 of	 control	 group	 is	 explained	 in	 the	methods	 section.		There	 is	 published	 evidence	 demonstrating	 that	 FXR	 expression	 is	 unaltered	 in	cancer	 patients	 in	 areas	 of	 tissue	 unaffected	 by	 the	 cancer	 itself(Modica	 et	 al.,	2008);	 for	example,	 in	a	patient	with	caecal	adenocarcinoma,	the	ileal	expression	
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of	FXR	is	the	same	as	a	healthy	volunteer.		However,	this	evidence	was	not	tested	specifically	in	our	control	cohort.		In	addition,	there	may	well	have	been	a	low	level	inflammatory	 stimulus	 associated	 with	 the	 cancer	 that	 could,	 theoretically,	confound	the	results.		Future	studies	should	mitigate	against	this	by	attempting	to	ethically	gain	ileal	tissue	from	patients	with	non-inflammatory	conditions.	
In	the	cytokine	assays,	 the	concentration	of	 IL-8	was	 found	to	be	at	or	above	the	level	of	detection	 for	 the	assay.	 	Given	 the	 findings	 in	 chapter	2	with	 regards	an	FXR	induced	reduction	of	IL-8	production,	it	would	be	interesting	to	repeat	these	experiments	 using	 a	 serial	 dilution	 of	 supernatant	 until	 any	 differences	 in	 IL-8	concentration	could	be	determined.		This	was	not	repeated	for	the	thesis	due	to	the	cost	of	further	V-PLEX	plates	and	also	time	constraints.	
In	 summary,	 FXR	 activity	 was	 decreased	 in	 the	 ileal	 of	 patients	 with	 CD	 as	compared	 with	 controls.	 	 An	 ex-vivo	 organ	 culture	 technique	 for	 small	 bowel	epithelium	 was	 optimised.	 	 Whilst,	 the	 treatment	 of	 ileal	 mucosa	 with	 1μM	 6-ECDCA	did	not	appear	to	ameliorate	the	cytokine	secretion	associated	with	TNFα	stimulation,	 these	 are	 pilot	 data	 and	 requires	 further	 study.	 	 It	 could	 be	 that	 an	alternative	dose	(e.g.	0.1μM)	of	6-ECDCA,	a	longer	incubation	time,	a	smaller	dose	of	TNFα	or	even	a	different	FXR	agonist	altogether	would	demonstrate	a	positive	effect.	
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Chapter	5	–	Conclusions	
5.1	 Introduction	The	aetiopathogenesis	of	Crohn’s	disease	(CD)	remains	 incompletely	understood.		There	 is	 a	need	 for	 safer,	more	efficacious	 treatments	 in	 the	management	of	CD.		Advancing	our	understanding	of	the	mechanisms	and	risk	factors	determining	the	development	of	CD	will	aid	in	the	development	of	these	potential,	new	therapeutic	compounds.	In	 this	 thesis,	 evidence	 has	 been	 presented	 regarding	 the	 role	 of	 farnesoid	 X	receptor	(FXR)	in	the	aetiopathology	of	ileal	CD.		Three	strata	of	experiments,	gut-derived	epithelial	cell	line	models,	an	animal	model	of	dietary	risk	and	human	ileal	mucosal	 tissue,	 have	 been	 used.	 	 This	 evidence	 supports	 the	 hypothesis	 that	disrupted	bile	acid	signalling,	via	FXR,	may	predispose	to	the	development	of	ileal	CD	by	impairing	gut	epithelial	homeostasis.	In	 this	 final	 chapter,	 the	 overarching	 hypothesis	 and	 supporting	 evidence	 is	explained.		A	discussion	of	the	thesis	limitations	and	plans	for	future	work	is	also	outlined.	
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5.2	 The	overarching	hypothesis	Figure	 5.1	 represents	 the	 overarching	 hypothesis	 with	 the	 healthy	 state	demonstrated	 in	 figure	5.1A	and	 the	pre-disposing,	at	 risk	state	demonstrated	 in	figure	5.1B.			Under	 normal	 conditions,	 a	 ‘healthy’	microbiota	 (healthy	 is,	 as	 yet,	 scientifically	undefined)	metabolises	 primary	 BA’s	 in	 the	 ileo-caecum.	 	 Central	 to	 the	 normal	human–microbiotal	co-metabolism	of	BA’s	 is	 the	BA	receptor,	FXR,	 found	 in	high	concentration	 within	 villous	 enterocytes	 of	 the	 ileum(Nicholson	 et	 al.,	 2005,	Inagaki	 et	 al.,	 2006).	 	 FXR	 has	 pleiotropic	 roles	 including	 the	 control	 of	 BA	metabolism	 in	 the	 liver,	 via	 FGF19,	 and	 the	 control	 of	 glucose	 and	 energy	metabolism(de	 Aguiar	 Vallim	 et	 al.,	 2013).	 	 Importantly,	 evidence	 has	 also	demonstrated	 that	 FXR	 is	 a	 modulator	 of	 intestinal	 innate	 immune	function(Vavassori	 et	 al.,	 2009).	 	 Appropriate	 activation	 of	 FXR	 by	 primary	 BAs	acts	to	maintain	epithelial	homoestasis.	In	 the	 pre-disposing	 state,	 a	 HF/HS	 western	 diet	 leads	 to	 alterations	 in	 the	microbiome	 (a	 dysbiosis)	 and	 alters	 BA	 production.	 	 This	 dysbiosis	 disrupts	 the	human–microbiotal	co-metabolism	of	BA’s,	leading	to	a	decrease	in	FXR	signalling	and	 activation	 of	 its	 downstream	 pathways.	 	 This	 leads	 to	 a	 disruption	 in	 BA	metabolism,	and,	more	importantly,	impairs	gut	immune	system	homeostasis.		The	epithelial	 barrier	 becomes	 more	 permeable	 to	 bacteria	 within	 the	 gut	 lumen.		Innate	 immune	 cells	 and	 epithelial	 cells	 are	more	 responsive	 to	 stressful	 stimuli	(such	 as	 LPS	 and	 muramyl	 dipeptide),	 with	 the	 secretion	 of	 pro-inflammatory	effector	cytokines	that	predispose	to	inflammation	and	induce	further	leakiness	of	the	epithelial	barrier.		In	patients	with	a	genetic	predisposition	to	the	development	of	 CD,	 these	 changes	may	 induce	 the	 chronic,	 relapsing	 inflammation	 that	 is	 the	hallmark	of	the	disease.	
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Figure	5.1;	Diagram	to	represent	potential	role	of	impaired	BA	signalling	in	pathogenesis	of	CD.		
‘A’	 is	 normal,	 healthy	 state.	 	 ‘B’	 is	 state	 imposed	 by	 diet-induced	 dysbiosis.	 	 Other	
environmental	risk	factors	include	exposure	to	antibiotics,	smoking	and	vitamin	D	deficiency.	
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5.2.1	 Data	to	support	the	hypothesis	The	 role	 of	 a	 dysbiosis	 and	 impaired	 BA	 signalling	 in	 the	 pathogenesis	 of	 CD	 is	supported	both	by	the	current	published	 literature	and	the	 findings	presented	 in	this	thesis.		Epidemiological	data	and	case-control	series	have	demonstrated	that	a	western	diet	is	a	risk	factor	in	the	development	of	CD(Gibson	and	Shepherd,	2005,	Hou	 et	 al.,	 2011).	 	 High	 fat/high	 sugar	 (HF/HS)	 feeding	 of	 mice	 will	 induce	 a	dysbiosis	similar	to	that	found	in	humans	with	IBD(Martinez-Medina	et	al.,	2014).		Duboc	et	al	demonstrated	an	impaired	BA	metabolism	in	association	with	a	typical	IBD	dysbiosis	in	patients	with	active	IBD(Duboc	et	al.,	2013).		In	a	mouse	model	of	NASH,	 an	 antibiotic-induced	 dysbiosis	 altered	 ileal	 BA	 composition	 with	subsequent	inhibition	of	intestinal	FXR	signalling(Jiang	et	al.,	2015).		BA	signalling	via	 FXR	 is	 central	 to	 the	 communication	 between	 the	 mammalian	 host	 and	 its	microbiota,	 facilitating	 the	 human-microbial	 co-metabolism	 of	 BA’s(Nicholson	 et	al.,	2005,	Martin	et	al.,	2007).		In	this	thesis,	I	have	demonstrated,	in	a	diet-induced	obesity	animal	model,	 that	HF/HS	feeding	could	 induce	 ileal	cytokine	expression.		This	 increase	 in	 cytokine	 expression	 may	 be	 reduced	 by	 activation	 of	 FXR,	suggesting	 that	 the	 diet-induced	 inflammatory	 stimulus	 may	 be	 mediated	 by	impaired	FXR	signalling.		Whilst	these	data	do	not	reach	statistical	significance,	the	trend	suggesting	that	supplementing	feed	with	an	FXR	agonist	can	ameliorate	the	diet-induced	 inflammatory	 cytokine	 expression	 is	 in	 keeping	 with	 the	 overall	hypothesis.	Several	studies	have	demonstrated	the	immuno-modulatory	function	of	FXR.		In	a	bile	duct	ligation	animal	model,	the	translocation	of	bacteria	to	mesenteric	lymph	nodes	is	reduced	by	treatment	with	an	FXR	agonist(Inagaki	et	al.,	2006).		In	an	FXR	knockout	mouse	model,	there	is	an	increase	in	lamina	propria	inflammatory	cells	and	 an	 increase	 in	 inflammatory	 cytokine	 expression(Vavassori	 et	 al.,	 2009).	 	 In	
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animal	studies,	an	FXR	agonist	was	able	to	attenuate	the	effects	of	a	DSS	and	TNBS	induced	 colitis(Gadaleta	 et	 al.,	 2011b).	 	 Several	 aspects	 of	 the	 data	 presented	 in	this	thesis	supports	the	current	published	evidence.		I	have	demonstrated	that	FXR	agonism	 reduces	 the	 potent	 neutrophil	 chemo-attractant	 IL-8	 response	 of	epithelial	 cells	 when	 stressed	 with	 TNFα.	 	 A	 variety	 of	 published	 evidence	 has	demonstrated	that	immune	cell	types	exposed	to	an	FXR	agonist	were	refractory	to	stimulation	with	LPS(Vavassori	et	al.,	2009,	Gadaleta	et	al.,	2011b,	Haselow	et	al.,	2013).	 	 The	 findings	 regarding	 an	 attenuated	 epithelial	 IL-8	 response	 would	appear	 to	 be	 another	 mechanism	 by	 which	 FXR	 maintains	 innate	 immune	homeostasis	in	the	ileum.			Disruption	to	the	epithelial	barrier	is	central	to	the	pathogenesis	of	CD(McGuckin	et	 al.,	 2009).	 	 It	 has	 previously	 been	 shown	 that	 FXR	 acts	 to	 maintaining	 the	epithelial	 barrier,	 although	 the	molecular	mechanism	 is	 unknown.	 	 Here,	 I	 have	begun	 to	 unravel	 this	 question	 by	 demonstrating	 that	 FXR	 agonism	 maintains	epithelial	 cell	 morphology	 in	 a	 cell	 line	 model	 of	 cytokine-induced	 epithelial	barrier	disruption.		In	experiments	with	IL-6,	it	would	appear	that	maintenance	of	epithelial	morphology	is	via	a	mechanism	involving,	at	least	in	part,	the	inhibition	of	MLCK	expression.	
Finally,	I	have	demonstrated,	for	the	first	time	in	patients	with	ileal	CD,	that	there	is	a	decrease	in	the	expression	and	activity	of	FXR	in	the	ileum.		The	same	pattern	is	demonstrated	 in	mice	 fed	a	HF/HS	diet,	with	a	decrease	 in	 the	activity	of	FXR	and	an	increase	in	CD	associated	inflammatory	cytokine	expression.		
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5.2.2	 Data	against	the	hypothesis	In	 the	 only	 published	 data	 regarding	 BA	 metabolism	 in	 patients	 with	 IBD,	 an	impairment	 in	 the	 transformation	 of	 primary	 BAs	 to	 secondary	 BAs	 was	demonstrated(Duboc	et	al.,	2013).		This	might	suggest	that	it	is	a	lack	of	secondary	BAs	that	predisposes	or	drives	an	inflammatory	process.		Secondary	BAs	are	only	weak	 FXR	 agonists	 and	 therefore,	 this	 finding	 would	 not	 fit	 the	 overarching	hypothesis.		However,	the	study	by	Duboc	did	not	measure	BA	species	in	the	ileo-caecum,	but	instead	measured	faecal	BAs.		Faecal	BAs	may	not	be	representative	of	BA	 dysmetabolic	 changes	 occurring	 in	 the	 ileo-caecum.	 	 TGR5	 is	 antagonised	 by	these	 secondary	 BA’s	 and	 therefore	 a	 study	 of	 the	 role	 of	 this	 receptor	 in	 gut	inflammation	would	be	of	interest.			The	 finding	 that	 FXR	 knockout	mice	 do	 not	 develop	 IBD(Vavassori	 et	 al.,	 2009)	would	 suggest	 that	 impaired	 BA	 signalling	 alone	 is	 not	 responsible	 for	 the	development	 of	 chronic	 inflammation.	 	 Other	 predisposing	 factors,	 genetic,	immune	 or	 environmental	 are	 clearly	 required	 in	 addition.	 	 As	 suggested	 in	chapter	 1	 (sections	 1.2.6	 to	 1.2.8),	 there	 is	 evidence	 that	 the	microenvironment	may	impact	on	intestinal	homeostasis	in	a	number	of	different	ways,	for	example	in	a	reduction	in	butyrate	producing	bacteria.		Several	studies	have	demonstrated	a	 CD	 associated	 dysbiosis	 in	 which	 several	 butyrate	 producing	 species	 (e.g.	
faecalibacterium	prausnitzii)	are	reduced(Joossens	et	al.,	2011).	 	 In	some	studies,	but	 not	 others,	 butyrate	 has	 been	 shown	 to	 have	 anti-inflammatory	properties(Marteau,	2013).	 	These	alternative	mechanisms,	by	which	a	dysbiosis	may	 induce	 inflammation,	 are	 not	 explained	 by	 disrupted	 FXR	 signalling.	 	 It	 is	possible	that	more	than	one	mechanism	may	be	important.	
The	 data	 presented	 from	 the	 ex-vivo	 organ	 culture	 model	 does	 not	 support	 the	overarching	 hypothesis.	 	 No	 attenuation	 of	 mucosal	 inflammatory	 cytokine	
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production	could	be	demonstrated	when	tissue	was	treated	with	an	FXR	agonist.		However,	 the	 data	 is	 limited	 by	 a	 small	 sample	 size	 and	 use	 of	 heterogeneous	mucosal	samples.		Further	work	is	needed	in	this	area.	
Also,	 in	a	cell	 line	model	of	 the	epithelial	barrier,	exposure	to	an	FXR	agonist	did	not	maintain	epithelial	electrical	resistance	when	the	epithelial	layer	was	stressed	with	 cytokine.	 	 Presumably,	 whilst	 the	 FXR	 agonist	 could	 maintain	 cell	morphology,	 there	were	 still	 cytokine-induced	 alterations	within	 the	 TJ	 complex	that	allow	the	paracellular	flow	of	charged	ions.	 	 If	we	accept	the	hypothesis	that	FXR	 maintains	 epithelial	 homeostasis	 within	 the	 gut,	 it	 is	 presumably	 not	 by	 a	mechanism	that	maintains	seal-forming	claudin	expression	at	the	TJ.	
5.3	 Limitations	of	the	thesis	In	 several	 experiments,	 in	 particular	 the	 animal	 data,	 only	 trends	 have	 been	demonstrated,	with	any	findings	failing	to	reach	significance.		This	may	be	because	the	 trends	 are	 fictitious,	 with	 no	 real	 difference	 between	 control	 and	 the	intervention.	 	 Sample	 sizes	 were	 small	 and	 often	 the	 underlying	 biological	variability	 large.	 	 Therefore,	 a	 larger	 sample	 size	 is	 required	 in	 order	 to	demonstrate	 whether	 there	 is	 any	 real	 difference	 between	 control	 and	intervention	 groups.	 	 Sample	 size	was	 limited	 in	 chapter	 4	 by	 the	 time	 taken	 to	enroll	enough	control	and	CD	patients	 in	the	study.	 	 In	chapter	3,	a	major	 failure	was	in	the	storage	of	tissue	after	en-bloc	resection	of	the	GI	tract.	 	Unfortunately,	due	 to	 a	 variety	 of	 circumstances,	 the	 GI	 tract	was	 not	 snap	 frozen,	 but	 instead	slowly	 frozen	 to	 -80°C.	 	 This	 impaired	 RNA	 quality	 and	 despite	 the	 use	 of	 the	frozen	tissue	transition	solution,	good	quality	RNA	could	only	be	extracted	from	a	subset	of	mice	in	the	study.	
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Much	of	the	data	in	chapters	3	and	4	makes	use	of	the	technique	of	RT-PCR.		Whilst	this	is	a	powerful	laboratory	technique,	able	to	detect	very	small	changes	in	mRNA	levels,	I	recognise	that	it	has	its	limitations.		Only	a	single	reference	gene	was	used	and	perhaps,	ideally,	a	second	reference	gene	to	control	for	changes	in	expression	between	 control	 groups	 and	 intervention	 should	have	been	 included.	 	 There	has	been	some	criticism	of	 the	use	of	both	GAPDH	and	β-actin	as	 reference	genes	as	their	 expression	 is	 not	 as	 uniformly	 stable	 as	 previously	 thought(de	 Jonge	 et	 al.,	2007).	 	 However,	 no	 such	 criticism	 for	 the	 use	 of	 these	 genes	 in	 studies	investigating	 GI	 tissue	 	 In	 addition,	 RT-PCR	 will	 only	 provide	 an	 assessment	 of	changes	 in	 relative	 gene	 expression.	 	 This	 is	 not,	 therefore,	 a	 direct	measure	 of	inflammation.		It	would	have	been	more	methodologically	robust	if	a	measurement	of	 tissue	 inflammation,	 in	 both	 the	 mouse	 and	 primary	 tissue	 experiments,	 by	histological	assessment	for	example,	had	been	used.	
Much	was	accomplished	in	the	2	years	of	research	that	contributed	to	this	thesis,	including	the	optimisation	of	an	ex-vivo	ileal	mucosa	culture	model	that	was	new	to	our	group.		However,	there	are	some	time-limited,	omissions	in	the	data.		It	would	have	 been	preferable	 to	 study	 other	 cytokines	 in	 addition	 to	 IL-6	 in	 the	RT-PCR	experiments	regarding	MLCK	expression.		Another	omission	is	in	the	study	of	IL-8	secretion	in	the	ex-vivo	organ	culture	experiments.		The	primary	mucosal	samples	produced	huge	concentrations	of	 IL-8,	above	 the	 level	of	assay	detection,	 in	both	control	and	intervention	groups.		Given	the	finding	that	FXR	agonists	could	inhibit	IL-8	secretion	 in	HT29	cells,	 an	analysis	of	 IL-8	production	 in	 the	primary	 tissue	would	 have	 been	 very	 interesting.	 	 Unfortunately,	 cost	 limited	 experiments	 to	 a	single	V-PLEX	plate	and	so	I	did	not	get	chance	to	repeat	the	assay	with	a	diluted	supernatant	 in	 order	 to	 ascertain	 whether	 there	 was	 any	 difference	 in	 IL-8	concentration	between	control	and	intervention	groups.	
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Finally,	an	analysis	of	the	BA	species	and	the	dysbiosis	induced	by	HF/HS	feeding	was	 not	 performed,	 due	 a	 lack	 of	 access	 to	 high	 performance	 liquid	chromatography-mass	spectrometry	and	16s	pyrosequencing.	 	These	are	areas	to	be	 explored	 in	 the	 future	 and	 research	 groups	 from	King’s	College,	 and	 Imperial	College,	London	have	approached	the	group	with	a	view	to	collaborating	on	such	studies.	
5.4	 Questions	arising	from	the	data	and	future	work	Other	 than	 the	 areas	 mentioned	 above,	 there	 are	 a	 variety	 of	 further	 areas	 for	research	suggested	by	this	thesis.	In	 chapter	2,	 an	apparent	 synergistic	 relationship	 is	demonstrated	between	high	doses	 of	 FXR	 agonist	 (10μM	 6-ECDCA)	 and	 TNFα	 stimulation	 with	 regards	 IL-8	production.		If	FXR	agonists	are	to	be	translated	into	use	as	therapeutic	compounds	in	 IBD,	 it	 would	 be	 important	 to	 investigate	 this	 finding	 further,	 as	 supra-therapeutic	doses	of	the	compound	may	in	fact	be	pro-inflammatory.	
Other	 environmental	 co-factors,	 in	 addition	 to	 impaired	 FXR	 signalling,	 may	 be	important	 in	 the	development	of	 IBD.	 	Much	 interest	has	 focused	recently	on	the	role	 of	 vitamin	 D	 in	 the	 development	 of	 chronic	 inflammatory	 immune	conditions(Mouli	 and	 Ananthakrishnan,	 2014,	 S.	 Wu	 et	 al.,	 2014).	 	 Given	 that	vitamin	D	receptor	(VDR)	is	a	nuclear	receptor,	similar	in	structure	to	FXR,	it	may	be	that	a	deficiency	in	both	pathways	may	produce	a	synergistic	pro-inflammatory	phenotype.	
As	discussed	in	chapter	1	(section	1.5.4),	a	wealth	of	recent	data	has	demonstrated	that	defective	autophagy	is	an	important	process	in	the	development	of	CD(Fritz	et	al.,	2011).		FXR	interacts	with	NOD2,	via	p62/Sequestosome	1,	which	both	targets	polyubiquitinated	 proteins	 to	 the	 autophagosome	 and	 also	 acts	 to	 maintain	 the	
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half-life	of	NOD2(Williams	et	al.,	2012,	Park	et	al.,	2013).		A	study	of	the	role	of	FXR	in	promoting	autophagy	would	also	be	of	scientific	and	clinical	interest.	
An	investigation	into	the	role	of	FXR	signalling	as	an	anti-fibrotic	pathway	could	be	of	great	clinical	significance.		Epithelial-mesenchymal	transition	(EMT)	describes	a	process	 during	 which	 fully	 differentiated	 epithelial	 cells	 undergo	 a	 phenotypic	change	 to	 develop	 mesenchymal	 cell	 (e.g.	 fibroblast)	 features(Radisky,	 2005).		EMT	 is	 both	 pro-inflammatory	 and	 pro-fibrotic	 and	 can	 disrupt	 the	 epithelial	barrier	and	so	is	of	great	interest	in	CD.		An	EMT-like	process	has	been	described	in	the	formation	of	CD	associated	fisulae(Bataille	et	al.,	2008)	and	an	EMT	induced	fibrosis	has	been	described	in	a	mouse	model	of	CD(Flier	et	al.,	2010).	 	Clinically,	fibrosis	and	fistula	are	important,	difficult	to	manage	sequelae	of	CD.		Certain	EMT-like	 epithelial	 cell	 markers,	 such	 as	 αSMA	 and	 TIMP-1,	 were	 found	 to	 be	upregulated	 in	 the	 FXR	 knockout	 model	 described	 by	 Vavasorri	 and	colleagues(Vavassori	et	al.,	2009).		Given	these	findings,	a	study	of	the	role	of	FXR	as	 an	 anti-fibrotic,	 EMT	 inhibiting	 molecule	 would	 be	 both	 interesting	 and	potentially	clinically	useful.	Finally,	an	important	question	raised	by	this	thesis	is	with	regards	the	role	of	ileo-caecal	resection	in	the	management	of	CD.		Approximately	80%	of	patients	with	CD	will	end	up	with	a	surgical	resection	to	treat	either	uncontrolled	inflammation	or	stricturing/penetrating	 disease(Rutgeerts,	 2003).	 	 The	 most	 common	 site	 for	disease	activity	is	within	the	ileo-caecum	and	therefore	an	ileo-caecal	resection	is	the	 most	 commonly	 performed	 operation.	 	 Post-operative	 disease	 recurrence	 is	extremely	common,	usually	at	the	site	of	the	surgical	anastomosis.		Recurrence	can	be	 rapid	 and	 aggressive	 with	 30%	 of	 patients	 demonstrating	 evidence	 of	inflammation	 within	 the	 anastomosis	 at	 3	 months	 post	 surgery	 and	 80%	 of	patients	 by	 1	 year(Baert	 et	 al.,	 2003,	 Van	 Assche	 and	 Rutgeerts,	 2004).	 	 More	
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importantly,	15-45%	of	patients	will	require	further	surgery	by	3	years	and	up	to	65%	 will	 require	 further	 surgery	 at	 10	 years(Rutgeerts,	 2003).	 	 To	 date,	 no	medical	intervention	has	consistently	been	shown	to	reduce	the	need	for	surgery.	Post	 ileo-caecal	 resection,	 the	 expression	 of	 FXR	 is	 upregulated	 in	 the	colon(Dekaney	et	al.,	2008).		For	this	reason,	it	has	been	argued	that	removing	the	ileo-caecum	 may	 provide	 an	 immuno-protective	 effect	 in	 the	 colon(Wildenberg	and	van	den	Brink,	2011).		However,	the	extent	to	which	FXR	is	upregulated	in	the	colon	 is	 unknown	 and,	 in	 addition,	 FXR-activating	 primary	 BAs	 are	 rapidly	metabolised	to	secondary	BAs	in	the	colon.		Therefore,	the	extent	to	which	FXR	is	active	within	the	colon	post	resection	is	unclear.	
Given	 that	 FXR	 in	 the	 ileum	 is	 immuno-modulatory,	 it	may	well	 be	 that	 surgical	resection	 of	 the	 ileo-caecum	 will	 actually	 predispose	 patients	 with	 CD	 to	 the	development	 of	 further	 disease.	 	 This	 would	 fit	 with	 the	 observation	 that	 post-operative	recurrence	is	common	and	can	occur	rapidly.		FXR	agonist	treatment	of	post-operative	patients	in	order	to	prevent	recurrence	is	an	intriguing	therapeutic	possibility	and	warrants	further	investigation.	
5.5	 From	bench	to	bedside	Given	 both	 the	 current	 published	 data	 and	 the	 evidence	 demonstrated	 in	 this	thesis,	is	it	reasonable	to	propose	FXR	agonists	as	a	treatment	option	in	active	CD?			
FXR	agonists,	in	the	form	of	6-ECDCA,	have	entered	phase	II	and	phase	III	clinical	trials	 in	 cholestatic	 liver	 diseases,	 like	 PBC,	 and	 in	 NASH(Nevens	 et	 al.,	 2014,	Neuschwander-Tetri	et	al.,	2015).	 	Adverse	outcome	reporting	 in	 these	 trials	has	been	 favourable	 other	 than	 the	 commonly	 reported	 problem	 of	 pruritus.	 	 The	development	 of	 pruritus	would	 appear	 to	 be	 a	 dose	 related	 effect	with	 between	23%-80%	of	patients	affected	with	doses	ranging	from	10	to	50mg	of	6-ECDCA.		A	
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small,	phase	I	study	has	been	conducted	in	patients	with	quiescent	Crohn’s	colitis	(9	 patients	 and	 12	 controls),	 again	 with	 6-ECDCA.	 	 This	 trial	 was	 able	 to	demonstrate	 that	pharmacological	 activation	of	 the	FXR	 receptor	was	 feasible	 in	patients	with	CD(van	Schaik	et	al.,	2012).	
There	 is,	 however,	 still	 scientific	 information	 that	 it	 would	 be	 useful	 to	 answer,	such	as	the	role	of	high	dose	FXR	agonists	on	the	stimulation	of	IL-8	from	epithelial	cells.	 	 Another	 potential	 safety	 concern	 is	 the	 potential	 for	 FXR	 agonists	 to	predispose	 to	 the	 development	 of	 hepatocellular	 carcinoma	 (HCC),	 induced	 by	FGF19	overexpression.		FGF19	is	a	hormonal	signal,	stimulated	in	the	intestine	by	FXR,	 which	 completes	 a	 negative	 feedback	 loop	 by	 reducing	 gallbladder	contraction	and	inhibiting	BA	neosynthesis	in	the	liver.		Overexpression	of	FGF19	has	been	 associated	with	 the	development	 of	HCC	 in	both	 animal	models	 and	 in	humans(Schaap	et	al.,	2015).	 	It	is	feasible	that	over-promotion	of	FXR	could	lead	to	high	levels	of	FGF19	which	in	turn	is	carcinogenic.	
Aside	from	these	safety	concerns,	is	the	question	as	to	whether	FXR	agonists	would	be	effective	in	reducing	inflammation	in	patients	with	CD?		The	evidence	presented	here	suggests	that	FXR	maintains	epithelial	homeostasis.		It	is	perhaps	more	likely,	therefore,	 that	 the	 clinical	 utility	 of	 an	FXR	agonist	may	be	 to	 reduce	 the	 risk	 of	relapse	 for	 patients	 who	 are	 already	 in	 disease	 remission.	 	 Even	 further	 in	 the	future	 is	 the	 potential	 for	 FXR	 agonists	 to	 be	 used	 to	 reduce	 the	 risk	 of	 disease	development,	 perhaps	 in	 people	 identified	 via	 genetic	 testing	 or	 with	 multiple	environmental	risk	factors,	as	being	at	high	risk.	
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Appendix 1: Proforma for submitting a request to 
collect/use samples in the Hepatopancreatobiliary 
(HPB) tissue bank by research groups in Newcastle 
University  
 
Request to perform research in Newcastle University 
using samples collected as part of the HPB tissue bank 
 
Written by:  	 Dr	Helen	Reeves	(HLR)	NICR	Newcastle	University		 Version 1  	 March		2010		 HLR	 Version	2	 4TH	July	2010		 	 	 	
 
 
Background  
Approval has been obtained from Newcastle and North Tyneside Research Ethics 
Committee to perform research on samples collected as part of the HPB 
(Hepatopancreatobiliary)  groups based in Newcastle University without the need to obtain 
specific consent for individual projects. However, it is a condition of this approval that 
details of the projects included are submitted to the LREC as part of an annual report, when 
they will be reviewed to ensure that they fall within the remit described in the 
accompanying protocol (Biological studies of samples).  
 
In order to do this please complete the sections below and send this form by e-mail to 
Professor Alastair Burt ( A.D.Burt@ncl.ac.uk). Applications will be considered by 
Professor Burt and designated individuals forming part of an approval committee.  The 
committee will include informed individuals from Newcastle University and the Newcastle 
Hospitals NHS Foundation Trust, who are able to act as independent assessors. The purpose 
of the review is to ensure that the work proposed does not duplicate ongoing studies in 
Newcastle, is adequately funded and has a reasonable prospect of producing meaningful 
results. Every effort will made to decide on the suitability of projects within 4-6 weeks. If 
access to samples is denied the reasons for this will be explained in writing.  
 
 
 
Please note that results of laboratory investigations covered by this protocol specifically 
exclude any which would be used to influence the treatment of individual patients.
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Contact details 
Name of Principal Investigator  Dr J C Mansfield 
e-mail  john.mansfield@nuth.nhs.uk	
Telephone  1912336161 
Address  
 
 
 
Ward 48 office, level 6 Leazes Wing 
Dept of Gastroenterology 
RVI 
 
 
 
Project details 
Title of project The role of bile acids in the aetiopathology of 
inflammatory bowel disease 
Source and amount of funding Department of gastroenterology, NUTH, 
£25,000 
Place where research will be conducted Newcastle University and NUTH 
Sponsor (eg NHS Trust) NUTH 
Details of peer review (eg through funding 
peer review or local research committee). 
 
 
 
This is an MD project that has been peer 
reviewed for approval by Prof J Kirby, Prof 
Julia Newton (Dean of Clinical Medicine) and 
Dr C Ward 
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Abstract (no more than 500 words). Please attach copy of full application and /or research 
protocol if available  
 
Inflammatory Bowel Disease (IBD) 
The inflammatory bowel diseases, Crohn’s disease and ulcerative colitis, are chronic, relapsing 
inflammatory conditions effecting the gastrointestinal (GI) tract.  The aetiopathology of IBD is 
incompletely understood but is thought to be due, in part, to epithelial barrier dysfunction.  There 
is a clinical need for safer, more efficacious treatments in IBD.  
 
The role of BAs in inflammation 
Primary BA’s are detergents to allow the absorption of dietary fats.  In addition, BA’s also act as 
signaling molecules regulating their own metabolism, glucose metabolism, lipid metabolism and 
immune function.  FXR acts as a transcription factor for a variety of anti-inflammatory genes.  In 
FXR KO mice, epithelial barrier function is impaired.  Also, treatment with an FXR agonist 
protects against colitis in a mouse model.  FXR agonists also inhibit proinflammatory cytokine 
production by epithelial cells in-vitro.   
 
This study aims to investigate the role BA’s play in maintaining epithelial barrier function via the 
nuclear receptor FXR. 
 
Planned Methodology 
To define the importance of primary bile acids as mediators of inflammation in IBD, quiescent 
disease and in healthy controls, ex vivo tissue will be collected during ileo-colonoscopy/flexible 
sigmoidoscopy, or operative intervention performed as part of planned clinical care.  This will 
include ileo-colonic biopsies from patients with IBD and controls (those attending endoscopy and 
no abnormality found during the test).  Resection specimens will be obtained from patients 
undergoing operative intervention for IBD, and control patients undergoing resection for 
diverticular disease or colorectal carcinoma (normal tissue will be taken from margins of 
specimen in the case of carcinoma).   
Tissue samples will be subjected to digestion and real time quantitative PCR will performed.  
Some tissue will be formalin fixed and processed for immunohistochemistry. 
 	
Is the proposed project a pilot study or a more substantive project?  
Substantive project 	
Have power calculations been performed, and if so how? 
This is an observational study and so a power calculation is not possible.  It is envisaged that 20 
to 30 patient samples will be collected. 
 
 
Are the results likely to contribute to a publication in the near future? If so, please give brief 
details.  
If significant findings, aim to submit for publication within the next two years. 	
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Sample	details	
Number and type 
required (eg bone 
marrow, blood, CSF, 
other)  	
Biopsy samples 
from colon and 
ileum (initially 
20 patients) 
Ileo-colonic 
resection 
specimens 
Paraffin 
embedded tissue 
slides 
	
Minimum size of 
sample (eg cell number 
or quantity of RNA, 
DNA or protein)  	
A minimum of 2 
biopsies from 
each patient 
Ideally 10cm by 
5cm depending 
on size of 
resection 
specimen and 
NHS 
requirements 
	 	
Please justify, 
including details of 
power equations where 
performed  	
	 	 	 	
 
 
To be completed by Biobank 
manager/committee Sample availability - How 
many samples are available of the type requested? 
Are you aware of other projects which are likely to 
benefit form the use of samples of this nature?  	
	
Date application received  	
Date sent for approval  	
Date of approval decision  	
Outcome  	
 Electronic	 versions	 of	 this	 form	 may	 be	 obtained	 from	 Professor	 Alastair	 Burt	(A.D.Burt@ncl.ac.uk)	 or	 Research	 Co-ordinator	 Diane	 Walia;	 Research Study Co-
ordinator, Hepatology, Freeman Hospital, Tel: 0191 21 31568. E-mail: Diane.Walia@nuth.nhs.uk. 	 	
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PATIENT INFORMATION SHEET                                                           
The hepatopancreatobiliary (HPB) and  
gastroenterology (GI) tissue bank. 
The collection and storage of diagnostic samples and those taken during therapy, to 
support  research into Hepatopancreatobiliary (HPB), gastrointestinal (GI) or 
retroperitoneal disease.  
Introduction   
Although progress has been made in understanding the development of chronic diseases and cancer in the last 20 
years, we still have a lot to learn if we are to detect diseases sooner and improve the treatments available for 
affected people in the future. Many of our research projects use blood, body fluids, tissues or cells to help us 
understand what is wrong.  In order to help with our research, in Newcastle we are co-ordinating a local collection of 
stored blood, fluids and tissues, taken at the time of routine tests or planned operations, but which are extra to 
those needed for diagnosis.  In particular, we undertake or collaborate with a variety of laboratory based research 
projects into chronic diseases and cancers of the hepatopancreatobiliary (HPB) and gastroinstestinal (GI) systems.  
The HPB system includes the liver, pancreas, gall bladder and biliary tree, while the GI system includes the 
esophagus, stomache, small and large bowel.  We also study those tissues in the retroperitoneal space, behind the 
liver and abdominal organs. To enable us to carry out this research, we would like to collect samples from people 
who are undergoing investigation or treatment of a part of these systems. 
We therefore invite you to give permission for a small amount of the samples which we take from you as part of 
your normal investigation or treatment to be kept for a variety of research projects to help us understand your 
disease.  The samples we keep come from material left over after we have completed our routine hospital tests or 
treatment. In some cases we may ask if we can take a small amount of extra material at the same time as routine 
samples (eg. Blood), but this will not involve an extra procedure. 
All of the research that we do has been approved by our tissue bank committee and will be regularly monitored by 
them, with annual reporting to the local research ethics committee who has approved the collection.  Occasionally 
we also send samples to other researchers in the UK or abroad.  We only do this if the research they are undertaking 
has also been approved by their local research ethics committee. Research does sometimes involve the testing of 
your DNA, but your identity will not be revealed to the research team.  Our research is not conducted for 
moneymaking purposes, but it may be that some results, once published, will be of value to commercial companies, 
eg. in the development of new treatments. 
This work will not directly benefit you but may help patients with similar diseases to you in the future.  You do not 
have to give permission for your samples to be stored.  If you decline, it will not affect your medical care in any way 
at all. 
What will happen if I take part? 
If you give your consent for samples to be stored and used for research purposes, these will be taken from material 
left over after routine elective tests or treatments have been performed.  An extra sample eg. blood would only be 
taken at a time when other samples were being taken for clinical reasons. Samples would be taken at various stages, 
including at your first visit, but may also be taken at any follow-up or treatment visits. The amounts needed are very 
small (2-4 teaspoonfuls of blood or aspirated fluid,) and the taking of them should not affect your health in anyway.  
If you are having a biopsy or an operation to remove some tissues, we may save a very small part of that which is 
surplus to diagnostic needs. Again, this would be a very small amount –  the size of a 0.5-1cm piece of spaghetti  for 
a biopsy, or small pea-sized samples if you are having tissues surgically removed. 
What will happen to my specimens? 
The samples will be stored in the HPB tissue bank or at another research laboratory approved for a similar purpose.  
These samples may be stored for many years before they are used. They may be used to extract DNA (the genetic 
The Medical School, 
Framlington Place, 
Newcastle-upon-Tyne, 
NE2 4HH, U.K. 
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material inside a cell) which will also be stored. The samples are stored and labelled with a code number, which 
means that the only link between the sample code and any medical information is held securely by the doctor who is 
the principal investigator for the project co-ordinating your samples collection.  This may be at Newcastle University 
in a secure location, or in the Newcastle Hospitals NHS Foundation Trust, depending on where the principal 
investigator responsible for collecting your tissues is based. Coded samples may be released from the tissue bank for 
approved research projects in other research laboratories, but only if the laboratory has approval for their research 
from their local ethical committee.  
Researchers may be given access to some information about your health and diagnosis, but they will not have any 
personal information that will enable them to identify you.  Similarly, any results from research projects will not be 
traceable back to you by the researcher. All coded information on you will be kept in accordance with current 
national regulations (the Data Protection Act and Caldicott guidelines). 
How do I know that my samples will only be used for ethically approved medical research? 
Approval has been given by the local research ethics committee to perform research in Newcastle-upon-Tyne on 
samples in the HPB tissue bank. The nature of this research will be regularly monitored by the tissue bank committee.  
Samples will only be released to other research centres  if they can confirm that their research is ethically approved 
in a similar fashion.  
Will I be told of the results of research tests on my samples? 
No. Nor will the results be given to any hospital doctor or practitioner. The research tests will not form any part of 
your medical treatment or record.  The overall results of the research projects will be published in the scientific 
literature.  In the future, if the research showed that there was a test which might be useful, it may – after 
independent review and validation – become part of standardised  NHS care for all people with similar conditions. 
What will happen to the information gathered about me? 
No personal identifiable information about you will be given to the scientists doing the research tests and any 
research carried out on your tissues that is linked to your condition will be done in a strictly anonymous way.  
Information from your medical notes relating to your diagnosis, treatment or response to treatment will be kept 
stored in a strictly confidential manner according to the Data Protection Act within the NHS Trust responsible for 
your care.   
What are the possible risks of taking part? 
There are usually no extra risks involved in collecting samples stored for research.  The numbers of biopsies required 
will be kept to a minimum and additional needle punctures for research blood tests will be avoided. Tissues taken at 
the time of an operation are from the part removed, after the surgery is complete. 
Are there any possible benefits? 
The information learned from studies using specimens obtained from you may help to improve treatment for future 
patients with similar conditions and possibly lead to the prevention of these diseases developing. 
Do I have to take part? 
No. Your participation is entirely voluntary. Whether or not you decide to allow your tissues to be stored for 
research will not affect the care you are given. If you give consent and then change your mind, any of your samples 
remaining will be disposed of, usually by incineration. 
What should I do if I have any concerns about taking part? 
If you have any problems, concerns or questions about this study, please feel free to speak to the medical and 
nursing staff who are responsible for your care.  Alternatively, you may contact the Designated Individual 
responsible for all Human Tissues research performed in Newcastle-upon-Tyne, Professor A G Hall on (0191) 246 
4411, who will put you in touch with appropriate clinical investigator to address your query. 
NO CELLS, TISSUES OR BODILY MATERIAL WILL BE TAKEN OR STORED FOR RESEARCH WITHOUT YOUR 
AGREEMENT  
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PATIENT CONSENT FORM  
The hepatopancreatobiliary (HPB) and 
 gastroenterology (GI) tissue bank.  
 
The collection and storage of diagnostic samples and those taken during therapy, to 
support research into hepatopancreatobiliary (HPB), gastrointestinal (GI) and 
retroperitoneal disease.  
You  are attending your NHS Trust for investigation and treatment.  During this process, both now and in the future, 
you may give blood samples or undergo and additional procedure, depending on your condition (eg. tissue aspiration 
or biopsy or a surgical procedure). These procedures are performed both to help diagnose, but also to monitor, your 
condition. Sometimes tissues are removed at a time of surgery, as a treatment. 
 
Once your sample has been taken for diagnostic, monitoring or treatment purposes, there may be some sample 
remaining.  This remaining sample is very valuable for research.  We therefore ask for your consent to use this 
remaining sample for research, by making a gift of it to our research tissue bank. In some cases we may also ask if we 
can obtain a small amount of extra material specifically for research purposes. These samples will only ever be taken 
at the same time as any routine procedures and will not involve any undue extra risk. A leaflet is available containing 
more information about the use of these samples and describing our policy for the safe keeping of tissue gifted in 
this way.  
 
Your diagnosis and treatment will not be adversely affected in any way by giving consent. Any research studies in 
which your samples are used will have been approved by our local research ethics committee or an equivalent 
organisation. This is to ensure that the research is justified and meets current ethical standards. Research will be 
conducted anonymously, which means that your samples will be identified only by a code. Your personal details will 
not be accessible to researchers. Your confidentiality will be respected at all times.  
 
In addition to collecting your surplus sample and clinical information, we may ask you to complete a questionnaire if 
it is relevant to your condition.  You may be asked to complete a questionnaire at the hospital at the time of your 
scheduled visit, or to take it home with you, returning it at your next visit.  Data collected for research purposes, 
including clinical information, that generated by your samples, as well as answers to questionnaires, will always 
remain anonymous, with all of you data being identifiable only by a code. 
 
We may use your samples and data in association with commercial research partners but human tissues are never 
sold (this is illegal). Our partnerships are organised on a not-for-profit basis, with any resulting benefits being used 
directly to improve patient care or to enable us to perform more research. Although the research will not be 
conducted for the purposes of making money it is possible that some of the results, once published, will be of value 
to commercial companies, for example in the development of new tests or treatments.  
 
Most of the research conducted using the samples we obtain is conducted in the UK but as the work we undertake is 
part of an international effort we sometimes send samples to centres outside the country- for example to mainland 
Europe or the USA. If you do not wish your samples, information or data to leave the country you can indicate this 
on the form we ask you to sign. 
Use of your tissue or cells for research in this way will not influence your treatment directly. Withholding consent 
will not affect your diagnosis or treatment in any way. If you do not wish to give consent, we guarantee that any 
sample surplus to needs for diagnosis is disposed of appropriately, following national guidelines.  
 
I agree to the use of my sample(s) after diagnosis for research:   YES / NO  
 
If yes, please answer the following questions (Please circle one response to each question)  
The Medical School, 
Framlington Place, 
Newcastle-upon-Tyne, 
NE2 4HH, U.K. 
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The patient should complete the whole of this sheet himself/herself  
  
x Have you read and understood the patient information sheet?      Yes/No  
                     (Please take a copy home with you to keep)  
 
x Have you had an opportunity to discuss the tissue bank and ask questions?    Yes/No 
  
x Have you had satisfactory answers to your questions from Prof/Dr/Sr ……………………………….?  Yes/No  
  
x Do you understand that you are free to withdraw your consent from the tissue bank at any 
      time, without having to give a reason and without affecting your future medical care?  Yes/No  
  
x Do you agree to donate samples in excess of what is required for medical purposes  
         and for these to be stored for future use in approved research projects?    Yes/No  
 
x Do you agree to donate small extra samples specifically for research purposes and  
         for these to be stored for future use in approved research projects?     Yes/No  
 
x Do you understand that you will not be told the results of any tests which may  
         be carried out on your samples ?           Yes/No  
  
x Do you give permission for your medical notes to be looked at, in relation to your condition,  
       by an NHS professional (doctor or research nurse), where it is relevant to research about your  
       condition and your stored sample(s)?         Yes/No 
 
x Do you give permission for your GP to be contacted if it is relevant to your having donated  
       samples to the research tissue bank.         Yes/No 
 
x Do you give permission for your medical information (data) to be stored?    Yes/No  
  
x Do you give permission for samples to be sent to centres outside the UK?    Yes/No  
 
x A de-identified sample of DNA obtained from your blood may be sent to a laboratory for detailed genetic 
analysis.  The remainder of your DNA, as well as your de-identified genetic information and medical 
information (data), may be stored for an unlimited amount of time.  Your data and DNA may be shared with 
other qualified researchers, including academic, commercial, domestic and foreign researchers, who have 
received appropriate approval.  Your data and DNA might be used for research on any disease, health condition 
or risk factor.  Do you give permission for storage and use of your data and DNA in this way?    
              
             Yes/No 
 
 
________________________ ________________ ____________________  
Name of Patient Date Signature & Hospital Number  
 
_________________________ ________________ ____________________  
Name of Person taking consent Date Signature  
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes  
Research Co-ordinator  Contact Details:  
Diane Walia; Research Study Co-ordinator; Hepatology; Freeman Hospital; Tel: 0191 21 31568; 
Diane.Walia@nuth.nhs.uk 
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Results 
Inflammatory cytokines reduced the TEER, as expected.  There was 
no statistical difference (ANOVA) in the TEER between the groups 
treated with the FXR agonist and those without (figure 1).  In terms 
of IL-8 production, the Caco-2 cells were unresponsive to stimulation 
with both TNF and IFN.  IL-1  stimulation induced a significant 
increase in IL-8.  The level of IL-8 production was increased when 
cells were treated with the FXR agonist (figure 2). 
 
Activation of the bile acid receptor,  
farnesoid-x receptor, does not maintain  
the epithelial barrier in a human cell line 
 
R A Speight1,2  C A Lamb1,2  J C Mansfield2,3  J A Kirby1  
1 Applied Immunobiology and Transplantation Research Group, ICM, Newcastle University, UK; 2 Department of Gastroenterology, Newcastle u Tyne Hospitals Trust, UK; 3 
Institute of Genetic Medicine, Newcastle University, UK 
 
Introduction 
The aetiopathology of inflammatory bowel disease (IBD) is 
incompletely understood, but is characterised by epithelial barrier 
dysfunction and immune dysregulation in a genetically susceptible 
host (Brant 2011).  Exposure to a western diet, bacterial dysbiosis 
and bile acid (BA) dysmetabolism have been implicated in the 
pathogenesis of IBD (Trauner, Fickert et al. 2013).  Farnesoid X 
receptor (FXR) is a BA receptor which promotes gut homeostasis by 
maintaining the epithelial barrier and exerting anti-inflammatory 
effects (Gadaleta, van Erpecum et al. 2011).  The mechanism by 
which FXR maintains the epithelial barrier is not known.  IBD 
associated inflammatory cytokines, such as TNF, IL-1, and IFN 
are known to disrupt epithelial barrier function (Adams 1993, Ma 
2004).The aim of this study was to assay the effect of FXR agonism 
in an in-vitro human model of epithelial barrier dysfunction. 
Methods 
Fully differentiated (>21 day old) Caco-2 cells were cultured as a 
polarised monolayer on hanging cell culture inserts.  Transepithelial 
electrical resistance (TEER), a marker of epithelial barrier function, 
was measured in the presence or absence of the pro-inflammatory 
cytokines TNF and IFN with or without an FXR agonist.  Enzyme-
linked immunosorbent assay (ELISA) was performed for IL-8 following 
stimulation with IL-1with or without an FXR agonist. 
 
Discussion 
From this provisional data, in a human cell line model, FXR agonism 
does not ameliorate the epithelial barrier dysfunction induced by 
TNF and IFN, as measured by TEER.  The chemotactic cytokine 
IL-8 is readily induced by IL-1.  Rather than attenuating this 
response, the FXR agonist, in this assay, would seem to increase the 
level of IL-8 produced.  These findings will be explored further  in 
further epithelial cell lines and in primary tissue. 
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Fig.1: Change in transepithelial electrical resistance (normalised to 
1.0), with time (in days), following exposure to tumour necrosis 
factor alpha or interferon gamma in the presence or absence of 10 
microM FXR agonist and control. 
Fig. 2:  IL-8 production in response to exposure with IL-1 
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Ac#va#on	of	the	bile	acid	receptor,	
Farnesoid-x	receptor,	may	reduce	
ileal	cytokine	expression	in	an	
animal	model	of	diet-induced	
obesity	
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Discussion	
•  HF/HS	feeding	increases	expression	of	ileal	
inflammatory	cytokines	in	model	of	diet-induced	
obesity	
•  FXR	agonist	may	reduce	the	cytokine	expression	
induced	by	HF/HS	feeding	
–  PotenAal	risk	factor	modificaAo	
•  Possible	FXR	mechanisms:	
–  AEenuated	epithelial	IL-8	response	to	sAmulaAon	
–  Maintains	epithelial	morphology	
–  Inhibits	various	primary	human	immune	cell	types	
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Activation of the bile acid receptor, farnesoid-X 
receptor, maintains gut epithelial cell morphology, 
possibly via inhibition of myosin light chain kinase 
expression 
 
 
Introduction 
By inducing epithelial barrier dysfunction, IBD associated 
inflammatory cytokines increase the leakiness of the gut 
mucosa, driving chronic inflammation1. Epithelial permeability 
increases, in part, due to cell-cell junction re- arrangement, 
mediated by myosin light chain kinase (MLCK)2. FXR agonism 
has been shown to maintain the epithelial barrier in a mouse 
model of colitis3. The aim of this study was to assay the effect 
of FXR agonism on epithelial cell morphology in a human, gut-
derived epithelial model of barrier dysfunction. 
 
Methods 
Fully differentiated Caco-2 cells were cultured as a polarised monolayer 
and treated with TNFα, IFNγ or IL-6 with or without INT747 (FXR agonist, 
Intercept Pharmaceuticals). At 48 hours, transmission electron 
microscopy (TEM) was performed to assess for morphological re-
arrangement of the cell-cell junction. Two independent researchers, 
blinded as to intervention, counted the number of morphological re-
arrangements in 20 samples, chosen at random. RNA was isolated from 
IL-6 treated monolayers and the expression of MLCK was measured by 
RT-PCR (ΔΔCt method). Unpaired t-tests were calculated using Prism 
version 6.0e. All P values were 2-tailed, and a P value of 0.05 or less was 
considered significant. 
 
Results 
FXR agonism reduced the number of epithelial cell-cell junction fissures (fig 1) for monolayers stressed with IFNγ (73% to 30%) and IL-6 (70% 
to 43%). This was significant in the IFNγ group (p = 0.03), but failed to reach significance in the IL-6 group (p = 0.08). There were no, or few, 
morphological re-arrangements in control, INT747 only or TNFα treated monolayers (fig 2). Cells stressed with IL-6 demonstrated a significant 
increase in the relative expression of MLCK (fold increase 435.4). The IL-6 induced upregulation of MLCK was completely abolished by co-
treatment with INT747 (fig 3).  
Discussion 
Evidence is presented to demonstrate that FXR acts to maintain 
human, gut-derived epithelial cell morphology after stress with IFNγ 
and IL-6, probably via a mechanism involving the regulation of 
MLCK expression. FXR agonists are potential therapeutic 
compounds in the management of IBD. 
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Fig 1:  Examples of electron micrographs of 
normal cell-cell junction (left) and cell-cell 
junction fissure (right) in epithelial 
monolayer 
Fig 2: % of cell-cell fissures seen at TEM 
(n=20) for monolayers stimulated with 
cytokine or vehicle +/- FXR agonist.  
Fig 3:  Relative gene expression for MLCK 
in monolayers following exposure to 
vehicle, FXR agonist or IL-6 +/- FXR 
agonist 
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Results 
In the control group, gut epithelial cells produced high 
levels of IL-8 when exposed to TNFα (6,316+/-870 pg/
mg).  Concomitant treatment with an FXR agonist at 
high dose (GW4064 10µM) completely abolished this 
IL-8 response (p=0.0004).  Lower doses of FXR 
agonist (0.1µM, 1µM) had no significant effect on the 
concentration of IL-8.  (continued) 
Farnesoid X receptor agonism modulates gut epithelial innate 
immune response 
R A Speight1,2, C Barker1, J Palmer1, J C Mansfield2,, J A Kirby1  
1 Applied Immunobiology and Transplantation Research Group, ICM, Newcastle University, UK, 2 Department of Gastroenterology, 
Newcastle u Tyne Hospitals Trust, UK 
` 
Introduction 
Disruption to the epithelial barrier is central to the 
pathophysiology of IBD (Zeissig et al., 2007, Su et al., 
2009).  A variety of innate immune mechansims 
contribute to the maintenance of the epithelial barrier.  
When stressed, either by pathogens or by 
inflammatory cytokine, gut epithelial cells produce IL-8 
which acts as a chemo-attractant for circulating 
polymorphonucleocytes (Eckmann et al., 1993).  
Farnesoid X receptor (FXR) is a bile acid (BA) receptor 
which promotes gut homeostasis by maintaining the 
epithelial barrier and exerting anti-inflammatory 
effects (Gadaleta et al., 2011).  The mechanism by 
which FXR maintains the epithelial barrier is not 
known. 
Methods 
The aim of this study was to assay the effect of FXR 
agonism on the production of IL-8 by human gut-
derived epithelial cells, in response to cytokine stress. 
HT29 cells were cultured with media containing an FXR 
agonist (GW4064) or control (vehicle) with or without 
an FXR antagonist (guggulsterone).  Following 
exposure to the FXR agonist +/- guggulsterone, HT29 
cells were stimulated with growth media containing 
TNFα.  IL-8 was measured both at a protein level by 
ELISA and a transcriptional level by RT-PCR. 
 
(Results continued) 
Guggulsterone was able to reverse the attenuating 
effect of high dose FXR agonist, with significantly more 
IL-8 detected in co-treated cells (p=0.0005).  
Measurement of the relative gene expression of IL-8 
confirmed the findings observed at the protein level 
(TNFα alone: fold change 640+/-20, TNFα+FXR 
agonist: fold change 0.08+/-0.02) (See figure). 
 
Discussion 
These experiments demonstrate that FXR activation 
decreases the IL-8 response of human gut-derived 
epithelial cells to TNFα at a transcriptional level.  Gut 
epithelial IL-8 expression is an important innate 
immune mechanism and this data is in keeping with 
other studies in demonstrating an immuno-modulatory 
role for FXR (Vavassori et al., 2009, Haselow et al., 
2013).  This is a potential mechanism by which FXR 
may act to maintain epithelial homeostasis. 
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